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  Insulin resistance and chronic hyperglycemia promote vascular damage, 
increase circulating levels of inflammatory cytokines and lead to increased morbidity 
and mortality. MicroRNAs (miRs) -103/107 have been shown to negatively regulate 
insulin sensitivity and glucose homeostasis. Based on complimentary binding profiles, 
the downstream target gene of miR-103/107 is caveolin-1 (Cav-1). We hypothesized 
that daily administration of the phosphodiesterase-5 inhibitor tadalafil (TAD) ± the 
	  	  
curcumin analogue (HO-3867) will attenuate inflammation, improve metabolic 
parameters and reduce infarct size after ischemia/reperfusion injury (IRI). Furthermore, 
we propose that TAD therapy will reduce myocardial expression of miR-103/107 and 
increase mRNA and protein levels of its target gene, Cav-1.  
Leptin receptor null mice were randomized to receive daily injections of TAD 
(1mg/kg), HO-3867 (25mg/Kg), combination therapy, or control for 12weeks with weight 
and fasting glucose monitored weekly. Upon completion, cardiomyocytes were isolated 
from each group and were subjected to simulated ischemia and reoxygenation (SI/RO) 
for cell viability and reactive oxygen species (ROS) measurement. Another set were 
subjected to IRI in a Langendorff model.  Plasma samples were taken to measure 
plasma concentrations of cytokines. For miR expression, total RNA was isolated from 
TAD and DMSO treated mice and was subjected to reverse transcription and real time 
PCR using miR assay probes to determine expression.   
TAD, HO-3867 and the combination of both attenuated fasting glucose levels, 
reduced myocardial infarct size after IRI and inflammatory cytokines when compared to 
control (p<0.05 for each vs. control). Cardiomyocytes isolated from each treatment 
groups and subjected to SI/RO demonstrated reduced necrosis as shown by trypan 
blue exclusion assay, ROS generation, and improved mitochondrial membrane potential 
as compared to DMSO (control). Likewise, both mRNA and protein expression of Cav-1 
were reduced in diabetic hearts but were significantly increased in TAD treated diabetic 
	  	  
mice, which may be a mechanism to improve insulin signaling through downregulation 
of miR-103/107 and upregulation of Cav-1.   
These studies suggest that TAD alone or in combination may be a unique 
strategy to improve metabolic parameters and precondition diabetic hearts against IRI.  
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CHAPTER 1 
 
BACKGROUND AND SIGNIFICANCE 
 
A. Diabetes and Heart disease  
 The prevalence of diabetes in the United States is increasing at an astronomical 
rate and the American Diabetes Association currently estimates that 8.3% of the 
population has diabetes and nearly 79 million people have insulin resistance and are 
currently at risk for developing diabetes.1 Accelerated vascular injury and inflammation 
are intimately associated with the complications of insulin resistance and diabetes and 
can lead to a number of micro- and macro- vascular insults such as retinopathy, 
nephropathy and painful neuropathy. Eventually more adverse complications result as 
the pathophysiologic consequence of the chronic hyperglycemic state. Hyperglycemia 
increases the expression of genes in the vascular smooth muscle cells (VSMC), tissue 
macrophages and endothelium, promoting the attraction, adhesion and subsequent 
transmigration of monocytes into the sub-endothelial space. In addition, the perpetual 
exposure of lipids and proteins to elevated glucose concentrations generates the 
formation of advanced glycation end products (AGEs), inducing reactive oxygen species 
(ROS), binding to cell surface receptors, inhibiting endothelial nitric oxide (NO) 
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production and increasing oxidative stress. The enhanced oxidative stress has several 
effects at the molecular and cellular level, which eventually contributes to 
macrovascular disease such as coronary heart disease (CHD). The oxidation of low-
density lipoprotein (LDL) and glucose oxidation generate the formation of superoxide 
anions within the mitochondria, which generates hydroxyl radicals and nicotinamide 
adenine dinucleotide phosphate (NADPH) production within macrophages. This leads to 
significant endothelial dysfunction, impairing vasodilatation and promotes vascular 
injury, oxidative stress and AGE formation.  
  Unfortunately, data from clinical trials suggest that despite intensive control of 
hyperglycemia, the reduction of glycosylated hemoglobin levels to 6% does not prolong 
life or reduce vascular morbidity.2 This indicates that endothelial dysfunction is likely at 
the crux of the problem that leads to poor long-term outcomes and not the 
hyperglycemia itself. There is data to suggest that reduced levels of NO within the 
vascular endothelium contributes to impaired insulin utilization in patients with insulin 
resistance.3 Vascular NO is critical for normal vasodilatation and endothelial function 
and impairment of NO bioavailability and the NO-cyclic guanosine monophosphate 
(cGMP)--dependent protein kinase (PKG) signaling cascade is the central mediator of 
endothelial dysfunction.4 A number of clinical studies have shown that hyperglycemia 
and increased AGEs are key factors in potentiating vascular inflammation and 
increasing levels of ROS and oxidative stress.5, 6  
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      Figure 1.  Interconnected pathways in Insulin Resistance and CHD. 
	  
The interconnected pathways in insulin resistance and heart disease reveal that 
endothelial dysfunction, insulin resistance, obesity, hyperglycemia, inflammation and 
oxidative stress are all interconnected with each perpetuating the next. This eventually 
leads to type II diabetes, which then further accentuates the vicious cycle. The common 
downstream event is the formation of atherosclerosis, peripheral vascular and coronary 
artery disease. This leads to the increased morbidity and mortality in this patient 
population.  
 
 This vascular milieu of elevated inflammation, impaired NO bioavailability, and 
oxidative stress plays an integral role in the progression of atherosclerosis and 
Inflammation
Endothelial	  Dysfunction
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Insulin	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subsequently acute coronary syndromes culminating in significant morbidity and 
mortality of the diabetic patient 7 (Figure 1).  
 Recent animal studies with NO synthase (NOS) inhibitors and genetically altered 
mice that lack the endothelial nitric oxide synthase (eNOS) gene, suggest that the NO 
signaling pathway may regulate and promote glucose uptake in myocytes.8-11 Moreover, 
when mice lack the eNOS gene, they were unable to catalyze the formation of NO in the 
endothelium, had decreased oxygen consumption, increased weight gain and were 
found to be insulin resistant.12 In addition, several studies have indicated that insulin 
resistance itself may impair NO release and damage the endothelium through 
mechanisms that are reciprocally interconnected.5,6 For example, chronic 
hyperglycemia increases circulating levels of inflammatory cytokines, chemokines, and 
expression of intracellular adhesion molecule-1 (ICAM-1), hence contributing further to 
this pathognomonic state.13  
 It was previously hypothesized that the vasodilatory action of a 
phosphodiesterase (PDE)-5 inhibitor would potentially release endogenous mediators 
from the endothelium such as bradykinin and adenosine and that this may trigger a 
signaling cascade that results in phosphorylation of eNOS and release of NO from the 
endothelium. The generation of NO activates soluble guanylate cyclase (sGC) resulting 
in enhanced formation of cGMP and subsequently downstream cGMP protein-
dependent kinases.  Within each cell, levels of cGMP are tightly regulated by PDEs, 
which cleave the 3’5’-cyclic-phosphate moiety of cGMP to produce the corresponding 5’ 
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nucleotide. PDE-5 selectively hydrolyzes cGMP and its inhibition increases the 
bioavailability of cGMP. The PDE-5 inhibitors, including sildenafil (Viagra™), vardenafil 
(Levitra™), tadalafil (Cialis™) and avanafil (Stendra), have been approved by the Food 
and Drug Administration for the treatment of erectile dysfunction (ED).14, 15 More 
recently, sildenafil and tadalafil (TAD) have been approved for the management of 
pulmonary arterial hypertension.16 TAD selectively inhibits PDE-5 hence increasing 
cGMP levels, however its effects can last up to 36 h, whereas the durations of action of 
sildenafil and vardenafil are generally 4 to 8 h.17 Moreover, TAD is a highly selective 
inhibitor of PDE with >10,000-fold selectivity for PDE-5 over PDE-1 to PDE-4 and 
approximately 700-fold selectivity for PDE-5 over PDE-6 17. TAD is also the only PDE-5 
inhibitor whose activity is unaffected by food and has a relatively short time to onset of 
action (16–17 min).17   
 Chronic administration of PDE-5 inhibitors has been associated with increased 
persistent vascular and endothelial function by increasing the level of endothelial cGMP 
generated by activation of eNOS.18 In streptozotocin-induced diabetic rats, long-term 
administration of the PDE-5 inhibitor DA-8159 prevented ED and preserved endothelial 
function.19 In a similar model, 14 days of treatment with sildenafil improved 
vasorelaxation through enhanced endogenous NO signaling.20 In addition, clinical 
studies have revealed a potential protective role of these compounds on endothelial 
function in short- and long-term assessments.21 In a large meta-analysis it was reported 
that endothelial dysfunction is a significant independent risk factor for cardiac death, 
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myocardial infarction (MI), stroke and the need for coronary revascularization.22 A study 
by Gazzaruso et al found that diabetic patients with ED were at increased risk for silent 
coronary artery disease and ED was a powerful predictor of cardiovascular (CV) 
morbidity and mortality.23 They went on to show that PDE-5 inhibitor use in type II 
diabetics was associated with a significant reduction of major adverse cardiac events. 
Likewise, a recent epidemiological study provided evidence of a strong correlation 
between the risk factors associated with metabolic syndrome (i.e. obesity, elevated 
fasting glucose levels, dyslipidemia, hypertension) and urinary cGMP excretion, 
suggesting that a reduction of NO bioactivity concurs with these CV risk factors.24 
Interestingly, one study found genetic variations of the eNOS gene influenced energy 
expenditure, severity of glucose intolerance, and risk of developing type II diabetes.25 In 
a clinical trial, chronic (alternate-day) administration of tadalafil in men with ED had 
improved endothelial function as indicated by marked changes in serum markers of 
endothelial function, increased insulin levels and a robust decrease in the inflammatory 
marker, high sensitivity C-reactive protein (hs-CRP).26 Similarly, both acute and chronic 
administration of sildenafil improved endothelial function in patients with type II diabetes 
as observed by improved flow-mediated dilatation of the brachial artery.27, 28 In this 
respect, the use of PDE-5 inhibitors are quite attractive for the long-term management 
of cardiovascular diseases. 
A number of studies from our laboratory have shown that PDE-5 inhibitors 
including sildenafil have a powerful protective effect against myocardial 
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ischemia/reperfusion (I/R) injury,29-33 doxorubicin and post-MI heart failure.34-38 
Mechanistically, we showed that sildenafil protects the heart against I/R injury through 
increased expression of inducible NOS (iNOS) / eNOS18, 39 activation of PKG,39, 40 
phosphorylation and inactivation of glycogen synthase kinase-β (GSK-3β),40 opening of 
mitochondrial KATP channels,29-31 and hydrogen sulfide (H2S) generation.33 Insulin 
resistant and type II diabetic patients have decreased expression of eNOS, iNOS and 
impaired NO synthesis, therefore the chronic use of PDE-5 inhibitors may be potentially 
therapeutic because these compounds improve ED, at least in part, by correcting 
damage to the vascular endothelium by upregulating eNOS and iNOS and increasing 
NO levels.27, 28, 41  
Currently there is an imperative need for understanding the molecular and 
biochemical mechanisms underlying diabetic vascular complications and a multifaceted 
therapeutic strategy that targets the problem on many levels would be optimal. 
Therefore based on this background information, we propose that PDE-5 inhibitors 
would be ideal candidates to treat endothelial dysfunction, insulin resistance, and 
inflammation while protecting the diabetic heart against I/R injury. 
According to WHO, ischemic heart disease (IHD) is the leading cause of 
morbidity and mortality in the world accounting for more than 7.2 million deaths each 
year and by the year 2030 over 26 million people will die from cardiovascular 
diseases.42 Prompt myocardial reperfusion of the infarct-related artery by either 
fibrinolysis or percutaneous coronary intervention (PCI) remains critical for reducing 
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infarct size. Recent advances in the field of cardiovascular medicine has led to new 
antiplatelet and antithrombotic drugs and novel anti-proliferative drug-eluting stents 
which represent a significant step forward in improving long term outcomes in patients 
presenting with acute coronary syndromes. Unfortunately despite intense research in 
the field of molecular cardiology, we have no definitive intervention nor approved 
pharmacological agent indicated to completely eliminate or reduce myocardial damage 
induced by reperfusion injury—a condition where ischemic myocardium is subjected to 
sudden intracellular metabolic and biological changes upon flow restoration.  With a 
monumental growth in the number of patients dying from IHD in both developed and 
underdeveloped countries, not only has it become imperative to reduce the time to 
reperfusion, but also to understand the fundamental pathological mechanisms of I/R 
injury so that safe and potent cardioprotective compounds can be developed that would 
render the myocardium resistant to reperfusion injury.  
 
B. Novel Pharmacological Agents in Cardioprotection and Insulin Resistance 
 
i. Phosphodieseterase-5 inhibitors 
 Phosphodiesterase-5 is an enzyme that catalyzes the degradation of cGMP 
and through inhibition with a PDE-5 inhibitor, leads to an increase in bioavailable cGMP. 
There have been 21 PDE genes identified and cloned, all of which can be further 
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classified into one of 11 PDE families based on homology and pharmacological and 
biochemical properties.43 PDEs are ubiquitous throughout the body and perform a 
number of functions.  PDE-5 is the predominant enzyme in the corpus cavernosum, and 
plays a crucial role in penile erection.  Likewise, immunohistochemical studies have 
demonstrated that PDE-5 is abundant in vascular and bronchial smooth muscle cells, 
renal tubules, lung tissue and platelets. Initially it was thought that PDE-5 was not 
expressed in the heart, but Shezaki et al provided the first evidence that PDE-5 was 
expressed in the canine myocardium and subsequently our laboratory showed its 
expression in the rodent heart.44, 45 It is known that PDE-5 inhibitors facilitate an erection 
by increasing NO signaling by preventing enzymatic hydrolysis of cGMP in endothelial 
cells. The PDE-5 isoenzyme is widely expressed in the vasculature and is found in other 
vascular beds other than the penis. The efficacy of PDE-5 inhibitors is much lower in 
diabetic patients with ED compared to those without it and similarly the endothelial 
effectiveness of drugs that improve endothelial function is lower in diabetics than non-
diabetics.14 However, it is quite possible that when part of a daily regimen, a PDE-5 
inhibitor improves the responsiveness of dysfunctional endothelium and ameliorates 
inflammation—which would make this a novel strategy for preventing the development 
and progression of atherosclerosis and CV diseases in the diabetic patient. 
In the last several decades, the overwhelming knowledge and understanding of 
the cardioprotective signaling pathways involved in protecting the heart from ischemic 
insult has laid the conceptual background for developing pharmacological agents that 
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target specific triggers and mediators which may provide similar effects.  In 2002, our 
laboratory was the first to show that the PDE-5 inhibitor sildenafil could induce a 
“preconditioning effect,” in which pre-treatment with the drug protected the heart against 
subsequent I/R injury. For example, in a rabbit model of I/R, the Kukreja laboratory 
found that opening of the mitochondrial adenosine triphosphate (ATP) sensitive 
potassium channel  (mitoKATP) was critical in the sildenafil-induced infarct-sparing 
effect.46 Using the mitoKATP blocker, 5-hydroxydecanoate (5-HD), the cardioprotection 
could be abolished, hence confirming a downstream signaling role of the adenosine 
triphosphate (ATP) sensitive potassium channel. We confirmed the findings in the 
rodent model, in the isolated perfused heart model, and in the in vitro cardiomyocyte cell 
culture model in which isolated cardiomyocytes were subjected to simulated ischemia 
and reoxygenation (SI/RO).45, 47 The results were consistent in that all PDE-5 inhibitors, 
whether sildenafil, vardenafil or tadalafil all had an infarct-sparing effect, could reduce 
cardiomyocyte necrosis and apoptosis, and on transthoracic echocardiography (TTE), 
could preserve post-ischemic left ventricular (LV) ejection fraction.47-50 Mechanistic 
studies revealed that the cardioprotective effects of PDE-5 inhibitors are largely 
dependent on: NO generation, opening of the mitoKATP channel, activation of Protein 
Kinase C (PKC), adenosine A1 receptor, and through inhibition of PDE-5 with 
subsequent accumulation of cGMP and activation of downstream PKG-dependent 
signaling.51 This includes PKG-dependent phosphorylation of extracellular signal-
regulated kinase (ERK)1/2 and GSK3β in conjunction with increasing B-cell lymphoma 
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protein (Bcl-2), which inhibits apoptosis through attenuating cytochrome c release and 
inhibiting opening of the mitochondrial permeability transition pore (mPTP)52 [Figure 2].  
Lastly, PKG has its own independent effect on I/R injury as it too can open the mitoKATP 
and limit infarct size through preserving ATP and decreasing the calcium (Ca2+) influx 
into the mitochondria.53 In a rabbit model of I/R injury we compared sildenafil and 
vardenafil with nitroglycerin (NTG) to evaluate their cardioprotective effect when 
administered immediately at the time of reperfusion.54 Animals were subjected to 30 min 
of ischemia followed by 3 h of reperfusion with intravenous (i.v.) sildenafil, vardenafil or 
NTG being given for 65 min, beginning 5 min before reperfusion. We found both PDE-5 
inhibitors had similar cardioprotective effects compared to control and the infarct-
sparing effect was mediated through the mitoKATP channel as the effect could be 
blocked by 5-HD. Surprisingly however, NTG failed to confer any cardioprotection.  
We hypothesized that this could be explained by either insufficient cGMP 
bioavailability relative to NO or a surge of free radicals at the time of reperfusion that 
could react with the NO derived from NTG forming peroxynitrite (ONOO-) that then 
could lead to protein nitration and myocardial damage.54  
PDE-5 inhibitors have also been shown to prevent adverse cardiac remodeling in 
the experimental arena of ischemic cardiomyopathy (ICM). In 2008, we showed for the 
first time in a murine model of ICM, that chronic sildenafil treatment can attenuate LV 
dysfunction.49 Recent evidence suggests that Rho Kinase (RhoK), which is activated by 
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the small GTPase RhoA, plays an important role in the development of cardiovascular 
disease and pulmonary hypertension. 
	  
Figure 2.   PDE-5 inhibitors and sGC activators: Mechanisms of action in cardioprotection. 
 
Activation of soluble guanylate cyclase (sGC) by either nitric oxide (NO) or 
independently of an oxidized heme group within sGC by a sGC activator, leads to an 
increase in cyclic GMP (cGMP), and downstream protein kinase G (PKG). 
Cardioprotective effects by PKG are induced through opening of the mitochondrial KATP 
channel and phosphorylation of glycogen synthase kinase (GSK)-3β, which prevents 
opening of the mitochondrial permeability transition pore (mPTP).  
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Moreover, RhoK functions as a signal transducer in actin cytoskeletal 
organization, gene expression, and muscular contraction. Non-selective inhibitors of 
RhoK reduce infarct size and adverse remodeling of the LV. Likewise, in two different 
models of pulmonary arterial hypertension, sildenafil inhibited RhoK and improved 
pulmonary pressures.55,56 Therefore, we evaluated if sildenafil treatment could attenuate 
the progression of heart failure and whether the signaling could be attributed to 
inhibition of the RhoA/ Rho-Kinase pathway.57 In our model of ICM, mice were 
subjected to permanent left anterior descending occlusion and 3 days post-infarction, 
when fractional shortening was less than 25%, were started on either twice a day 
treatment with sildenafil or equivalent volume saline. Mice treated with sildenafil showed 
preservation of LV function and less end-diastolic dilatation compared to control at 7 
and 28 days post-MI. Similarly, fibrosis and apoptosis were significantly reduced in the 
sildenafil treated group. Western blot analysis of sildenafil treated homogenates 
revealed enhanced Bcl-2: Bcl-2 associated X protein (Bax) ratio, that RhoK was 
significantly inhibited, and this was directly associated with PKG activation. Moreover, 
RhoK inhibition was PKG-dependent as use of the PKG inhibitor KT-5823 completely 
abolished any RhoK inhibition.57  
Today, more than 100 clinical trials with PDE-5 inhibitors have been completed 
or are currently ongoing focusing on the drugs’ potential cardiovascular benefits.58 
These potent agents have shown promising results in patients with diastolic heart failure 
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and reactive pulmonary hypertension and intense research is ongoing in patients with 
valvular and congenital heart disease, diabetes mellitus, and systolic heart failure.58 
However, there have yet to be trials designed to evaluate its direct preconditioning 
effects. Future demonstration of the cardioprotective effects in patients with PDE-5 
inhibitors could have a considerable impact on post-MI morbidity and mortality by 
bringing the phenomenon of pharmacologic preconditioning from the bench to the 
bedside.  
 
ii. Soluble Guanylate Cyclase Activators 
The gaseous ligand NO is an important signaling molecule involved in regulating 
a variety of biological and physiological processes.  Intense research on NO in the past 
few decades has led to significant clinical evidence that reduced NO bioavailability or 
responsiveness to NO is a fundamental component in the pathogenesis of 
cardiovascular and endothelial diseases.  NO is a potent vasodilator, which prevents 
platelet adhesion and aggregation and inhibits vascular smooth muscle proliferation.59 
Currently there are a variety of cardiovascular diseases, including hypertension, IHD 
and congestive heart failure (CHF) that are treated by one of the many pharmacologic 
agents termed “NO-donors or nitrovasodilators.” These drugs mimic the action of 
endogenous NO by either bioconversion to NO and NO-associated compounds and 
activate its intracellular receptor sGC by nitrosylation of the heme moiety. This in turn, 
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increases by 200-fold the catalytic conversion of guanosine triphosphate (GTP) into the 
secondary messenger cGMP.60 Most often than not, the intracellular signal are then 
potentiated by activation of PKG. However, the use of these medications is quite limited 
secondary to the development of nitrate tolerance, insufficient bio-metabolism and non-
specific interactions of NO, including peroxynitrite (ONOO-) -mediated tyrosine 
nitration.60 Furthermore, ROS within the vasculature reacts with NO and inhibits NO 
signaling, creating a state of NO resistance and decreased NO bioavailability in the 
endothelium. To avoid these disadvantages of nitrate therapy and oxidant stress, a new 
class of compounds have been recently discovered which can activate sGC 
independently of NO and may have a significant advantage over current NO-donor 
therapeutics.  
Guanine nucleotidyl (guanylate) cyclases (GCs) are a widely distributed key 
signal transduction enzyme, which in response to various cellular stimuli, converts GTP 
to the secondary messenger cGMP. The transmembrane particulate GC (pGC) serves 
as a receptor for atrial (a-type), brain (b-type) and c-type natiuretic peptide and 
analogues of these peptides have become a mainstay for treating severely 
decompensated CHF.60 The cytosolic form of sGC is a heterodimer consisting of two α 
and two β subunits with the β subunit having a prosthetic heme group. The heme 
moiety is positioned in the heme-binding domain of the β subunit and has a length of 
about 200 residues.61 The ferrous iron of the prosthetic heme group is coordinated 
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between four heme nitrogens and the axial ligand histidine-105 and the anchoring 
residues of the heme propionates tyrosine135, serine137 and arginine139 all together 
constitute the heme-binding motif.61 NO can then bind to the heme and activate sGC, 
but only if the heme moiety is in its reduced form (ferrous state) (Figure 3).  In 
pathological conditions of excessive oxidative stress, there is perpetual endothelial and 
vascular damage that also promotes platelet aggregation. In these conditions, there is 
an abundance of ROS and NO is rapidly scavenged by superoxide (O2-
⋅) to form 
ONOO- and the heme moiety of sGC is quickly oxidized from ferrous heme to ferric 
heme, rendering NO ineffective as its ligand—making conventional NO donor 
pharmacologic agents futile.60 This has led many scientists to search for a way to 
directly activate sGC and restore the NO-sGC-cGMP pathway, whether under 
conditions of reduced NO availability, or in pathological states where sGC is largely in 
the oxidized form.  
The effects of cGMP are mediated by various cGMP effector systems such as 
cGMP-dependent protein kinases (PKG-1α, PKG-1β), cGMP-dependent ion channels 
(PKG-2) and PDEs.60 The substrates of PKG include inositol triphosphate receptor-
associated cGMP-kinase substrate (IRAG) and recognition of the substrates by the 
PKG-1 isozymes is mediated by the NH2-terminal leucine/isoleucine zipper (LZ) 
domain.62 Both PKG-1α and PKG-1β are derived from the same gene and differ only in 
the terminal NH2 LZ domain. Overall, PKG-1 substrates fulfill various cellular functions 
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such as intracellular Ca2+ and potassium concentration, Ca2+ sensitivity, and 
organization of the intracellular cytoskeleton. PKG-2 substrates are involved in chloride 
transport, sodium/proton transport and transcriptional regulation. The degradation of 
cGMP is catalyzed by one of several PDEs and this led to the discovery of specific PDE 
inhibitors, notably the PDE-5 inhibitors. PDE-5 inhibitors have been successfully used to 
treat disorders of endothelial dysfunction such as erectile dysfunction and pulmonary 
hypertension while attempting to the restore the NO-cGMP intracellular signaling by 
preventing cGMP breakdown60 (figure 3).   
Since in a majority of cardiovascular diseases such as atherosclerosis, 
hypercholesterolemia, and insulin resistance, insufficient NO-sGC-cGMP signaling and 
endothelial dysfunction is at the crux of the problem, two novel drug classes have 
recently been discovered—the sGC stimulators that can activate sGC independent of 
NO and the sGC activators that can activate sGC independent of NO and independent 
of the redox status of the prosthetic heme group.60 Therefore, these compounds could 
potentially allow for restoration of the NO-sGC-cGMP signaling cascade in these 
pathological states—which would have otherwise been lost due to NO scavenging 
and/or oxidation of sGC. 
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            Figure 3.  Nitric oxide signaling pathway. 
 
Illustration of the activation of sGC by nitric oxide, which increases cGMP and 
subsequently PKG formation. This leads to the favorable effects of vasodilatation, 
inhibition of apoptosis, platelet aggregation and inflammation. Likewise, the particulate 
guanylate cyclase (pGC) can be activated by one of the natriuretic peptides (atrial, b-
type, c-type) and activate the same pathway producing the same downstream effects.  
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           Figure 4.   BAY 58-2667 signaling pathway. 
 
Oxidation of sGC makes NO unable to bind this receptor given the Ferrous to Ferric 
state of the heme-moiety and hence is unable to form cGMP. One of the newest  sGC 
activators, BAY 58-2667, can bind independently of the heme-moiety, regardless of its 
oxidative state and still form cGMP and downstream PKG.  
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the sensitivity of the reduced enzyme to low levels of NO bioavailability. In 1994, after 
testing thousands of compounds, Ko and coworkers at Bayer Healthcare AG discovered 
that an indazole derivative, YC-1, could independently activate sGC by 10-fold and 
could synergistically activate sGC with submaximal NO up to 200-fold.63 YC-1 became 
known as the first “NO sensitizer” and was a major breakthrough in the ability to restore 
the NO signaling cascade even under conditions of decreased NO availability. YC-1 had 
shifted the EC50 for NO to the left by one order of magnitude and was shown to slow 
down the deactivation of NO stimulated sGC.63, 64 The next two compounds developed 
were BAY 41-2272 and 41-8543, both of which were synthesized based on YC-1 
structure.63 Both drugs have been shown to inhibit vascular smooth muscle proliferation 
and platelet aggregation and produce significant vasorelaxation of the coronary arteries 
and veins in rat hearts using a Langendorff isolated perfused heart model.65, 66 
In 2002, after nearly a decade of research, scientists at Bayer identified a 
completely new mechanism of enzyme activation, they had created a compound which 
could not only activate sGC independent of NO, but could even activate it after removal 
or oxidation of the heme and in fact, it preferred the oxidized or heme-free enzyme.65 
This exciting new compound was called BAY 58-2667 and it was the first NO- and 
heme-independent activator of sGC. BAY 58-2667 was found to activate sGC with EC50 
and Kd in the extremely low nanomolar range, making it the most potent NO-
independent activator to date.66 In addition, removal or oxidation of the heme group only 
seemed to potentiate sGC activation, making it quite the ideal compound for use in 
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cardiovascular diseases that are plagued with high oxidative stress, excessive amounts 
of ROS and low NO availability 66, 67. Further studies into the mechanistic action of this 
new drug show that BAY 58-2667 is able to mimic the spatial structure of the sGC 
porphyrin ligand and therefore binds into the empty heme binding pocket or replaces an 
oxidized, weakly bound heme66, 67 (figure 4). Therefore, these novel compounds which 
activate sGC independent of NO, the oxidation status or even presence of the heme 
moiety, represent a significant therapeutic potential for the treatment of various 
cardiovascular diseases.  
In the past several years, a number of key animal studies have demonstrated the 
robust cardioprotective effects of sGC activators. In 2009 Korkmaz et al used a model of 
isoproterenol-induced MI after preconditioning rats with cinaciguat (BAY 58-2667) for 4 
days and then subjected them to acute myocardial infarction (AMI). They then 
measured cardiac function by Millar catheter, gene expression, mRNA levels of 
transforming growth factor (TGF)-β and cyclooxygenase (COX)-2, and performed 
immunohistochemistry for cGMP and nitrotyrosine.68 They found cinaciguat treated rats 
had significantly higher cGMP levels in plasma, higher concentrations in the 
myocardium, decreased mRNA expression of COX-2 and TGF-β, and overall a lower 
mortality rate. During the post-infarction period, the treatment group had improved 
cardiac relaxation, contractility was restored to baseline, and there was no change in 
coronary blood flow after I/R, both of which were significantly reduced in the control 
group.68 Our lab recently evaluated the effects of cinaciguat on ischemic preconditioning 
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(IPC) and I/R injury by giving the drug prior to ischemia and immediately at the time of 
reperfusion in the rabbit and mouse model of AMI and then confirmed these findings in 
a primary adult cardiomyocyte cell culture model of SI/RO by determining the 
compound’s ability to reduce cell necrosis and apoptosis.69 We found that cinaciguat 
caused a 63 and 41% reduction in infarct size when given before I/R and at reperfusion 
in rabbits, respectively. In mice, cinaciguat pretreatment had an even more impressive 
80% reduction vs. 63% when given before I/R compared to at the time of reperfusion.69 
Treatment groups had preserved cardiac function as measured by TTE and likewise, 
cinaciguat reduced myocyte necrosis and apoptosis. Furthermore, using an inhibitor of 
the H2S generating enzyme, cystathionine-γ-lyase (CSE), or an inhibitor of PKG, these 
infarct-sparing and functional improvements were lost thus providing evidence that 
cinaciguat likely induces protection through PKG-mediated H2S generation.69 Recently, 
Radovitz et al used a canine model of hypothermic cardioplegic arrest and 
extracorporeal circulation of coronary artery bypass surgery (CABG) to evaluate if 
cinaciguat could precondition the myocardium and effect endothelial function.70 They 
found that treatment with a sGC activator led to higher myocardial ATP levels, improved 
contractility, improved coronary blood flow and endothelial function.  
Even though sGC activators have yet to be pursued for their infarct-sparing 
effects in the patient setting, ongoing research in various in vivo and in vitro models has 
been promising. However, given the recent termination of several major randomized 
controlled trials including: COMPOSE 1, COMPOSE 2 and COMPOSE EARLY using 
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cinaciguat for the treatment of congestive heart failure, it may be too early to explore 
clinical therapeutic options until the drug is thoroughly studied in various animal 
models.71 Conversely, the oral sGC activator Riociguat (BAY 63-2521), is actively being 
evaluated for the treatment of patients with pulmonary hypertension and thus far seems 
to be much more promising with at least a dozen clinical trials currently underway 72.  
 
iii. Curcumin 
Turmeric (curcuma longa) has been used by those practicing “Ayurvedic 
medicine” since its early discovery in 3000 b.c. in order to treat a variety of inflammatory 
conditions and ailments including obesity. Curcumin (diferuloymethane) is the yellow-
pigment, beta-diketone constituent of the spice turmeric derived from the rhizome of the 
curcuma long plant (Figure 5). It is a natural polyphenolic phytochemical compound that 
is cell-permeable and known to possess histone acetyltransferase (HAT) inhibitory 
activity with specificity for p300/cAMP response element binding protein (CBP).73 It has 
a diverse range of molecular targets; including transcription factors, cytokines, and 
enzymes and as a result it has potential anti-inflammatory, anti-oxidant, anti-thrombotic, 
and cardiovascular protective effects. In experimental studies, it has been shown to 
lower plasma cholesterol, fasting glucose levels and increases hepatic glycogen 
levels.74 Likewise, through inhibiting p300/CBP it ameliorates post-infarction LV 
remodeling and by activating pro-survival kinases, limits infarct size.75-77 However, one 
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major caveat is that it has poor bioavailability and potency.  Recently, a novel class of 
curcumin analogues have been synthesized, namely the diarylidenylpiperidones 
(DAPs), which have been chemically created to elude this problem. By incorporation of 
a piperidone ring in the β-diketone backbone structure and fluorinating the phenyl 
group, 4 DAPs have been synthesized by the Kuppusamy group—H-4073, HO-3867, 
HO-4318 and HO-4200.78 Of these compounds, HO-3867 (3,5-bis(4-fluorobenzylidene)-
1-[(2,2,5,5-tetramethyl-2,5-dihydro-1-hydroxy-pyrrol-3-yl) methyl]piperidin-4-one)78, has 
been shown to be promising in a number of cancer studies, and a recent study has 
shown it to be cardioprotective against doxorubicin-induced cardiotoxicity.78,79 In 
general, when compared to curcumin, the DAP compounds are significantly more 
effective and exhibit potent anticancer efficacy in vitro against breast, colon and ovarian 
cancers.80-82  
The first report to show that curcumin could lower blood glucose in human 
diabetic subjects dates back to 1972 and since then, more than 3000 papers have been 
written on its effect on obesity and obesity-related complications. Likewise, numerous 
recent publications have confirmed that treatment with curcumin can modulate targets 
involved in metabolic diseases and prevent high-fat diet-induced diabetes in rat models 
and genetically induced diabetes in both mouse and rat models.83 
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Figure 5.   Curcumin – the natural turmeric powder extract 
 
From a mechanistic perspective, these beneficial effects are likely afforded by 
attenuation of insulin and leptin resistance, amelioration of inflammatory cytokine 
expression and by increasing fatty acid oxidation and antioxidant enzyme levels.84 One 
recent study showed that curcumin-treated diabetic rats had lower blood glucose levels 
and glycosylated hemoglobin levels in addition to oxidative stress levels.74 When 
looking at other metabolic parameters such as cholesterol in diabetic animals, dietary 
curcumin significantly lowered blood triglycerides, cholesterol, and inhibited lipid 
peroxidation in liver microsomes and mitochondria.85  
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C. Ischemia/Reperfusion Injury 
Numerous experimental studies over the past 25 years have demonstrated the 
importance of the mPTP as a critical determinant of cardiomyocyte injury and necrosis 
after coronary I/R.86 Under normal physiologic and ischemic conditions, the mPTP is 
closed and the inner mitochondrial membrane remains impermeable to nearly all ions 
and metabolites. However during reperfusion, Ca2+ overload and ROS accumulation 
within the mitochondria leads to formation of transition pores allowing molecules up to 
1.5 kDa to equilibrate across the membrane.86,87 Upon permeability transition, 
mitochondria lose their ability to maintain a pH gradient and produce ATP.  This leads to 
the loss of ionic and metabolic homeostasis. Similarly, due to newly created osmotic 
forces, the mitochondrial matrix swells and as a result, the outer membrane ruptures 
causing cytochrome c and other proapoptotic factors to be released into the cytosol.87,88 
Accordingly, opening of this inner mitochondrial membrane transition pore is strongly 
linked with lethal reperfusion injury which ultimately leads to cardiomyocyte necrosis 
and apoptosis.87 Griffiths et al demonstrated that opening of the mPTP does not occur 
during periods of non-lethal ischemia, but rather during the first few minutes of 
reperfusion.89 The opening of transition pore actually coincided with the rapid correction 
of the acidosis which occurred during the ischemic phase (figure 5).90  
The significance of the mPTP in I/R-induced cell death was first recognized by 
Hausenloy and Yellon with the use of the mPTP inhibitor—cyclosporine A (CsA).91 
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Despite the powerful immunosuppressive effects of CsA, it has potent inhibitory effects 
on the transition pore through modulating cyclophilin D (CypD), a key molecular 
component of the mPTP. Under the presence of high matrix Ca2+ concentrations, during 
reperfusion the CypD can modify the conformation of the inner mitochondrial membrane 
allowing for the formation of a large pore/channel and creating significant permeability 
transition.87, 92 Hausenloy et al demonstrated that CsA significantly reduced infarct size 
when given at the time of reperfusion in an isolated rat heart model.91 Similarly, using an 
in vivo rabbit model, a pharmacological ischemic postconditioning (IPOC) effect was 
demonstrated when CsA was given 1 min prior to reperfusion and a 50% reduction in 
infarct size was obtained.93 Additionally, the role of CypD-dependent mPTP in IPOC has 
been evaluated using transgenic mice lacking CypD.94 These mice developed smaller 
infarcts and could not be post-conditioned. This further suggests that lethal I/R injury is 
mediated by Ca2+ overload, conformational change of the transition pore by CypD and 
subsequent pore opening.  
 
D. Ischemic Preconditioning and Cardioprotection 
The search for infarct-sparing treatment spans nearly four decades when in 1971 
Braunwald and colleagues introduced a novel concept: measures designed to improve 
coronary perfusion or reduce oxygen demand as late as 3 h after an acute thrombosis 
might limit infarct size.95 
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Figure 6.  Reperfusion injury and mitochondrial-induced ROS production and apoptosis. 
	  
During reperfusion, there is an acute overload of Ca2+ ions within the cell as the cell 
attempts to compensate for the build-up of H+ ions during the ischemic phase. This 
triggers formation transition pores and increases ROS formation. This leads to loss of 
the mitochondrial membrane potential and cytochrome c, which triggers activation of 
apoptosis.  
 
Over the next 15 years, angioplasty became the only reperfusion therapy proven 
successful at limiting infarct size despite intense pre-clinical research with a number of 
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pharmacological agents in a variety of animal models. It wasn’t until 1986 when Murry et 
al discovered the phenomenon of IPC in a canine model of I/R.96 They discovered that 
several brief periods of left circumflex coronary artery occlusion prior to prolonged 
ischemia reduced infarct size by 75% when compared to canines subjected only to the 
prolonged ischemia.96 These brief periods of sublethal ischemia induced protective 
signaling mechanisms by which the myocardium became preconditioned to the 
subsequent ischemic insult. Interestingly years leading up to the discovery of IPC, 
clinicians noticed that patients with CHD, particular those presenting with unstable 
angina or acute AMI and had at least one or more prior episodes of angina had less 
chest pain, less ST-segment deviation on electrocardiogram (ECG), and smaller infarct 
sizes despite an overall increase in ischemic time.97 This clinical paradox became aptly 
termed the “warm-up phenomenon.” The exact etiology is still unknown, but one of the 
speculated mechanisms is thought to be through triggered activation of the 
preconditioning signaling pathways in the “at risk” myocardium. 
The protective effects of IPC occur in two distinct phases: an “early phase” that 
rapidly develops after an ischemic insult and dissipates within 2-3 h and a “delayed 
phase” which reappears about 24 h and persists for nearly 72 h.98 The major difference 
between these two phases is that the early phase is effective at limiting I/R injury and 
less effective at preventing post-infarction myocardial “stunning” or contractile 
dysfunction.99 From a cellular level, early IPC results in activation of transcription factors 
and results in compartmentalization, modification and translocation of existing 
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molecules and proteins.100 The delayed phase is less effective at limiting infarct size but 
helps dampen ischemia-induced stunning. Furthermore, in this delayed phase the 
cardioprotective effects are largely exerted by newly synthesized proteins that were 
activated for de novo synthesis during the early phase.100  
In 1991 Downey and colleagues discovered that IPC was in fact a receptor-
mediated phenomenon by reporting the adenosine A1 receptor acted as a trigger to 
protect the rabbit heart.101 Further research led to the conclusion that activation of any 
Gi-coupled receptor can trigger a preconditioned state and can work in parallel. 
Interestingly, blockade of one of these receptor types does not abrogate IPC but rather 
increases the threshold needed to trigger the preconditioning.100 Therefore adenosine 
and other endogenous autacoids such as opioids and bradykinin, all activate their 
respective receptor G-protein coupled receptor and trigger downstream cardioprotective 
signaling pathways which include: ERK1/2, phosphatidylinositol-3-kinase (PI3K)/Akt, 
PKC and PKG which can ultimately lead to the phosphorylation and inactivation of 
GSK3β.102 This inactivated form of GSK3β inhibits the opening of the mPTP, which 
plays a critical role in cardiomyocyte death. Other key mediators of cardioprotection are 
the ATP-sensitive potassium channels of which there are two types—the sarcolemmal 
(surface KATP channel) and mitochondrial (mitoKATP channel). First described in cardiac 
ventricular myocytes, their significance in preconditioning was initially shown by Gross 
and colleagues.103 Pharmacological mimetics that could open the KATP channel would 
protect the myocardium, whereas blockers of the channel abolished the 
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cardioprotection. Subsequently, it was found that the mitoKATP channels played a more 
significant role in IPC than the surface channels.  However as years of research carried 
on, we learned both channel types likely have some role in preconditioning. In fact, the 
most convincing data demonstrates that transgenic mice without functioning 
sarcolemmal KATP channels could not be preconditioned despite having completely 
intact mitoKATP channels.104  
 
E. Endothelial dysfunction 
 Vascular endothelial cells form the vascular endothelial layer and healthy cells 
play an important physiological role.105 They respond to maintain vascular integrity, 
regulate vascular tone and permeability, vessel wall inflammation and 
thromboresistance.106 Likewise, they can secrete a variety of vasoactive substances 
including vasodilators such as NO, prostacyclin (PGI2), and endothelium-derived 
hyperpolarizing factor along with vasoconstrictors such as endothelin-1 (ET-1) and 
thromboxane A2 (TXA2).107 Endothelial dysfunction is characterized by various 
functional alterations in the vascular endothelium that include an imbalance in the 
release of vasoactive substances, that can lead to thrombosis, vasospasm or impaired 
vasodilator responses; enhanced ROS generation, inflammation, apoptosis and adverse 
remodeling.107 Several mechanisms are implicated in the pathogenesis of endothelial 
dysfunction of which impaired NO bioavailability plays a pivotal role and is likely the 
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result of reduced NO production and its increased inactivation by ROS.107 Although 
considered the earliest marker of impaired vascular health, endothelial dysfunction is 
initially asymptomatic and it often precedes the development of atherosclerosis.106 In 
the insulin resistant patient, the endothelium is exposed to hyperglycemic conditions 
that activates an apoptotic process and leads to intimal denudation. Initially β1-intergrin 
cascade acts as the initial sensor for programmed cell death and initiates the apoptotic 
process.107 Upon integrin activation, p38 mitogen activated protein kinase (MAPK) and 
C-jun N-terminal kinase (JNK) are activated downstream, which lead to endothelial cell 
apoptosis. Likewise, flow stress can also initiate apoptosis through activation of the 
endoplasmic reticulum (ER) stress response and downregulation of vascular 
endothelial-cadherin, both of which activate caspase proteins.107 The end result is loss 
and detachment of endothelial cells into the plasma.  Recently McClung et al have 
shown that diabetic patients, irrespective of glucose control, have significantly higher 
levels of circulating endothelial cells.108 Moreover, it has been shown that endothelial 
derived microparticle levels are predictive of coronary artery lesions, lipid levels, 
hypertension, and duration of diabetes.109 Accordingly, as endothelial cells have limited 
ability for self-repair with low proliferative potential, an effective means of endothelial 
repair is necessary to re-establish vessel integrity and attenuate the pro-atherosclerotic 
process.107  
 Endothelial repair is accomplished through the contribution of circulating 
endothelial progenitor cells (EPCs) in both physiological and pathological conditions. 
	   	   P a g e 	   | 	   3 3 	  
	  
	  
EPCs are immature cells that can differentiate into mature endothelial cells and play a 
critical role in endothelial homeostasis and cardiovascular health.107 Recent data show 
that many different risk factors for CHD directly correlate with circulating EPCs and that 
higher EPCs portend a decrease in CV morbidity and mortality.110 Diabetic patients 
have less circulating EPCs than healthy controls and the progenitor cells they have 
display functional impairment such as reduced proliferation, adhesion, migration and 
incorporation into tubular structures.111 One explanation is the increased oxidative 
stress in diabetic patients that interferes with the interaction between the vascular wall 
and normal EPCs. In addition, angiogenic factors such as vascular endothelial growth 
factor (VEGF) and hypoxia inducible factor-1α (HIF-1α) are reduced in the diabetic 
patient whereas diabetic animal models have shown reduced mobilization of EPCs from 
the bone marrow after myocardial I/R injury.112 This data was supported as HIF-1α 
upregulation improved post-ischemic neovascularization in diabetes. Likewise, in an in 
vitro model, hyperglycemia through the production of ROS impaired proliferation, 
survival, and function of cultured EPCs with a concomitant decrease in NO production, 
however this could be corrected with insulin therapy.113  
 It is now well accepted that endothelial dysfunction is part of an interconnected 
pathological process of which long term vascular complications in the diabetic patient 
are often fatal. In the hyperglycemic setting, both reduced NO bioavailability and 
increased oxidative stress are key determinants compromising vascular health. 
Therefore therapeutics designed to improve both parameters would be an ideal dual 
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strategy. In addition, there is a remarkable amount of literature supporting EPCs central 
role in the development and progression of diabetic complications and data suggest the 
metabolic interventions that improve glucose homeostasis may also be able to improve 
vascular biology and EPC levels.  
 
i. Nitric oxide pathway and its dysfunction 
 
 Nitric oxide which has long been known as endothelium-derived relaxing factor 
was discovered in 1980s by Nobel laureates Ferid Murad, Louis Ignarro and Robert 
Gurchgott.114 Initially deemed a toxic air pollutant and pro-oxidant mediator, novel 
experiments and extensive studies carried out revealed NO to be one of the most 
ubiquitous biological substances within our physiological system. NO is known for its 
vital regulatory roles in vascular and metabolic health and in 1992 it was deemed 
“molecule of the year” by Science.115 Apart from its potent vasodilatory effects, it has 
powerful and important anti-thrombotic, anti-proliferative and anti-inflammatory features 
and today nitrate donor therapy is used for acute angina, CHF and pulmonary 
hypertension.116  
 Nitric oxide is produced by many different tissues through a five-step oxidation 
process of L-arginine to NO and L-citrulline by one of the 4 isoforms of NOS (iNOS, 
eNOS, neuronal NOS and mitochondrial NOS).117 The production of NO via eNOS can 
be manifested through two different pathways—either a receptor-dependent mechanism 
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or receptor-independent pathway which leads to elevated intracellular Ca2+ levels and 
Ca2+-calmodulin dependent activation of eNOS.118,119 Additionally, eNOS activity is 
increased upon phosphorylation at serine1177 mediated by the Akt pathway. More 
importantly, under basal conditions eNOS is kept in a tonic “inhibitory” state by being 
bound to caveolin-1 (Cav-1). Upon activation by stimuli, eNOS dissociates from Cav-1 
and efficient NO production occurs. Conversely, iNOS-mediated NO production can 
occur independent of a Ca2+-calmodulin mechanism and furthermore, iNOS expression 
has been shown to be upregulated in a number of cardiovascular diseases. Each NOS 
isoenzyme consists of two different domains, an oxygenase and reductase domain and 
coupling of the two domains is required for proper NO production.117 For NO synthesis, 
a number of co-factors are required such as O2, nicotinomide adenine dinucleotide 
phosphate (NADPH), tetrahydrobiopterin (BH4), flavin adenine dinucleotide (FAD) and 
flavin mononucleotide (FMN).118,120 Following release from an endothelial cell, NO 
diffuses to vascular smooth muscle where it can bind to sGC and it can increase cGMP 
levels. This induces smooth muscle relaxation, vasodilatation, and increases blood 
flow.53 In conditions where NOS becomes “uncoupled,” thereby becoming a monomer, 
molecular O2, as opposed to L-arginine, becomes the substrate for the NOS, which 
generates superoxide (O2-
⋅) anion instead of NO and increases cellular oxidant 
stress.117 
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 Nitric oxide is a highly lipophilic free radical with a short half-life, readily forms 
nitrogen oxides, and is extremely reactive which limit its bioavailability. However, NO-
containing compounds can serve as reservoirs of bioactive NO and thus can not only 
participate in NO-related reactions, but also travel to remote tissue via the circulation.117 
NO signaling occurs via one of 3 different mechanisms—via sGC activation, S-
nitrosylation in which NO covalently and reversibly forms S-nitrosothiol groups with 
reactive cysteine thiols, and through formation of peroxynitrite, can activate MAPKs. 
Most of its effects are mediated through S-nitrosylation in a cGMP-independent 
mechanism.121  
 The most important determinant of NO generation is blood flow, shear stress and 
pulsatile stretch.122 The laminar shear stress and dragging force exerted by fluid over 
the endothelial surface is a critical stimuli for endothelial NO release. Acutely, this leads 
to activation of eNOS and NO release for vasodilatation, which reduces the shear stress 
and chronically upregulates eNOS expression.122 In contrast low shear stress, turbulent 
blood flow, local shear gradients, stasis of flow, and rapidly changing flow disrupt 
endothelial cell function and endothelial derived NO production.117 In addition, NO acts 
as a counter measure against basal vasoconstrictors such as sympathetics, angiotensin 
II and ET-1 123. Angiotensin II potently stimulates vascular and leucocyte nicotinomide 
adenine dinucleotide (NADH) /NADPH and PDE thereby increasing cGMP hydrolysis 
and attenuating PKG-dependent kinase activity. Likewise, ET-1 is not only a potent 
vasoconstrictor, but is highly inflammatory, stimulates endothelial NADH/NADPH, which 
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increases oxidant stress and decreases vascular NO production via ET-A receptor 
binding.117  
 The impairment of NO bioavailability has been implicated in a number of 
cardiovascular diseases including pathophysiological processes associated with insulin 
resistance, hyperlipidemia and hypertension. Under physiological conditions, insulin 
stimulates NO production in endothelial cells, and insulin resistance disturbs 
intracellular signal transduction, which results in an attenuated PI3K-Akt cascade, 
decreased eNOS activation and subsequently NO bioavailability.117 In fact, Insulin 
sensitivity is enhanced directly through NO-cGMP-PKG signaling through inhibition of 
the small GTPase Rho/Rho Kinase with insulin-receptor substrate-1 (IRS-1). In normal 
conditions, NO reacts and scavenges O2-
⋅anion, thus effectively protecting the vascular 
tissue from oxidative stress and dampening the inflammatory response. 
 Both impaired NO bioavailability and dysfunctional NOS link vascular and 
metabolic disease and represent an early link between increased cardiovascular 
mortality in the diabetic patient. One theory for the overall decrease in NO in this patient 
population is the increased levels of the endogenous NOS inhibitor asymmetric 
dimethylarginine (ADMA).124 Similarly, given the overall increased oxidative stress in 
diabetics, BH4 is oxidized which uncouples NOS and leads to even higher levels of O2-
⋅ 
anion and reduces NO production by NOS.125 It has also been demonstrated that 
diabetic patients that have had an i.v. infusion of L-arginine had lower levels of NO 
	   	   P a g e 	   | 	   3 8 	  
	  
	  
formation than did normal controls.126 In addition to the reduced bioavailability of NO, 
the diabetic milieu impairs the anti-proliferative properties of NO.120 This occurs 
primarily through cGMP-dependent and independent pathways. In the cGMP dependent 
manner, activation of cGMP also leads to an increase in cyclic adenosine 
monophosphate (cAMP) and its downstream effector, protein kinase A (PKA) which 
results in reduced intracellular Ca2+ flux and attenuation of the proliferative MAPK 
cascade.120 In the cGMP independent pathway, NO indirectly limits polyamine formation 
necessary for DNA synthesis by inhibiting arginase and ornithine decarboxylase while it 
also upregulates Fas expression in VSMC which induces apoptosis.120 With the 
attenuated NO bioavailability, this pathway is interrupted and leads to VSMC 
hypertrophy. Furthermore, VSMC proliferation has been linked to augmented 
stimulation of the MAPK pathway by insulin receptor activation.127  
 Nitric oxide also has potent anti-thrombogenic properties, can be released from 
the endothelium and platelets, limits activation and aggregation of platelets through 
inhibition of the PI3K cascade, and suppresses platelet expression of adhesion 
molecules.128 Similarly, NO can react with O2-
⋅anion to form ONOO-, which can block 
production of the thrombogenic metabolite TXA2. Moreover, NO regulates and inhibits 
the upregulation of adhesion molecules on endothelial cells which would otherwise lead 
to leucocyte recruitment, adhesion, and migration and the initiation of plaque 
formation.120 The diabetic is known to have upregulated adhesion molecule expression, 
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circulating inflammatory cytokine levels with enhanced response to vascular injury 
primarily associated with enhanced insulin signaling through MAPK, as this pathway 
has also been shown to increase adhesion molecule expression.129  
 
F. Insulin and Insulin resistance 
 Insulin is a key hormone with a critical role in growth and development of various 
tissues and for the homeostasis of plasma glucose levels. It is secreted as pre-
proinsulin by the β-pancreatic cells as an inactive single precursor that directs its 
passage into vesicle cells.130 The proteolytic removal of the signal sequence results in 
the formation of pro-insulin. During periods of elevated plasma glucose levels and 
increased amino acid concentration, pro-insulin is secreted and converted to its active 
form, insulin, by various proteases.131 The active insulin molecule consists of an A and 
B chain that are held together by two disulfide bonds.131 The primary function of insulin 
is to stimulate glucose uptake into skeletal muscle and adipose tissue through 
increasing glucose transport, while reducing hepatic glucose production (via 
glycogenolysis and gluconeogenesis). Furthermore, it regulates lipid metabolism by 
inhibiting lipolysis within adipose tissue and increasing hepatic lipid synthesis.130, 131  
 Type II diabetes is a complex disease state resulting from altered insulin 
secretion combined with the resistance of specific target tissue to the effects of insulin, 
most notably liver, adipose tissue, and skeletal muscle. Insulin resistance was first 
described in 1936 by Harold Himsworth, a preeminent clinician who concluded that 
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diabetes could be distinguished into two different types—insulin-sensitive which 
appears to be caused by a deficiency in insulin levels, and the insulin-insensitive type, 
which was not due to any deficiency in circulating insulin levels.132 Today, insulin 
sensitivity is synonymous with the ability of insulin to mediate disposal of an infused 
glucose load and the more efficient this process, the more insulin sensitive the person. 
Therefore, the inefficient person is deemed to be insulin insensitive and to maintain 
normal or near-normal glucose levels, the body must secrete higher than normal levels 
of insulin to compensate—a state of hyperinsulinemia.133 In 1988, it became evident 
that patients with compensatory hyperinsulinemia had associated complications and 
that this state contributed significantly to the development of CHD. Likewise, it was 
shown that many other abnormalities were persistently associated with insulin 
resistance in addition to glucose intolerance and hyperinsulinemia, such as decreased 
HDL, increased plasma triglyceride concentrations and hypertension.134 This cluster of 
pathologies became known as metabolic syndrome X and was associated with a 
significant risk of CHD. In adipose tissue, insulin decreases lipolysis thereby reducing 
free-fatty acid (FFA) efflux from adipocytes; in the liver, insulin inhibits gluconeogenesis 
by inhibiting key enzyme activities, while in the skeletal muscle it predominantly induces 
glucose uptake by stimulating glucose transporter 4 (GLUT4) translocation to the 
plasma membrane.135 In insulin resistance, FFA concentrations and the increase in fat 
accumulation significantly attenuate insulin-mediated glucose uptake in the skeletal 
muscle and glucose production within the liver. Together with impaired insulin secretion 
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and the resistance of peripheral tissue to the affects of insulin leads to type II diabetes 
mellitus.  
 The insulin signaling cascade is quite complex and upon insulin binding to the α 
subunit of its specific receptor, which belongs to a member of receptor tyrosine kinases, 
the inhibition of tyrosine autophosphorylation by the β subunit is released.136 
Accordingly, the receptor is autophosphorylated at specific tyrosine residues. The 
activated insulin receptor directly phosphorylates IRS-1 to -4 on specific tyrosine 
residues with IRS-1 and IRS-2 being the most important and crucial for glucose 
transport.137 The tyrosine phosphorylated IRS proteins then act as specific binding sites 
for molecules that contain the Src-2 homology-2 (SH-2) domain such as pyruvate 
dehydrogenase lipoamide kinase isoenzyme 1 (PDK1), SH2 domain containing protein 
tyrosine phosphatase (SHP2) and growth factor receptor bound protein-2 (GRB-2)/ 
mammalian Son of Sevenless homolog (mSOS), a guanine nucleotide exchange 
factor.138 Upon binding to the tyrosine phosphorylated-IRS, they form signaling 
complexes to mediate further downstream signaling of which the PI3K-Akt cascade is 
mostly responsible for the action of insulin, glucose uptake, and inhibition of 
gluconeogenesis.137, 138 PI3K is composed of a p85 regulatory subunit which binds to 
IRS proteins and a catalytic subunit, p110.138 This allows for phosphorylation of its 
substrate phosphatidylinositol(4,5)P2 (PIP2) on the 3’ position of the inositol ring to 
generate phosphatidylinositol(3,4,5)P3 (PIP3). Then the secondary messenger, PIP3, 
recruits serine kinases PDK1, Akt and PKC to the plasma membrane via their PH 
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domain and upon their activation results in GLUT4 translocation to the membrane, 
glycogen synthesis via GSK3 phosphorylation, and lipogenesis by upregulation of the 
fatty synthase gene.136 In addition to activating the PI3K-Akt pathway, insulin can also 
activate the MAPK ERK as means to regulate gene expression, control cell growth and 
cell differentiation.135 In contrast to activating tyrosine phosphorylation of IRS, the serine 
phosphorylation on critical serine sites will inhibit insulin signaling. Specific serine 
kinases that can phosphorylate IRS-1 include inhibitor of nuclear factor κ-B kinase β 
(IKK-β), JNK-1, and other members of the MAPK.139,140 Insulin is capable of activating 
JNK and other serine kinases and this is seen as a possible negative feedback 
mechanism for the signaling cascade. At the molecular level, there are many other 
mediators especially within the inflammatory system which may play a role in the 
inhibitory cross-talk for insulin signaling. These include suppressor of cytokine signaling 
(SOCS) 1 and 3, which during inflammation, are induced by interleukin (IL)-6 and lead 
to ubiquitinylation and degradation of the IRS proteins.141,142  
 The pathophysiological effects of insulin resistance are multifaceted and complex 
and can vary from tissue to tissue. Notably, once compensatory hyperinsulinemia is 
established to maintain near normal glucose levels, there is increased sodium retention 
and over-activation of the sympathetic nervous system.143 This phenomenon helps 
contribute to the increased prevalence of hypertension in this patient population.  
Furthermore, insulin signaling plays a role in both NOS and ET-1 expression as shown 
in isolated endothelial cells from mice lacking vascular endothelial insulin receptors. 
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While the exact relationship remains unclear, it is evident from the literature that insulin 
resistance plays a role in diabetic-induced endothelial dysfunction and remains an 
important predictor of CHD and stroke.  
 
i. Hypertriglyceridemia  
 
 In 1967, it was first demonstrated that there is a strong association between 
insulin resistance, the compensatory hyperinsulinemia and elevated fasting plasma 
triglyceride levels.144 Further research led to the discovery of the potential mechanism 
behind this relationship. Hyperinsulinemia was shown to trigger hepatic very low-density 
lipoprotein (VLDL)-triglyceride secretion, which in turn increases plasma triglyceride 
levels.145 It is postulated that in the insulin-resistant state, the liver is resistant to the 
effects of insulin with regard to lipoprotein metabolism and accordingly cannot inhibit 
VLDL-triglyceride secretion.146 In fact, acute infusion of insulin has been shown to 
directly suppress hepatic VLDL-triglyceride secretion in addition to causing a substantial 
decrease in adipose tissue lipolysis.147  
 
G. Obesity and Inflammation 
 According to WHO, obesity and metabolic syndrome is the fifth leading cause of 
death worldwide and as of 2008, there were approximately 1.4 billion overweight adults 
globally of whom at least 200 million are clinically obese.148 Diabetes and obesity have 
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been considered at least in part to be inflammatory conditions, with adipose tissue being 
the first organ to be affected.149 The primary etiology for obesity-induced inflammation is 
not completely understood, however one potential basis for the initiation of inflammation 
in obese individuals may be ER stress. Excess nutritional intake and obesity lead to ER 
stress within the liver and adipose tissue secondary to excess lipid accumulation and 
dysregulated energy metabolism.150 The ER stress activates the “stress response 
signaling network” known as unfolded protein response (UPR), which activates 
protective pathways such as apoptosis and inflammatory cascades and is an adaptive 
response of cells to a large metabolic load.151 The UPR occurs through three different 
transmembrane molecules which transmit the ER stress signal to the nucleus through a 
number of cytoplasmic signaling molecules and kinases with the downstream activation 
and transcription of pro-inflammatory genes.152 During ER stress, the protein 
kinase/endoribonuclease inositol requiring protein-1 (IRE1), a key transmembrane 
protein, initiates non-spliceosomal splicing of the mRNA transcription factor X-box 
binding protein-1 (XBP-1) that controls protective mechanisms to ER stress. 
Accordingly, IRE1 also can induce the inflammatory cascade by activating IKK-β, two 
different MAPKs—p38 and JNK, and the key inflammatory transcription factor, nuclear 
factor kappa B (NF-κB). The second molecule involved is the UPR is the membrane 
localized transcription factor, activating transcription factor-6, that is cleaved in response 
to ER stress and once cleaved, enters the nucleus to activate transcription of chaperone 
genes and further augment NF-κB transcription.153 The final molecule is PKR-like 
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eukaryotic initiation factor 2α kinase, which inhibits protein translation by 
phosphorylating transcription initiation factor eIF2α. This activates the alternative 
translation of activating transcription factor-4, which induces the production of 
inflammatory cytokines, stimulates NF-κB transcription, and inhibits translation of the 
NF-κB inhibitor, I kappa B alpha (IκBα).153 The ultimate goal of UPR is to re-establish 
ER homeostasis and facilitate proper protein folding with the assistance of chaperone 
proteins, arrest further protein synthesis and degrade mis-folded proteins. If the ER 
function does not recover, UPR will stimulate apoptosis signaling pathways for 
programmed cell death. Obesity-induced ER stress occurs secondary to metabolic flux, 
increased lipid stores, lipogenesis, increased insulin production from β pancreatic cells, 
and gluconeogenesis and all have a negative impact on cells causing ER stress. In β 
pancreatic cells, the excessive demand and ER stress for the cells to produce insulin in 
the insulin resistant state, ultimately leads to the decrease in insulin synthesis and β-cell 
apoptosis.152 In addition it leads to IRS serine phosphorylation and inhibition of insulin 
signaling. The ER stress hypothesis is supported by experiments using XBP-1+/- mice in 
which the protective effects towards ER stress are significantly attenuated and these 
mice are especially prone to insulin resistance.150 Moreover, use of chaperones to 
further reduce ER stress restores insulin sensitivity in obese mice.154 During in vitro 
experiments, ER stress was shown to downregulate expression of GLUT4 in cultured 
adipocytes 155 and these data support the notion that ER stress affects insulin signaling, 
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likely through activating inflammatory signaling pathways in target cells, particularly 
adipocytes, which contributes to insulin resistance.  
Inflammatory cytokines, chemokines and adhesion molecules have recently 
gained significant attention as potential therapeutic targets.156 Likewise, in obese 
individuals it is not only inflammation, but also oxidative stress within the adipose tissue 
the leads to insulin resistance.157,158 In addition, inflammation plays a central role in 
vascular disease, from plaque inception to progression and destabilization, which 
represents a significant paradigm shift from the old idea that vascular disease and 
atherosclerosis is a problem of lipid accumulation and oxidized cholesterol. The 
association of inflammation with obesity and insulin resistance dates back to 1993 when 
Hotamisligil et al found that adipocyte expression of the pro-inflammatory cytokine 
tumor necrosis factor (TNF)-α was significantly increased in db/db mice.159 TNF-α also 
effects insulin signaling through phosphorylation of S6K1 (p70S6K), which impairs the 
normal insulin response through serine phosphorylation of IRS-1 and inhibition of 
tyrosine kinase activity of the insulin receptor in adipocytes and hepatocytes.160 Another 
explanation that has recently emerged is that mice lacking a key phosphatase, 
phospho-tyrosine protein phosphatase 1B (PTP1B), were protected from TNF-α induced 
insulin resistance. This tyrosine phosphatase has been shown to tyrosine 
dephosphorylate and deactivate IRS-1 to balance the actions of the kinases involved in 
insulin signaling. Adipose tissue inflammation via high-fat diet and TNF-α, induced 
expression of PTP1B in adipose tissue, muscle, liver and hypothalamic arcuate nucleus 
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occurs through a mechanism involving NF-κB.161 Interestingly, sirtuin1 (SIRT1) was 
shown to inhibit PTP1B through repression at the chromatin level and improves insulin 
sensitivity whereas direct inhibition with a PTP1B inhibitor also improved insulin 
resistance and obesity-related complications162, 163 (figure 5).  
Recently, more and more evidence has emerged that obesity is associated with 
inflammation that is causally involved in the development of insulin resistance and 
diabetes. Obese patients have increased levels of hs-CRP, TNF-α, IL-6, monocyte 
chemotactic protein (MCP) -1 and IL-8 and leptin.164 Genetically altered mice lacking 
TNF-α, or the TNF-α receptor 1 gene were shown to be protected from insulin 
resistance both in diet induced obesity and a genetic obesity (ob/ob) model.165 
Experiments using cultured murine adipocytes confirmed that TNF-α stimulates IKK-β 
and SOCS3, both of which negatively affect the insulin signaling cascade. Likewise, the 
obesity-induced IL-1β, also plays an important negative role in the signaling pathway.   
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Figure 7.  Obesity-induced inflammation and disruption of the insulin-signaling cascade. 
	  
Inflammation induced by obesity leads to downstream disruption of the insulin signaling 
pathway. Excess nutrition leads to elevated lipids, free-fatty acids (FFA), long-chain 
fatty acids (LCFA) and endoplasmic reticulum (ER) stress. This causes activation of 
(protein kinase C [PKC]-θ, c-Jun-N kinase [JNK], inhibitor of κ B α [IκBα]), which 
activate inflammation in adipose tissue. Likewise, obesity itself is an inflammatory 
disorder, which increases levels of tumor necrosis factor-α, interleukin (IL)-1β, IL-6. This 
leads to decreased phosphorylated Akt and increase in serine phosphorylation of the 
insulin receptor substrate-1 (IRS-1), which inhibits effective insulin signaling.  
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One study showed that obese individuals with detectable levels of IL-1β and 
elevated IL-6 concentration had an independent risk (3.3-fold increase) of developing 
type II diabetes as compared to those with only elevated IL-6 levels.166 In fact, treatment 
with an IL-1β antagonist improved blood glucose levels, pancreatic β cell function, and 
inflammatory markers IL-6 and TNF-α.167 Using 3T3-L1 and human adipocytes, chronic 
treatment with IL-1β, induced insulin resistance through IRS-1 downregulation and 
decreased IRS-1 tyrosine phosphorylation.168   
The signal transduction induced by endothelial derived NO involves the 
downstream activation of sGC and cGMP within the VSMC, which activates its effector, 
the cGMP-dependent kinase. This kinase can then phosphorylate vasodilatory 
stimulated phosphoprotein (VASP) at serine239. It has been recently shown that 
disruption of VASP phosphorylation or eNOS signaling in this pathway leads to adipose 
tissue inflammation, which can be attenuated by use of PDE-5 inhibitors and that this 
leads to an attenuated inflammatory response.169  
 
H. Oxidative Stress and Reactive Oxygen Species 
Oxidative stress is a major risk factor in the onset and progression of insulin 
resistance to diabetes mellitus.  Similarly, ROS and the cellular redox state have been 
increasingly shown to play a significant role in affecting a variety of biological signaling 
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pathways.170 ROS are formed by the reduction of molecular oxygen or oxidation of 
water to yield superoxide (O2-
⋅) anion, hydrogen peroxide (H2O2) and hydroxyl radical 
(⋅OH). Within various biological tissues, the primary source of ROS is derived from the 
mitochondria and NADPH oxidase (NOX).170 In some situations, moderate amounts of 
ROS are crucial for normal physiological processes, however in significant quantities 
they are capable of cellular damage to DNA, proteins, membranes and lipids. Despite 
many beneficial cardioprotective effects, NO can be potentially detrimental when 
contributing to the formation of reactive nitrogen species (RNS).170 The NO radical 
(NO⋅) is formed from NOS and can react with O2-
⋅ to form peroxynitrite (ONOO-) which 
is an extremely potent oxidizing agent and is capable of severe cellular damage and 
oxidative stress. When the cellular capacity and efficiency to scavenge and remove 
ROS or RNS is reduced and/or there is a gross overproduction, the end result is 
oxidative stress.  
The main redox buffer within the cell is glutathione and using the Nerst equation 
allows the intracellular redox potential to be determined. Increases in ROS leads to an 
imbalance of the cellular oxidation state thus altering the redox balance.171 Several 
studies have shown that the diabetic has extremely high levels of ROS and this 
abnormal state leads to the long term complications and progression associated with 
the disease.172 Both hyperglycemia and increased FFA intake are associated with 
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oxidative stress and activation of stress pathways such as NF-κB, JNK and p38 
MAPK.173 This leads to an alteration of insulin signaling and potentiation of the 
inflammatory cascade (figure 8).  
There are numerous studies which support that hyperglycemia in diabetic 
patients causes an increase in ROS production and a concomitant decrease in 
antioxidant defenses. Likewise, as a marker of oxidative stress it can cause membrane 
lipid peroxidation.174 In one study, investigators showed that blood glucose 
concentrations directly correlated with the degree of erythrocyte lipid peroxidation.174 
Moreover, the same group went on to show that control of the plasma glucose levels in 
streptozotocin-diabetes induced rats lead to a decrease in membrane lipid 
peroxidation.175 The key sources of ROS generation within the vasculature are the 
electron transport chain (ETC), NOX, and eNOS uncoupling. In 2001, Brownlee and 
colleagues developed the “unifying hypothesis” of which the major premise is that in the 
diabetic, ROS produced within the mitochondria initiates the development of nearly all 
diabetic complications.176 
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            Figure 8.  The effects of oxidative stress on insulin resistance. 
	  
In obesity and conditions of hyperglycemia, there is a significant increase in oxidative 
stress. This leads to activation of serine/threonine (Ser/Thr) kinases, which 
phosphorylates the insulin receptor and prevents effective insulin signaling. Similarly, 
the mitochondria produce ROS, which leads to an increase in uncoupling protein-2 
(UCP-2). Mitochondrial dysfunction ensues which decreases ATP and fatty acid 
oxidation. Diacylglycerol (DAG) production increases, which can also activate the 
Ser/Thr kinases blocking insulin signaling at the IRS.    
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It further states that ROS generated within the mitochondria migrate to the 
nucleus, cause DNA damage that results in activation of poly (ADP-ribose) polymerase-
1 (PARP-1), and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) which after 
undergoing ADP-ribosylation by PARP-1, is inactivated. The activation of PARP-1 by 
DNA damage promotes NADPH depletion and further ADP-ribosylation of other 
proteins.177 The polyol pathway is a mechanism in which glucose is reduced to sorbitol 
in an NADPH-dependent manner by the enzyme aldose reductase. Sorbitol is then 
oxidized to fructose by sorbitol dehydrogenase along with the reduction of NAD+ to 
NADH.176 Under normoglycemia, aldose reductase has a low affinity for glucose but 
under elevated glucose conditions, it has a higher than normal production of sorbitol 
and therefore an overall decrease in NADPH.176 
The subsequent decline in GAPDH activity leads to a rise in glycolytic 
intermediates and is the primary means of hyperglycemic-induced injury as these 
intermediates activate various pathways and mechanisms including: the polyol pathway 
flux, hexosamine pathway, activation of the PKC cascade, intracellular formation of 
AGEs, and through an overproduction of ROS via the mitochondrial ETC 176 (figure 9).  
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Figure 9.  Unifying hypothesis of ROS-induced diabetic complications. 
	  
Brownlee’s unifying hypothesis of ROS-induced diabetic complications hinges around 
increased mitochondrial ROS production, which migrates to the nucleus to cause DNA 
damage. This causes PARP-1 activation and ADP-ribosylation of GAPDH and leads to 
an increase in glycolytic intermediates. This shuttles the intermediates into a number of 
pathways leading to hyperglycemic-induced injury.   
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groups of proteins.178 The Schiff’s base then forms a more stable ketoamine in the form 
of an Amadori product, which undergoes autoxidation to form reactive dicarbonyl 
intermediates such as 3-deoxyglucose, glyoxal and methylgloxyl.179 These 
intermediates undergo further chemical rearrangements until the final irreversible AGE 
is formed.179 The AGE is noted to signal through the receptor for AGE (RAGE). One of 
the primary consequences of ligand-RAGE binding is activation of the NOX system and 
generation of ROS which then activates the pleiotropic transcription factor NF-κB 
causing pathological changes in gene expression.176 AGEs also play a significant role in 
failure of adequate angiogenesis as hyperglycemic conditions induces a decrease in 
transactivation by the transcription factor HIF-1α which is responsible for mediating the 
hypoxia stimulated increase in VEGF and eNOS within endothelial precursor cells within 
the bone marrow.178 Likewise, AGE binding to its receptor within endothelial cells was 
shown to alter expression of several genes including thrombomodulin, tissue factor and 
vascular cell adhesion molecule (VCAM)-1 thus increasing adhesion of inflammatory 
mediators to endothelial cells and inducing a pro-coagulant state.176, 178  
Protein kinase C has various isoforms and is capable of phosphorylating a 
number of target tissues. Its function is largely dependent on Ca2+ ions and 
phosphotidylserine and its function can be enhanced by diacylglycerol (DAG).176 During 
hyperglycemia, DAG synthesis is significantly enhanced from glucose via triose 
phosphate secondary to the inhibition of the glycolytic enzyme GAPDH. The resulting 
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increase in PKC activity (β and γ isoforms) activates p38α MAPK and subsequently the 
protein tyrosine phosphatase, SH-2.180, 181 In addition, PKC signaling can induce 
oxidative stress through decreasing NO bioavailability and altering the prostanoid profile 
characterized by an increase in TXA2 and a reduction in PGI2.182 Further activation of 
NOX by TXA2 can uncouple eNOS leading to increases in intracellular ROS 
production.183 Likewise, elevated glucose can activate PKC inducing VEGF, TGF-β1, 
fibronectin and type IV collagen, which has been implicated with overexpression of 
plasminogen activator inhibitor-1 (PAI-1), a fibrinolytic inhibitor.184   
Fatty acid oxidation is another pathway that contributes to oxidative stress and 
vascular complications in hyperglycemia and insulin-resistance. Known as the 
hexosamine pathway flux, an influx of fructose into this cascade whereby fructose-6-
phosphate is diverted from glycolysis to provide the necessary substrate for the rate-
limiting step, glutamine:fructose-6-phosphate amidotransferase (GFAT).181,185 GFAT 
then converts fructose-6-phosphate into glucosamine-6-phosphate, which can be 
converted into uridine diphosphate (UDP)-N-acetylglucosamine.181 Then specific O-
linked aceytlglucosamine transferases use O-linked acetylglucosamine to modify, in a 
post-translational manner, serine/threonine residues on various proteins within the cell. 
The resultant increase flux through the hexosamine pathway leads to upregulation of 
key genes such as TGF-α, TGF-β1, and PAI-1.181,184 Additionally, this pathway may play 
a role in cardiomyocyte dysfunction and the development of cardiomyopathy as 
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increases in nuclear O-linked acetylglucosamine reduces sarcoplasmic reticulum Ca2+ 
ATPase 2a mRNA levels and protein expression and could impair β-agonist induced 
inotropy.186   
The majority of ROS within the physiological system is produced by the 
mitochondrial ETC.  In this process, electrons from NADH and FADH2 produced during 
glucose and fatty acid synthesis are used to create an electrochemical gradient 
sufficient for the production of ATP.187 The rate of oxidative phosphorylation is dictated 
by energy demands of the cell and as cellular demands increase, production of NADH 
and FADH2 must also increase for adequate ATP production. While normal function of 
the ETC is to produce ATP, it also serves as a source for O2-
⋅ formation.187 The primary 
sources for “electron leak” to oxygen occurs at complex I (NADH-CoQ reductase) and 
complex III (CoQH2-cytochrome c reductase) whereas in the heart and lung tissues, 
complex III appears to be the primary source of O2-
⋅ formation.181 
 The mitochondria however are equipped with an antioxidant defense mechanism 
to protect against the lethal effects of ROS. Within the intermembrane space is the 
cytosolic superoxide dismutase 1 (SOD1) also known as Zn,Cu-SOD and within the 
mitochondrial matrix is superoxide dismutase 2 (SOD2) also known as Mn-SOD, and 
both are capable of rapidly catalyzing the formation of O2-
⋅ to hydrogen peroxide 
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(H2O2).181 Hydrogen peroxide can readily diffuse across membranes and can be further 
degraded by antioxidants such as catalase, peroxiredoxins (Prx1, Prx2) and glutathione 
peroxidases (Gpx1-4).181   
Several studies have recently shown that mitochondrial dysfunction in genetic 
diseases correlates with a propensity to develop insulin resistance.188 Similarly, the 
oxidative capacity of a cell correlates with the number and density of mitochondria and 
relates to the reduction in expression of mitochondrial proteins involved in mitochondrial 
biogenesis and ATP production.189 A reduction in fatty acid oxidation by the 
mitochondria caused by either a decrease in mitochondrial biogenesis or dysfunction, 
leads to increased acyl-CoA and DAG. This in turn activates stress-induced 
serine/threonine kinase activity which inhibit glucose transport.189 According to 
Brownlee’s unifying hypothesis, hyperglycemia mediated increases in reducing 
equivalents NADH and FADH2 enhances flux through the ETC and increases the 
mitochondrial membrane potential (Δψm) which partially inhibits flux through complex 
III.176 This allows diversion of electrons from a reduced Coenzyme Q to O2 thus forming 
O2-
⋅ anion.  Rosca et al recently published data supporting this hypothesis in that 
hyperglycemia led to a ROS-dependent partial inactivation of complex III and 
downregulation of genes encoding for complex III.190 Likewise, oxidative stress can 
cause an increase in uncoupling protein-2 (UCP-2), a protein that upon activation, 
allows for protons to leak across the mitochondrial membrane hence contributing to the 
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dissipation of the Δψm.191 A number of animal and in vitro models have shown that 
UCP-2 is a negative regulator of glucose-stimulated insulin secretion.192 In a transgenic 
diabetic model, UCP-2-/- mice had improved pancreatic β-cell function with improved 
insulin secretion despite being on a high fat diet.193 Likewise, in vitro models have 
confirmed these findings as cells subjected to hyperglycemic conditions demonstrated 
significant elevations of UCP-2 expression.194 The elevated risk of developing CAD in 
obesity, insulin resistance is caused, at least in part, by mitochondrial ROS production 
from FFA and antioxidant inactivation by ROS. 
Endothelial nitric oxide synthase is an enzyme made up of two separate 
domains, a reductase domain which contain co-factors FAD, FMN, and NADPH and an 
oxidase domain containing a heme-active site.195 It is a calcium-dependent flavoprotein 
which catalyzes the oxygen dependent oxidation of L-arginine to form NO. In normal 
conditions, NADPH oxidation generates an electron, which is transferred to FAD and 
then FMN and finally the oxidase domain for NO production.195 In eNOS uncoupling, 
NADPH oxidation becomes “uncoupled” from the oxidation of L-arginine and electrons 
flow directly from the flavoproteins to molecular oxygen to form O2-
⋅. The most common 
cause for is low levels of the cofactor BH4, as it serves to stabilize the dimeric structure 
of the enzyme and facilitates formation and stabilization of the Fe2+-O2 intermediate.196 
During hyperglycemia, higher than normal levels of ONOO- oxidizes BH4 to BH2. 
Likewise, eNOS uncoupling plays a key role in reducing vascular tone and leading to 
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the development of micro- and macro-vascular complications associated with 
diabetes.197  
Similar to NOX, xanthine oxidoreductase is another key enzyme capable of 
forming oxidative stress.  It is a ubiquitous enzyme and exists in two different forms—
xanthine dehydrogenase, which catalyzes the oxidation of hypoxanthine to xanthine 
using NAD+ as an electron acceptor, and xanthine oxidase, which is formed via 
oxidation of sulfhydryl residues or proteolytic cleavage of the parent enzyme.195 
Xanthine oxidase serves as an important source of oxidative stress during I/R injury and 
can also catalyze the oxidation of hypoxanthine to xanthine.198 In a study on diabetic 
animals, higher than normal levels of xanthine oxidase were found in the systemic 
circulation and ROS levels were significantly attenuated in aortic rings after treatment 
with the xanthine oxidase inhibitor, allopurinol.198,199  
In summary, ROS are involved in a number of pathological processes and the 
“unifying hypothesis of diabetes” provides an explanation and a link between ROS, 
mitochondrial dysfunction, oxidative stress and diabetic complications. Hyperglycemia-
induced glycolytic flux, which is inhibited, subsequently has its intermediates diverted to 
pathological pathways such as the PKC cascade, hexosamine pathway, AGE formation 
and polyol pathway all of which serve as critical mechanisms behind ROS and oxidative 
stress-induced vascular injury. Likewise, mitochondrial O2-
⋅ generation leads to cell 
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death, and PKC-γ activation by NOX upregulation—one of the critical mechanisms 
behind diabetic oxidative-stress induced complications.  
 
I. MicroRNAs  
MicroRNAs (miRs) are a large class of phylogenetically conserved, non-coding 
single-stranded RNA molecules of 19-25 nucleotides that negatively regulate gene 
expression by base pairing with the 3’ untranslated region (UTR) of messenger RNA 
(mRNA), and inducing mRNA degradation or translational inhibition.200 Once considered 
simple by-products of mRNA transcription, the first animal miR was described in 1993 
as a regulator of developmental timing in Caenorhabditis elagans.201 MiRs that bind to 
mRNA targets imperfectly regulate their target gene at the protein translation level 
whereas perfect miR-to-mRNA binding induces target mRNA cleavage. Based on new 
computational algorithms, approximately 60% of human transcripts are potentially 
regulated by miRs as they contain miR binding sites within their 3’ UTR.202 MiRs are 
transcribed as precursor mRNAs from intergenic, intronic or polycistronic genomic loci 
by either RNA polymerase II or RNA polymerase III. This forms the primary miRNA, also 
known as pri-miRNA, and subsequently forms a stem-loop structure that is cleaved and 
further processed by the enzyme Drosha and its cofactor Pasha.202 In the non-canonical 
pathway, miRs are generated directly through splicing of introns to form hairpin 
structures upon refolding. These pre-miRs are then transported out of the nucleus by 
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exportin 5 and a RAN-GTP-dependent process to the cytosol where they are processed 
further by Dicer and transactivation-response RNA binding protein RNAse III enzyme 
complex to form mature double-stranded 22-25 base pair miRNA. Argonaute proteins 
then facilitate the unwinding of the miR duplex to allow incorporation of the miR-
targeting strand into the argonaute-containing RNA-induced silencing complex (RISC). 
This subsequent complex, RISC-miR assembly, can then be guided to its target 
sequence in mRNA to become a “post-transcriptional regulator.” The recognition of the 
target is primarily driven by the Watson-Crick base-pairing of nucleotides 2-8 in the 
mature miR which is termed the seed sequence, to the target sequence within the 3’ 
UTR of the mRNA. Further base-pairing leads to additional affinity and efficiency.  A 
single miR can potentially bind to more than 100 target mRNAs and multiple miRs can 
cooperate to fine tune the expression of a single transcript. Although this area of 
research has only just begun, the deregulation of miR biogenesis and function has 
already shown to play a critical role in a variety of physiological and pathophysiological 
processes especially in cardiovascular diseases and the metabolic syndromes such as 
insulin resistance, lipid dysmetabolism and obesity.203  
 
i. MicroRNAs in Cardiovascular Diseases 
Microarray studies have identified specific miRs that are upregulated and/or 
downregulated in specific pathological conditions such as vascular inflammation and 
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include: miR-126, miR-17, miR-92a and miR-155. In a recent study, each of these 
inflammation-associated miRs were significantly downregulated in patients with IHD 
when compared to healthy controls, whereas the cardiac-muscle enriched miR-133a 
and miR-208a were both significantly higher in patients with CHD.203 
One of the first miRs identified to have a role in I/R was miR-1 because it is 
preferentially expressed in adult cardiomyocytes and skeletal muscle.  MicroRNA-1 is 
involved in cardiac development and heart disease and regulates a number of key 
functions.200 These include: apoptosis through targeting synthesis of HSP60, HSP70 
and Bcl-2, and arrhythmogenesis by targeting the KCNJ2 and GJA1 genes.204 The 
KCNJ2 gene encodes kir 2.1, a subunit of the potassium ion channel, whereas the 
GJA1 gene encodes connexin43, a major component of the gap junction. Moreover, 
decreased expression of kir2.1 and connexin-43 delays membrane repolarization and 
conduction, thereby increasing the risk of fatal arrhythmias.205-208 In two different rat 
models, miR-1 was found to be significantly upregulated in response to reperfusion 
injury and acute MI.207,209 Likewise, oxidative stress and subsequent miR-1 upregulation 
decreases cardioprotective HSPs including: HSP60 and HSP70. In H9c2 cells, 
overexpression of miR-1 augmented H2O2-induced apoptosis whereas inhibition of miR-
1 conferred resistance of cells to H2O2.206  
MicroRNA-126 may play a critical role in AMI. The survival rate after in vivo I/R 
injury in miR-126-/- mice was significantly reduced as compared to the wild-type.210 Our 
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lab has previously evaluated the induction of miRs in response to IPC. We induced IPC 
with short bursts of global ischemia (2 bursts of 30 sec ischemia followed by 90 sec 
reperfusion) in a Langendorff isolated perfused heart model and found a significant 
induction miR-1, miR-21 and miR-24.211 To determine a causal relationship between 
IPC-induced endogenous miRs and cardioprotection, pools of extracted miRs were 
taken from non-preconditioned and preconditioned hearts and directly injected in vivo 
into the risk zone of the LV wall in mice. Forty-eight hours later, these mice were 
subjected to in vivo I/R injury. We demonstrated that the IPC-derived miR-injected 
group had a cardioprotective phenotype with significantly smaller infarcts compared to 
saline treated or non-IPC-derived miR injected group (18.8±2.5 vs. 37.5±2.2 vs. 
39.3±2.3%, p<0.05; n=6). It is also noteworthy that there was a significant upregulation 
of eNOS protein (92±8.1%), HSP transcription factor-1 (42.7±3.0%) and HSP70 (102.3± 
8.9%), 48 h after treatment with miR derived from IPC hearts.  
In a study by Dong et al, it was shown that miR-21 is upregulated in the risk-area 
after I/R injury and is downregulated within infarcted myocardium.202 They found that 
IPC abrogated the downregulation of miR-21 in the infarcted area whereas miR-21 
overexpression leads to reduced apoptosis, smaller infarct sizes, and improved LV 
remodeling at 2 weeks. The mechanism of miR-21 cardioprotection has recently been 
elucidated  and found to be downstream of the PI3K-Akt signaling cascade. Sayed et al 
have demonstrated that miR-21 is a downstream effector of Akt which upon 
phosphorylation, mitigates apoptosis.212 Transgenic mice lacking miR-21, showed Akt 
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mediated suppression of Fas ligand (a key activator in the apoptosis cascade) and 
abrogated caspase-8 activity. This provided direct evidence that Akt-mediated 
antiapoptotic effect on Fasl and caspase-8 may be directly mediated through miR-21.  
In a study by Zhang et al, showed that GATA-4, a key transcription factor in the 
heart, could activate miR-144/451. Using a cardiomyocyte model of SI/RO, they 
demonstrated that individual expression of miR-144 or miR-451 augmented cell 
survival, which then could be further improved upon by overexpression of either miR. 
Congruent with these findings, knock-out of either miR revealed attenuated cell 
survival.213 Conversely, miR-320 has been shown to be downregulated in mouse hearts 
after I/R Injury and overexpression enhances cell death and apoptosis in isolated 
cultured rat cardiomyocytes subjected to SI/RO.214 Moreover, genetically engineered 
mice with cardiac-specific overexpression of miR-320 have increased infarct size and 
apoptosis after I/R injury whereas knockdown of miR-320 with use of an antagomir led 
to a significant reduction in both infarct size and apoptosis. It is proposed that miR-320 
exerts its effect by downregulating HSP20, a protein known to protect the myocardium 
against I/R injury, thus indicating HSP20 as a possible putative target of miR-320.215 In 
a recent study by Wang et al, miR-499 was shown to inhibit apoptosis and infarct size 
induced by anoxia and coronary ischemia through mechanisms involving the apoptotic 
pathway including p53, cacineurin, and Drp1.216 They went on to show that an 
antagomir of miR-499 could produce the opposite effect and increase apoptosis and 
infarct size. Hullinger et al showed that miR-15 is significantly upregulated 24 h after 
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ischemic injury in the infarcted region and increased cardiomyocyte apoptosis.217 Using 
locked nucleic acid (LNA)-modified oligonucleotide modified anti-miR-15, inhibition of 
miR-15 caused a dose-dependent cardioprotective effect in both murine and porcine 
models of I/R injury.  
In the recently published prospective study by Zampetaki et al, baseline levels of 
19 candidate miRs were identified in 820 participants in the Bruneck population and 
over a 10 year period (1995-2005), they sought to explore if any association existed 
between circulating miRs and incident MI.218 In a multivariable Cox regression analysis, 
miR-126 showed a strong positive correlation with MI hazard ratio (HR) of 2.69 [(95% 
confidence interval (CI) of 1.45 to 5.01, p=0.002] and miR-223 and miR-197 had a 
strong negative association with MI [HR 0.47, 95% CI 0.29 to 0.75, p=0.002], and [HR 
0.56, 95% CI 0.32 to 0.96, p=0.036]. They further suggested upon further I/R analysis in 
healthy volunteers that these 3 miRs are all part of the same miR pool and that 
endothelial enriched miR-126 is part of a miR signature associated with the incidence of 
MI in the general population independent of previous cardiovascular disease, sex or 
cardiovascular risk factors.  
The exact mechanism behind individual miRs and their effect on preconditioning 
and other signaling pathways need to be fully elucidated before specific therapies to 
modulate expression are taken further. However once these intricacies have been 
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delineated, targeted miR or antagomir delivery may have tremendous therapeutic 
potential in reducing long-term complications associated with CHD.  
 
ii. MicroRNAs in Glucose Homeostasis and Insulin Resistance   
 Microarray studies have highlighted certain miRs that promote insulin resistance, 
regulate glucose metabolism and insulin sensitivity.219 Likewise, many have been 
directly implicated in the insulin signaling and glucose uptake pathways. For example, 
miR-375 is required for the maintenance of β- and α- pancreatic cells in mice and was 
found to decrease insulin exocytosis and secretion through repression of the myotrophin 
gene—a gene involved actin depolymerization and potentially vesicular fusion.220,221 
Additionally it affects downstream signaling through inhibition of PDK1, an intermediary 
in the insulin signaling pathway.222 MicroRNA-126 has been shown to inhibit IRS-1 and 
accordingly promote insulin resistance as another mechanism of insulin regulation.  
In a study by Lu et al, they found that in LV tissue samples taken from patients with 
and without type 2 diabetes and from patients with LV dysfunction, quantitative analyses 
of 155 miRs revealed that miR-223 was consistently upregulated in the diabetic 
hearts.223 They went on to evaluate the downstream physiological effects of miR-223 on 
glucose metabolism in a rat neonatal cardiomyocyte model using adenoviral-mediated 
overexpression of miR-223 and found that glucose uptake was significantly increased. 
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Next they looked at the effects on the insulin signaling pathway with miR-223 
overexpression and found that neither PI3K, nor AMPK activity increased, however 
GLUT4 protein expression did increase. These findings were confirmed in vivo using 
siRNA knockdown of GLUT4 and a synthetic inhibitor of miR-223.  
 Several miRs are preferentially expressed within the pancreas but the most 
notable and abundantly expressed in the islet cells is miR-375. This miR, under the 
control of transcription factors pancreatic and duodenal homeobox-1 (Pdx-1), also 
known as insulin promoter factor-1, and neurogenic differentiation-1 (NeuroD1), plays a 
negative role in glucose-induced insulin secretion.221 It affects the final step in the 
secretory pathway and this is partly attributed to expression of myotrophin, a gene 
involved in insulin-granule fusion. Additionally, miR-375 has also been shown to 
contribute to glucose homeostasis in genetically modified animal models lacking miR-
375 which became severely hyperglycemic, glucose intolerant yet in spite of normal 
insulin secretion and clearance.220, 221  
Evidence has also shown that prolonged hyperglycemia can lead to aberrant cellular 
signaling through the activation of pro-inflammatory pathways and fibrosis that 
eventually lead to long term cardiovascular morbidity and mortality.149, 224 Rat neonatal 
myocytes under conditions of hyperglycemia have elevated levels of miR-1 and miR-
206 and through modulation of MEK1/2, negatively regulate HSP60 and contribute 
hyperglycemia-induced cardiomyocyte apoptosis.225 Other miRs upregulated under 
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hyperglycemic conditions include: miR-124a, miR-107 and miR-30d whereas miR-296, 
miR-484 and miR-690 are downregulated. Specifically, miR-30d overexpression causes 
a reduction in insulin gene expression, hence suggesting that perhaps this miR may 
play a role in regulating key transcription factors for insulin biosynthesis. He et al 
showed that the miR-29 family is upregulated in the adipose tissue as well as the 
skeletal muscle of diabetic Goto-Kakzaki rats and that this elevation could be recreated 
by incubating 3T3-L1 adipocytes with insulin and subjecting them to chronic 
hyperglycemia.226  
 Let-7 was one of the miRs discovered and it is implicated in both malignancy and 
pluripotency.227 In the mouse, there are 12 genes that encode the Let-7 family which 
include nine different miRs [Let-7a, Let-c, Let-7f—which are encoded by two genes; Let-
7b, Let-7d, Let-7e, Let-7i, and miR-98—all encoded by one gene]. As all family 
members share a common seed sequence, they are believed to exert similar 
functions.227 In a recent study by Frost et al, transgenic mice were created with tissue-
specific overexpression of Let-7. Mice with global overexpression of Let-7 had lower 
body weight and size with impaired glucose tolerance secondary to diminished glucose-
induced insulin secretion.228 Using LNA-modified anti-miRs to inhibit Let-7 activity, they 
found improvements in blood glucose levels and insulin resistance in obese mice. In 
addition after anti-miR treatment, these obese mice were found to have an increase in 
lean body mass, increase in muscle mass, without an increase in fat mass or any 
ectopic fat deposition. They concluded that Let-7 may in fact regulate glucose 
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metabolism in a number of organs and in the future, Let-7 anti-miR therapy may be a 
feasible treatment option for obese diabetic patients.228   
MicroRNA-103 and miR-107 are introns located in the panthotenate kinase 1 
(PANK1), PANK2, and PANK3 genes. Bioinformatics analyses have shown that both of 
these miRs probably act synergistically with PANK in regulating Acetyl CoA and lipid 
metabolism. MiR-107 was first associated with glucose dysmetabolism and diabetes 
mellitus in 2003 by Tang et al when they showed that miR-107 was significantly 
upregulated in a β-pancreatic cell line under hyperglycemic conditions.229  
Recently, Trajkovski et al reported that Cav-1, which influences lipid raft signaling, is 
a regulator of the insulin receptor and is the key target of miR-103/107 as it was 
upregulated upon inactivation of both miRs using antagomir therapy. Moreover, this was 
concomitant with stabilization of the insulin receptor, enhancement of insulin signaling 
and improvement of insulin-stimulated glucose uptake.219 Using recombinant 
adenovirus to overexpress miR-103 and -107, they found a significant rise in random 
and fasting blood glucose levels and insulin levels. Similarly, glucose tolerance was 
decreased after i.p. glucose load and insulin sensitivity also decreased when compared 
to controls. In contrast, using antagomirs against miR-103 and -107, the found hepatic 
glucose production decreased and glucose uptake by adipose tissue increased. Hence, 
silencing of miR-103 and -107 through antagomirs enhanced hepatic insulin sensitivity 
and adipose tissue.219 Conversely, it is also possible the miR-103 and -107 only exert 
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some of their effects on insulin signaling and glucose homeostasis through negative 
regulation of Cav-1 as both miRs have recently been shown to also strongly inhibit the 
miR processing enzyme, Dicer.229 Some experiments using Dicer-/- mice have revealed 
that that this enzyme is necessary for the development and maintenance of pancreatic 
cells and insulin signaling.230   
Caveolin-1 is the primary protein of caveolae, which are lipid and cholesterol 
enriched vascular invaginations of the plasma membrane.231 Peptides within the 
scaffolding domain of Cav-1 have been shown to enhance insulin receptor kinase 
activity, whereas Cav-1-/- mice develop insulin resistance on a high fat diet.232 Data from 
Trajkovski et al supports that Cav-1 is a direct target of miR-103 and they showed that 
silencing of miR-103 and -107 resulted in a significant increase in Cav-1 levels within 
adipose and hepatic tissue but not skeletal muscle.219 This was supported by increases 
in insulin-stimulated phosphorylated Akt and insulin receptor-β. They concluded that 
miR-103 and -107 negatively regulate insulin sensitivity and one possible mechanism 
may be through downregulation of Cav-1, which diminishes the number of insulin 
receptors in caveolae-enriched plasma membrane and prevents effective downstream 
insulin signaling.  
In adipogenesis, miR-103 exhibits a nine-fold increase in expression in early 
3T3-L1 adipocytes and increases lipid droplet formation when ectopically expressed 233 
whereas the exact role of miR-107 in adipogenesis is still unclear. However, both miR-
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103 and miR-107 levels are significantly upregulated in adipogenesis, whereas they 
decrease in adipocytes taken from diet-induced obese animals.234 This was the first 
time miRs involved in adipogenesis were shown to have an inverse expression pattern 
in obesity.   
 
iii. MicroRNAs in Lipid Dysmetabolism  
  
 The maintenance of metabolic and energy homeostasis is critical for normal 
physiology and health; abnormalities and dysregulation have been shown to lead to 
obesity and insulin resistance. Likewise, defects in cholesterol and fatty acid synthesis 
and use are associated with the atherosclerotic process prevalent in type II diabetes 
mellitus. A number of recent novel studies have found that miRs play a pivotal 
regulatory role through post-translational repression of key energy homeostatic 
processes. Additionally, abnormal expression of miRs in response to intrinsic factors 
(genetic or epigenetic) or extrinsic factors (environmental cues or stress) may contribute 
to aberrant gene expression patterns and accordingly have been implicated in 
contributing to the development and progression of atherosclerotic disease, loss of 
endothelial integrity, and VSMC hyperplasia.235 Recently the direct regulation of insulin 
sensitivity and glucose homeostasis by miRs has been shown in obese, diabetic mice 
which have upregulated expression of miR-103 and miR-107.219 Moreover, miRs have 
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also been well characterized in their regulatory role in cholesterol and lipid homeostasis, 
especially the liver specific miRs, miR-122 and miR-33a and miR-33b with their host 
gene, sterol regulatory element binding protein (SREBP).  
 Lipids are the structural components of cell membranes and are critical for 
metabolism, energy storage, and even cellular signaling. Lipids such as cholesterol and 
FFAs are synthesized by the liver once taken up in the gastrointestinal tract and the 
regulation process is under strict control through feedback inhibition by end-products 
and transcription factors such as SREBPs.236 Cholesterol is transported within the 
plasma by various lipoproteins such as LDL, VLDL and high-density lipoprotein (HDL). 
Low-density lipoprotein transports cholesterol to the peripheral tissues where it can be 
taken up via the LDL receptor. HDL however removes cholesterol from the periphery 
and returns it to the liver for further metabolism in a process called reverse cholesterol 
transport (RCT). MicroRNA-122 was the first miR to be linked to hepatic and cholesterol 
metabolism. Two studies show that antisense targeting of miR-122 significantly 
(approximately 25-30%) reduces circulating plasma cholesterol levels by altering gene 
expression of 3-hydroxy-methyglutaryl-CoA-reductase.237,238 Likewise, using antisense 
based silencing of miR-122, shows decreased hepatic cholesterol and fatty acid 
biosynthesis in addition to increasing fatty acid β-oxidation.237 This lead to lower total 
circulating cholesterol and triglyceride levels in mice on a high-fat, Western diet. Given 
these promising results, LNA technology was utilized to antagonize miR-122 in non-
human primates and was found to be non-hepatotoxic and resulted in lower circulating 
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cholesterol.239 However, lower levels of LDL came at the expense of lower levels of the 
cardioprotective HDL.   
 One of the most extensively studied regulators of cholesterol and lipid 
metabolism is the SREBP family of basic helix-loop-helix leucine-zipper (LZ) 
transcription factors (SREBP-1a/c and SREBP-2). Together they regulate and influence 
the biosynthesis and trafficking of fatty acids, cholesterol, triacylglycerols and other lipid 
metabolites and co-factors such as acetyl-CoA.236 The SREBP-encoding genes were 
found to be host genes to highly conserved miRs that largely have overlapping target 
gene sets and only differ by two nucleotides—miR-33a (SREBP-2 gene) and miR-33b 
(SREBP-1 gene).240-242 Current data suggest that miR-33a/b regulate cholesterol and 
lipid homeostasis in cooperation with their host genes by targeting the ATP-binding 
cassette (ABC) A1 cholesterol efflux pump for translational repression/mRNA 
degradation, thus leading to increased levels of intracellular cholesterol.242 The ABCA1 
pump is a key mediator for cholesterol efflux from the liver to apoprotein A-1 for the 
generation of HDL.235,241 Likewise, it plays a significant role in the peripheral tissue by 
mediating HDL trafficking back, also known as RCT, to the liver for bile acid synthesis. 
Recently, Najafi-Shoushtari et al showed that injection of LNA-antisense 
oligonucleotides against miR-33a significantly increased HDL levels in mice on a 
Western-type diet. Similarly, other groups have showed that lentivirus mediated 
overexpression of miR-33a significantly reduced circulating HDL, whereas genetic 
deletion of miR-33a increased HDL levels.241,243  
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 MircoRNAs are critical regulators of normal physiology and the development of 
pathophysiology and recently their function in the metabolic homeostasis has emerged 
to the forefront in lipid research. To date, miR-122 and miR-33 are the best-
characterized miRNAs for the maintenance of normal cholesterol and lipid homeostasis. 
As this field continues to development, novel discoveries yield therapeutic concepts and 
strategies for the treatment of metabolic syndrome through targeted inhibition or 
overexpression of miRs, raising considerable excitement for both scientists and 
clinicians alike.  
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CHAPTER 2 
 
HYPOTHESIS AND SPECIFIC AIMS 
 
Hypothesis # 1:  Chronic treatment with the long-acting PDE-5 inhibitor TAD and the 
synthetic curcumin analogue, HO-3867, will improve fasting glucose levels and insulin 
tolerance in leptin receptor null mice through increased cGMP dependent kinase 
signaling and downregulation of key inflammatory cytokines. Accordingly, there will be a 
potent anti-inflammatory effect seen which will improve glycemic parameters, 
determined by fasting glucose levels, glucose and insulin tolerance tests. Likewise 
when the two compounds are combined, given each compound works by different 
pathways, the potential benefit may be greater than when each agent is given 
individually. In addition, given data supports that curcumin upregulates antioxidant 
genes such as Nrf-2 and HO-1 and that PDE-5 therapy improves NO bioavailability 
through cGMP-dependent signaling, these potent agents together may significantly 
attenuate cellular oxidant stress. The glycemic improvements that we have already 
shown with TAD leads to an increase in cellular signaling through the PI3K-Akt pathway 
and AMPK activation.244 Accordingly, we will assess for protein expression of 
activated/phosphorylated Akt and AMPK in TAD treated groups. These two key proteins 
play a key role in insulin signaling, energy metabolism and in cardioprotection. 
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Specific Aim #1: Chronic treatment with TAD and HO-3867 will reduce fasting blood 
glucose levels, improve insulin and glucose tolerance, attenuate inflammation, cell 
necrosis, oxidative stress, ROS formation and accordingly preserve the mitochondrial 
membrane potential (Δψm) after I/R injury or SI/RO. 
 
Rationale  
 The goal of this aim is to show that chronic treatment with TAD and HO-3867 will 
improve glucose and insulin tolerance, attenuate inflammation by restoring NO 
signalling, and enhance glucose utilization. We further plan to show that this 
combination treatment will reduce oxidative stress, ROS formation, inflammation and 
preserve the Δψm after 40 min SI and 1 h or 18 h of RO. Curcumin has been shown to 
be a free radical scavenger and potent antioxidant and inhibitor of oxidative DNA 
damage. In one study, curcumin inhibited oxygen free radical production caused by high 
glucose concentrations and increased glucose utilization by erythrocytes. Our 
preliminary results supported the findings that TAD therapy for 4 weeks can ameliorate 
pro-inflammatory cytokines and reduce fasting glucose levels.244 We propose that TAD 
therapy will attenuate oxidative stress, ROS, and preserve the Δψm in addition to 
providing a potent anti-inflammatory effect and upon combining this with HO-3867 will 
be additive if not synergistic given the anti-oxidant and anti-inflammatory properties of 
curcumin. In our preliminary experiments, two groups (n=6/group) of leptin receptor null, 
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homozygous db/db mice (strain B6.Cg-m +/+Leprdb/J) were treated for 4 weeks and 
were assigned to either TAD (1mg/Kg) or 10% DMSO and similarly had weekly fasting 
blood glucose levels, body weight, and at the end of the treatment period were 
subjected to I/R in a Langendorff isolated perfused heart model. Blood samples were 
collected and tested for plasma levels of circulating inflammatory cytokines and 
triglyceride levels. As seen in figures 10, 12-13, TAD lead to a significant reduction in 
infarct size, fasting glucose levels, circulating levels of key inflammatory cytokines such 
as TNF-α, IL-1β, and IFN-γ. Likewise, chemokines MCP-1, MIP-1α and MIP-1β were 
also reduced. This hypothesis generating data led to the specific aim #1. The 
preliminary hypothesis generating results are given below and were recently 
published:244 
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                          Figure 10.   Fasting glucose levels after 4 weeks of TAD treatment. 
© PLoS ONE 2012 
 
The db/db mice treated with TAD showed a significant decrease in fasting plasma 
glucose levels (292±31.8 mg/dL vs. 511±19.3 mg/dL) compared to controls after the 
treatment period, n=6/group. 
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Figure 11.  Mean body weight after 4 weeks of TAD treatment. 
© PLoS ONE 2012 
 
Body weight remained unchanged between control db/db and TAD treated db/db mice 
41.4±1.2 g vs. 45.8±1.7 g, n=6/group.  
	  
Week of treatment
W
ei
gh
t (
gr
am
s)
0 1 2 3 4 5
35
40
45
50
55
DMSO
TAD
P=NS
	   	   P a g e 	   | 	   8 1 	  
	  
	  
 
Figure 12.  Infarct size after global I/R injury. 
© PLoS ONE 2012 
	  
Following I/R, infarct size was reduced after chronic treatment with TAD as compared to 
vehicle (DMSO)-treated db/db mice, 23.2±1.5% vs. 47.8±3.7%, p<0.01; n=6/group.	   	  
In
fa
rc
t S
iz
e
(%
 A
re
a 
at
  R
is
k)
TA
D
DM
SO
0
20
40
60
*
* P<0.01 vs. DMSO
	   	   P a g e 	   | 	   8 2 	  
	  
	  
 
Figure 13.  Reduction of cytokines and chemokines after TAD treatment. 
© PLoS ONE 2012	  
 
Key inflammatory cytokines and chemokines such as IL-1β, TNF-α, and chemokines, 
MIP-1β, and MCP-1 were attenuated with chronic TAD treatment and there was an 
increase in IL-10 levels when compared to the control group.  
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                                  Figure 14. Rate-force product as % of pre-ischemia baseline. 
	   © PLoS ONE 2012  
 
The post-ischemic rate-force product (expressed as % of pre-ischemic baseline 
compared to the control group) was not changed, 72.2±2.9% vs. 63.8±3.8%, p=0.10; 
n=6/group. 
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Figure 15.  Coronary flow rates as % of pre-ischemia baseline. 
© PLoS ONE 2012 
 
 
The coronary flow rate improved in the TAD treated db/db mice (147.4±3.2% of the pre-
ischemic baseline vs. 98.3±1.2% in the DMSO treated mice, p=0.005; n=6/group. 
Baseline and post-ischemic coronary flow rates ranged from 1.8 to 2.1 mL/min and 1.7 
to 1.9 mL/min in the TAD group, respectively and 1.7 to 2.0 mL/min and 1.5 to 1.6 
mL/min in the control group, respectively.   
 
 
  
%
 o
f P
re
-Is
ch
em
ia
 B
as
el
in
e
TA
D
DM
SO
0
50
100
150
200
P=0.005
Coronary Flow Rates
	   	   P a g e 	   | 	   8 5 	  
	  
	  
	  
Figure 16.  Number of TUNEL positive (Apoptotic) cells after SI/RO. 
© PLoS ONE 2012 
 
After 18h of RO, apoptosis was also inhibited as indicated by reduced number of 
TUNEL-positive cells in TAD treated cardiomyocytes 23.4±1.9% vs. 8.8±1%, p<0.001. 
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Figure 17.  LDH assay to determine necrotic cells after SI/RO. 
© PLoS ONE 2012	  
	  
An LDH assay was also performed to determine the amount of necrosis after SI/RO. 
Isolated cardiomyocytes from TAD treated mice showed much lower LDH release into 
the cell medium than mice treated with DMSO.  
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Figure 18.  Number of Trypan Blue positive (necrotic) cells after SI/RO. 
© PLoS ONE 2012	  
	  
After 40 min of SI and 1 h of RO, the percent of trypan blue-positive (necrotic) 
cardiomyocytes was 59.8±1.5 in the control group. Treatment with TAD resulted in 
decrease of ~64% of trypan blue-positive cardiomyocytes, i.e., 21.3±1.5%; p<0.001 vs. 
control. 
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Figure 19.  PKG activity after TAD therapy 
© PLoS ONE 2012 
 
TAD treated cardiomyocytes had a 44.3±2.5 % increase in PKG activity compared to 
C57BL/6 non-treated controls whereas the DMSO treated group had a 16.7±1.8% 
decrease compared to the non-diabetic control, p <0.001; n=4. 
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Hypothesis #2:  Recent studies have shown that two related miRs, miR-103 and -107, 
negatively regulate insulin sensitivity and glucose metabolism and are upregulated in 
insulin resistance and obesity.219 In diabetic mice, silencing of both miRs improves 
insulin signaling and glucose homeostasis.219 Based on predicted miR targets, target 
downregulation scores, and observed expression patterns, it has been shown that miR-
103/107 has a complimentary sequence alignment with caveolin-1 (Cav-1), which is a 
key protein making up caveolae within plasma membranes.245-248 Cav-1 has been 
shown to play a critical role in stabilizing the insulin receptor and enhancing insulin 
signaling. Hence, we contemplated that downregulation of Cav-1 by increased miR-
103/107 expression in obese, diabetic mice may have in a role in preventing effective 
insulin signaling and glucose homeostasis. In addition, it is known that PDE-5 inhibitors 
effect eNOS expression and that eNOS itself temporally and spatially regulates caveolar 
microdomains that facilitate signal transduction. We therefore contemplated that 
downregulation of Cav-1 by increased miR-103/107 expression in obese, diabetic mice 
may have in a role in preventing effective insulin signaling and glucose homeostasis 
and that chronic daily treatment with TAD may decrease the expression of miR-
103/107. We further speculate that the mechanism for improving glucose regulation 
may be through increased expression of Cav-1 protein and that increased Cav-1 would 
lead to insulin receptor stabilization and improved insulin signaling.  
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Figure 20.  Complimentary sequence alignment between miR-103/107 and Cav-1. 
	  
The above figure depicts the complimentary sequence alignment between both miR-103 
and miR-107 and Caveolin-1 thus making it, based on target downregulation scores and 
observed expression patterns, the likely downstream target gene.   
 
Specific Aim #2: To demonstrate that chronic treatment with TAD will decrease 
myocardial expression of miR-103/107, thus increasing mRNA and protein expression 
of its downstream target Cav-1. This may be one of the potential mechanisms by which 
TAD improves glucose homeostasis and insulin sensitivity in obese diabetic mice.  
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Rationale 
MicroRNAs are novel endogenous short single-stranded non-protein encoding 
RNA’s with 19-25 nucleotides in length and been shown to play a key regulatory role in 
post-transcriptional gene expression. In recent years miRs are being increasingly 
recognized as potential therapeutic targets for a variety of diseases in addition to 
possible biological markers for making early diagnoses in a number of diseases. Given 
that miRs -103 and -107 have been shown to play a role in glucose metabolism and 
insulin sensitivity, and cGMP-dependent signaling is a key signaling pathway that upon 
activation can improve glucose homeostasis, we proposed that TAD therapy would 
decrease myocardial expression of miR-103 and -107 and since recent data supports 
these miRs target Cav-1, would increase mRNA and protein Cav-1 expression.  
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CHAPTER 3 
 
METHODS 
 
 Thirty-two leptin receptor null, homozygous db/db mice (strain B6.Cg-m 
+/+Leprdb/J) were used for these experiments at a mean age of 12 weeks. All animals 
were purchased from The Jackson Laboratory (Bar Harbor, ME), and had the same 
genetic background.249 The animal experiment protocols were approved by the 
Institutional Animal Care and Use Committee of Virginia Commonwealth University. All 
animal experiments were conducted under the guidance on humane use and care of 
laboratory animals for biomedical research published by the National Institutes of Health 
(No. 85-23, Revised 1996).   
 
Specific Aim #1 
 The db/db mice were randomized to receive daily TAD (1 mg/Kg), HO-3867 (25 
mg/Kg) [kindly provided by Dr. Periannan Kuppusamy, Ohio State University], a 
combination of TAD and HO-3867, or control (an equal volume of 10% DMSO) for a 
total duration period of up to 12 weeks. Each had metabolic parameters monitored such 
as body weight and fasting glucose, and plasma samples taken for evaluating 
inflammation (n=6-8/group). Eight db/db mice (n=2/group) were used to measure 
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oxidative stress and isolated cardiomyocytes from the latter groups were used to 
evaluate for ROS formation and preservation of Δψm after 40 min SI and either 1h or 18 
h of RO (figure 21). 
 
	  
     Figure 21.   Experimental protocol  
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Metabolic monitoring 
Each mouse had body weight and 12 h fasting blood glucose level at the start of 
all experiments and then weekly for the mean 12-week treatment period. Food and 
water intake was monitored throughout the study.  
 
Insulin and Glucose Tolerance tests 
Blood glucose concentrations were obtained using a handheld glucometer 
(Lifescan, Milpitas, CA). After 10 weeks of treatment, a glucose tolerance tests was 
performed after 12 h of fasting. After initial blood glucose determinations, 1.5 g/Kg of d-
glucose was administered, followed by glucose determinations at 30 min intervals for 
120 min. For the insulin tolerance test, human regular insulin (1.5 U/Kg) was injected 
into random-fed mice and tail vein samples for blood glucose levels were taken at 30 
min intervals for 120 min.  
 
Measurement of Cytokines, Chemokines and Triglyceride levels  
At the time of sacrifice, each mouse had blood collected by cardiac puncture into 
2 separate ethylenediaminetetraacetic acid (EDTA) tubes, stored immediately on ice 
and centrifuged at 4°C, 3,000 g for 10 minutes. The serum and plasma were separated 
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and stored at -80°C until analyzed. Plasma concentrations of representative cytokines: 
IL-1α, IL-1β, IL-2, IL-3, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, TNF-α, interferon (IFN)-
γ and chemokines: RANTES (Regulated upon Activation, Normal T-cell Expressed, and 
Secreted) also known as CCL (C-C chemokine ligand)-5, MIP-1α and -1β (macrophage 
inflammatory protein) which are also known as CCL-3 and CCL-4, Eotaxin (CCL-11 
family), was quantified using the Bio-Plex Pro magnetic cytokine assay (Bio-Rad, 
Hercules, CA) in the initial set of hypothesis generating experiments with TAD [70]. 
Subsequently, using the same Bio-Plex magnetic cytokine assay, all groups had 
cytokine and chemokine measurements of IL-1β, IL-6, IL-10, IFN-γ, MCP-1, MIP-1α and 
-1β, TNF-α, and RANTES. 
 
Langendorff Isolated Perfused Heart 
The methods for the isolated, perfused mouse heart preparation have been 
previously described in detail.18 In brief, each mouse (from each of the treatment 
groups) was anesthetized with pentobarbital sodium (100 mg/Kg) and the heart was 
quickly removed from the thorax and placed in a small dish containing ice-cold 
perfusate and heparin. In this case, heparin was not used in the peripheral circulation as 
its use would prevent miR analysis from the plasma at a later date. The aortic opening 
was rapidly cannulated and tied on a 20-gauge blunt needle that was connected to a 
Langendorff perfusion system. After cannulation, the heart was retrogradely perfused at 
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a constant pressure of 75 mm Hg with modified Krebs–Henseleit (K–H) solution 
containing (in mM) 115 NaCl, 4.0 KCl, 2.0 CaCl2, 25 NaHCO3, 1.1 MgSO4·H2O, 0.9 
KH2PO4, and 5.5 glucose. The perfusion solution was continuously gassed with 95% O2 
+ 5% CO2 (pH ∼ 7.4) and warmed by a heating/cooling bath. The heart temperature 
was continuously monitored and maintained at 37 °C throughout the experiment. 
Ventricular function was measured by a force-displacement transducer (model FT03, 
Grass) attached to the ventricular apex with a no. 5 surgical thread and a rigid metal 
hook. The resting tension of the isolated heart was adjusted to approximately 0.30 g. 
Ventricular developed force was continuously recorded with a PowerLab 8SP 
computerized data acquisition system connected to the force transducer (AD 
Instruments, Colorado Springs, CO) after daily calibration. Coronary effluent was 
collected by timed collection of the perfusate to determine flow rate. The hearts were 
not paced. All hearts were subjected to 20 min of stabilization, followed by 30 min of 
ischemia and 1 h of reperfusion. After the 1 h reperfusion period, hearts were collected, 
frozen at -20° C for infarct size assessment 24-48 h later using triphenyltetrazolium 
(TTC) staining method (figure 22).  
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      Figure 22.   Langendorff isolated perfused heart protocol. 
 
Isolation of Ventricular Cardiomyocytes 
Adult male leptin receptor null, homozygous db/db mice (strain B6.Cg-m 
+/+Leprdb/J), 249 were used to isolate ventricular cardiomyocytes. The ventricular 
cardiomyocytes were isolated using an enzymatic technique modified from the 
previously reported method.249-251 In brief, the animal was anesthetized with 
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pentobarbital sodium (100 mg/Kg, i.p.) and the heart was quickly removed. Within 
3 min, the aortic opening was cannulated onto a Langendorff perfusion system and the 
heart was retrogradely perfused (37 °C) at a constant pressure of 55 mmHg for 
approximately 5 min with a Ca2+-free bicarbonate-based buffer containing (in mM): 120 
NaCl, 5.4 KCl, 1.2 MgSO4, 1.2 NaH2PO4, 5.6 glucose, 20 NaHCO3, 10 2, 3-butanedione 
monoxime, and 5 taurine, which was continuously bubbled with 95% O2 + 5% CO2. The 
enzymatic digestion was commenced by adding collagenase type II (Worthington, 
0.5 mg/mL each) and protease type XIV (0.02 mg/mL) to the perfusion buffer and 
continued for ∼ 15 min. Fifty µM Ca2+ was then added in to the enzyme solution for 
perfusing the heart for another 10–15 min. The digested ventricular tissue was cut into 
chunks and gently aspirated with a transfer pipette for facilitating the cell dissociation. 
The cell pellet was resuspended for a 3-step Ca2+ restoration procedure (i.e., 125, 250, 
500 µM Ca2+). The freshly isolated cardiomyocytes were then suspended in minimal 
essential medium (Sigma catalogue# 6 M1018, pH 7.35–7.45) containing 1.2 mM Ca2+, 
12 mM NaHCO3, 2.5% fetal bovine serum, and 1% penicillin–streptomycin. The cells 
were then plated onto the 35 mm cell culture dishes, which were pre-coated with 
20 µg/ml mouse laminin in PBS + 1% penicillin–streptomycin for 1 h. The 
cardiomyocytes were cultured in the presence of 5% CO2 for 1 h in a humidified 
incubator at 37 °C, which allowed cardiomyocytes to attach to the dish surface prior to 
the experimental protocol. 
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Measurement of Reactive Oxygen Species 
Isolated myocytes were plated onto 96 well microplate and subjected to 40 min 
SI and 18 h RO. After plating, they were incubated with 50 µM of 
dichlorodihydrofluorescein diacetate (H2DCFDA) in growth medium for 30 min at 37°C. 
Cardiomyocytes were rinsed with PBS, and ROS levels were determined using a 
fluorescence microplate reader at an excitation of 485 nm and emission of 538 nm.   
 
Measurement of Mitochondrial Membrane Potential (Δψm)  
Isolated ventricular cardiomyocytes subjected to 40 min simulated ischemia and 
1h reoxygenation were stained with 5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazole-
carbocyanide iodine (JC-1; Biocarta) by incubating with 2 µg/mL JC-1 for 10 minutes at 
37°C. Fluorescence was analyzed with a Texas red–FITC filter cube using a Nikon 
Eclipse Ti inverted research microscope (Melville, NY). The ratio of mitochondrial 
aggregates (red) to the monomeric form of JC-1 (green) was analyzed with the use of Q-
Capture Professional image analysis software (QImaging). Myocytes were counted from 
8-10 separate fields per group and expressed as the ratio of mitochondrial aggregates 
to monomeric form of JC-1. 
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Western Blot 
The mouse heart samples were collected and the proteins were extracted in a 
buffer containing (in mmol/L): 50 potassium phosphate 1 EDTA, 1 EGTA, 0.2 PMSF, 5 
beta-glycerophosphate, 2 NaF, 2 Na3VO4 10 β-mercaptoethanol, 1µg/ml pepstatin, and 
0.5 µg/ml leupeptin, (pH 7.0) with a tissue homogenizer. The homogenate was 
centrifuged at 10,000 g for 15 min under 4°C and then supernatant was recovered. Fifty 
milligrams of protein from each sample were separated by SDS-polyacrylamide gel 
electrophoresis and transferred onto nitrocellulose membranes. The membrane was 
incubated with primary antibodies at a dilution of 1:1000 for each of the respective 
proteins, i.e. [PKG, actin (goat polyclonal), phosphorylated Akt (pAkt), Akt, pAMPK, 
AMPK, (rabbit polyclonal), pCav-1, and Cav-1 (Santa Cruz Biotechnology, Santa Cruz, 
CA). The membrane was then washed and incubated with horseradish peroxidase-
conjugated secondary antibody (1:2000 dilution, 1h at room temperature). Detection of 
the signals was performed using LumiPhosTM reagent (Pierce) and chemical 
luminescence was detected using X-omat Kodak film. The densitometry quantification 
was performed with Bioquant image analysis software.  
 
Evaluation of Cell Viability and Apoptosis  
Cell viability was assessed by trypan blue exclusion assay in the cell medium. At 
the end of protocol, 20 µL of 0.4% trypan blue (Sigma-Aldrich) was added into the 
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culture dish. After approximately 5 min of equilibration, the cells were counted under a 
Nikon Eclipse Ti inverted research microscope (Melville, NY). Cardiomyocyte apoptosis 
for the preliminary experiments was evaluated by using the ApoAlert DNA 
Fragmentation kit (ClonTech, Mountain View, CA) according to manufacturer’s 
specifications. The quantification of apoptosis was determined by counting the TUNEL-
positive myocyte nuclei from a mean of seven random fields per section and was 
expressed as percentage of total myocyte nuclei, as previously reported.40  
 
Infarct size assessment  
At the end of reperfusion, the heart was immediately removed from the 
Langendorff apparatus and frozen at -20 °C for 24-48 h. The frozen heart was cut into 
six to seven transverse slices, stained by 10% TTC for 30 min at room temperature 
(∼22 °C), and subsequently fixed with 10% formalin for 24 h. The infarct area was 
determined by computer morphometry by using ImageJ Software (National Institutes of 
Health, Bethesda, MD). The infarct size was presented as percentage of the total 
myocardium (at risk myocardium).  
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Protein Kinase G Activity  
PKG activity was examined after the preliminary hypothesis generating 
experiments using a commercially available PKG activity kit (Cyclex; MBL International, 
Japan) in ventricular cardiomyocytes isolated from each group (Activity was measured 
according to the manufacturer's instructions. Spectrophotometric absorbance was 
measured at 450 nm. Results were normalized as per milligram of protein. 
 
SPECIFIC AIM #2  
In recent years miRs are being increasingly recognized as potential therapeutic 
targets for a variety of diseases in addition to possible biological markers for making 
early diagnoses.218 MiR-103/107 was recently shown to be upregulated in obese mice 
and impair glucose tolerance and insulin sensitivity.219 Moreover, it is suggested that 
Cav-1, which is a critical regulator of the insulin receptor, is the direct target gene of 
miR-103/107. Likewise, given that PDE-5 inhibitors effects eNOS expression and since 
eNOS temporally and spatially regulates caveolar microdomains that facilitate signal 
transduction, we propose that TAD would decrease the myocardial expression of miR-
103 and -107 and that this may be one of the potential mechanisms by which TAD 
effects glucose regulation in diabetic mice. Furthermore, to confirm our findings, we will 
evaluate the expression of its downstream target gene, Cav-1.  
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Experimental Design 
  Mice were randomized to receive TAD (1 mg/Kg) or 10% DMSO for a mean of 5 
weeks. A third group of non-diabetic mice C57BL/6J mice (n=3) also received vehicle 
(DMSO). At the end of the treatment period, hearts were extracted to determine 
myocardial expression of microRNA-103/107, mRNA expression of Cav-1 and protein 
expression by Western blot analysis of Cav-1.   
 
MiRNA extraction and verification  
Total RNA including miRNA was isolated using miRNeasy Mini kit (Qiagen 
Sciences, MD, USA) according to manufacturer’s protocol. The concentration of RNA 
was measured using Agilent NanoDrop ND-1000 Spectrophotometer (Houston, Texas, 
USA). Complementary DNA (cDNA) was synthesized from either 10 ng or 2ug of total 
RNA using microRNA specific primer (TaqMan miRNA reverse-transcription kit, Applied 
Biosystems, USA) for microRNA profile and hexamer for mRNA expression 
 (High capacity cDNA synthesis kit (Applied Biosystems, USA). 
 
Real-time qPCR 
Real-time PCR was performed on an Applied Biosystems 7900HT Real-Time 
PCR System (Forest City, CA) using amplicon specific TaqMan microRNA or Gene 
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expression assay probes. The following are the details of the primer used: For the 
expression of microRNA 103/107 hsa-miR-103 – AGCAGCAUUGUACAGGGCUAUGA 
and hsa-miR-107-AGCAGCAUUGUACAGGGCUAUCA were used, respectively, and 
were normalized using small nucleolar RNA -202 (sno-202). Gene expression 
quantification for caveolin-1 mRNA expression was carried out using exon spanning 
primers and an amplicon specific gene assay probe. The mRNA expression of caveolin-
1 was normalized using GAPDH as the housekeeping gene.  The results were analyzed 
both by delta-delta cT and absolute quantification using a standard curve method. 
 
Western blot 
The mouse heart samples were collected and the proteins were extracted in a buffer 
containing (in mmol/L): 50 potassium phosphate 1 EDTA, 1 EGTA, 0.2 PMSF, 5 beta-
glycerophosphate, 2 NaF, 2 Na3VO4 10 β-mercaptoethanol, 1µg/ml pepstatin, and 0.5 
µg/ml leupeptin, (pH 7.0) with a tissue homogenizer. The homogenate was centrifuged 
at 10,000 g for 15 min under 4°C and then supernatant was recovered. Fifty milligrams 
of protein from each sample were separated by SDS-polyacrylamide gel electrophoresis 
and transferred onto nitrocellulose membranes. The membrane was incubated with 
primary antibodies at a dilution of 1:1000 for each of the respective proteins, i.e. [actin 
(goat polyclonal), Cav-1 (N-20) - sc-894, Santa Cruz biotechnology, CA, USA]. 
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The membrane was then washed and incubated with horseradish peroxidase-
conjugated secondary antibody (1:2000 dilution, 1 h at room temperature). Detection of 
the signals was performed using LumiPhosTM reagent (Pierce) and chemical 
luminescence was detected using X-omat Kodak film. The densitometry quantification 
was performed with Bioquant image analysis software.  
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CHAPTER 4 
 
STATISTICS 
 
Continuous variables are expressed as mean ± standard error. Two-way analysis 
of variance (ANOVA) was used to compare pre- and post-intervention values between 
the 2 groups. Student’s T test was used for comparison of unpaired data between 2 
groups and the one-way ANOVA to compare unpaired data between 3 or more groups 
followed by a Tukey or Bonferroni post-hoc analysis (Prism 5, GraphPad Software, 
LaJolla, CA). Discrete variables are expressed as percentage and the Chi-square or 
Fisher’s exact tests are used accordingly. Unadjusted two-tailed P values <0.05 are 
considered statistically significant. 
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CHAPTER 5 
 
 
EXPERIMENTAL LIMITATIONS 
 
The initial study design had experiments that included in vivo I/R protocols to 
simulate clinical scenarios and then analyze cardiac function by TTE after reperfusion. 
However, during our preliminary work we discovered that the db/db mouse is especially 
prone to mortality in the first 24 h after MI. This made post-MI follow-up extremely 
difficult albeit the ideal scenario for I/R injury. We abandoned this plan and decided to 
perform an ex vivo isolated perfused Langendorff model of I/R. This allowed us to 
assess cardiac function before and after ischemia as well as determine infarct size 
although in an ex vivo model.  
A second limitation was that given the large number of animals required for the 
study and that only 2-3 mouse hearts could be isolated for Langendorff per day, not all 
mice finished the study in the same week. This gave us a mean completion time of 11 
weeks 5 days for all mice.  Hence for all results, we selected an end or completion time 
of “12” weeks. Interestingly, the study was proposed to be 8 weeks in length but 
temporary limitations in resources, availability of materials, staff, etc., it was decided to 
expand the length of treatment to 12 full weeks.  
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During the cytokine analysis not all plasma sample values determined by the 
cytokine magnetic assay could be used. One or more were reported below the standard 
concentration curve and were not reported by the system. However, a mean of 4 per 
group was utilized in calculation.  
Utilizing a group of age-matched non-diabetic controls for all experiments 
throughout the 12 weeks would have been ideal. Instead only non-treated diabetic mice 
served as controls for most experiments. Having a non-treated, non-diabetic control 
would have provided valuable additional data and will be utilized for future experiments.  
 Finally, in the isolated cardiomyocytes experiments, myocytes were isolated from 
each group using one mouse per group. Although the results we found were significant 
and comparable to results we have previously published, we would need to repeat this 
portion of the aim with a larger “n” number. This was limited in part due to the number of 
mice and the ability to carry out the isolation of more myocytes in the prescribed 
treatment period without altering the “end time” for each group.  
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CHAPTER 6 
 
RESULTS 
 
The effects of TAD and HO-3867 on the basic metabolic characteristics of the 
diabetic mouse 
 
The health status of each mouse was evaluated in terms of body weight and 
fasting blood glucose over the 12-week period as shown in Table 1 and 2. The diabetic 
mouse showed significant increases in bodyweight and fasting glucose levels over the 
12 week period, however, each of the three treatment regimens: TAD alone, TAD with 
HO-3867 and HO-3867 alone, all lead to statistically significant reductions in fasting 
glucose levels with significant improvements in both insulin and glucose tolerance tests. 
The most robust improvements were seen in the treatment groups that included HO-
3867.  
However, by the end of the 12-weeks of treatment, mean body weight was 
reduced with HO-3867 and combination therapy but not TAD when compared to control 
(61.6±2.1g, 57.0±1.19g, 57.0±1.5g, vs. 65.5±1.5g, respectively [Figure 26]; P<0.05 for 
HO-3867 and combination groups vs. control). Both HO-3867 and combination 
treatment led to a dramatic decrease in body weight and fasting glucose, whereas TAD 
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therapy only led to improvements in glucose and not body weight. This is congruent with 
our preliminary study using TAD in diabetic mice (Figures 10-11) in which we were 
unable to show significant weight loss but did demonstrate slight improvements in 
fasting glucose levels over 4 weeks of treatment.244 
	  
Figure 23. Mean fasting blood glucose levels of each group at the start of treatment. 
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As shown in figures 23 and 24, at the start of the study there was no significant 
difference between the groups in terms of mean body weight or fasting glucose levels.	  
	  
            Figure 24.  Mean body weight of each group at the start of treatment. 
 
Similar to fasting glucose levels, there was no significant difference in mean body 
weight between the 4 groups at the start of the study.  
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Table 1.  Mean weights over the 12 week treatment period 
 
Table 1 above shows the mean± standard error for each group during the 12 week 
course of treatment. During weeks 11 and 12, the “n” decreased in each group as we 
began the isolated perfused heart protocol and collected plasma samples for cytokine 
assay. The mean weight of the C57BL/6J mouse, which has the genetic background for 
the leptin receptor null mouse, is around 30 grams.    
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Table 2.  Mean glucose levels over the 12-week treatment period 
 
Table 2 above shows the weekly fasting glucose levels (mean ± standard error) for each 
group during the 12-week course of treatment. During weeks 11 and 12, the “n” 
decreased in each group as we began the isolated perfused heart protocol and 
collected plasma samples for cytokine assay.  
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Figure 25.  Mean fasting glucose levels of each group at the end of treatment. 
	  
Mean fasting blood glucose values at the end of the study reveal that treatment with 
HO-3867 and TAD together provided the largest benefit in glucose reduction although 
the benefit of combination therapy did not provide any added benefit than either 
compound given individually. Similarly, drugs individually also led to statistically 
significant reductions in glucose levels. 
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Figure 26. Mean weight of each group at the end of treatment. 
	  
Figure 26 depicts the mean weight of each group at the end of the 12 week treatment 
period. There was a significant reduction of weight in both the HO-3867 and 
combination treatment arms, however treatment with TAD alone did not significantly 
alter weight, albeit there was a trend towards reduction.  
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Figure 27.  Mean fasting glucose levels of each group plotted over the entire treatment period. 
	  
In figure 27, mean fasting glucose levels in each treatment group are plotted over the 
entire treatment period. There was no significant difference in the initial levels and by 
week 5, treatment with HO-3867 and combination of TAD and HO-3867 show a 
statistically significant difference in glucose levels that persist until the end of the study. 
Likewise, TAD alone also improved glucose readings when compared to control over 
the treatment period after approximately the 6th week of treatment.   
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     Figure 28. Mean body weight of each group plotted over the entire treatment period. 
	  
The mean body weight in each treatment group gradually increased over the 12 week 
treatment period with the exception of groups being treated with HO-3867. At 
approximately week 5, those two groups started to have decline from their mean 
starting weight, however at the end of the study period the starting and ending weights 
were nearly the same. Both the TAD and control groups had significant increases in 
weight during the 12-week period, although net weight gain was less in the TAD treated 
mice, this did not reach statistical significance.  
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Figure 29. Insulin tolerance test at the end of treatment. 
	  
During the insulin tolerance test, random fed mice were fasted for 6 hours, given 1.5 
Units/Kg of regular insulin after baseline reading and then had blood glucose levels 
monitored over 120 min. Both HO-3867 and combination treated groups had improved 
insulin sensitivity with enhanced glucose homeostasis at 30 min onwards when 
compared to control. At 60 min and 90 min, both HO-3867 containing groups had 
improvements that were statistically significant when compared to TAD as well. 
Treatment with TAD alone led to only one point in time, at 30 min, in which insulin 
tolerance was statistically better than control.  
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Figure 30.   Glucose tolerance test at the end of treatment. 
	  
There was a notable improvement in glucose tolerance in the treatment groups vs. 
control. This demonstrates the improved ability of the treated db/db mice to clear 
circulating glucose and utilize it for oxidation.  We were able to show that at all time 
points a significant difference existed between TAD, HO-3867 and combination groups 
vs. control, however no significant difference between the groups was found. 
 
TAD, HO-3867, and combination therapy protects against global I/R Injury 
After 12 weeks of chronic therapy with TAD, HO-3867 and combination treatment 
we found that following global I/R injury, myocardial infarct size (mean ±SEM) was 
Glucose tolerance test at 12 Weeks 
0 30 60 90 120
200
300
400
500
600
TIME
TAD
HO-3867
Combo
Control
**
**
**
****
**
**
**
** **
**
^
^
^
^
**
**
^ ** p<0.001 vs. TAD and  
    control
^ p<0.001 vs. control 
P
la
s
m
a
 g
lu
c
o
s
e
 le
v
e
l (
m
g
/d
L
)
	   	   P a g e 	   | 	   1 2 0 	  
	  
	  
greater in the db/db mice treated with control (DMSO). Control mice had an infarct size 
of 43.14±10.5% vs. TAD, which had 20.7±6.0%, HO-3867 of 28.4±8.4% and 
combination therapy of 25.2±11.1%; p<0.05 for each group vs. control; Figure 31.  
	  
Figure 31.  Infarct size after I/R injury. 
	  
A total of 4-6 diabetic mice from each group were subjected to I/R injury in a 
Langendorff isolated perfused heart model. After 30 min ischemia and 60 min 
reperfusion, the mean infarct sizes in TAD, HO-3867 and the combination group were 
significantly smaller than in the control group.   
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The subsequent photographs (Figures 32-35) depict one example of the gross 
cardiac pathology after global I/R injury using the Langendorff isolated perfused heart 
model from each of the treatment arms.  
 
 Figure 32. TTC stained sections of myocardium after I/R injury from a control (DMSO) treated 
mouse. 
	  
After I/R on the Langendorff apparatus, hearts were collected and immediately 
frozen at -20° C overnight. The following day, each heart was cut into 6-7 transverse 
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sections and stained with TTC for 30 min and then fixed with 10% formalin overnight. 
Using ImageJ software (National Institutes of Health, Bethesda, MD), we measured 
infarct size as the % of the total myocardium. 
	  
Figure 33. TTC stained sections of myocardium after I/R injury from a HO-3867 treated mouse. 
 
Infarcted myocardium is depicted as white/beige tissue whereas healthy, viable 
myocardium is surrounding the infarcted area and is red/pink in color.  
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Figure 34.  TTC stained sections of myocardium after I/R injury from a combination treated mouse. 
	  
After a 20 min stabilization period, each heart was subjected 30 min ischemia 
followed by 60 min of reperfusion. Hearts preconditioned with TAD, HO-3867 or the 
combination of the two had significantly smaller infarct sizes when compared to the 
control treated mice.  
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Figure 35.  TTC stained myocardium after I/R injury from a TAD treated mouse. 
	  
	  
	  
Cardiac Hemodynamics and Contractile Force  
Coronary flow rates did improve in the HO-3867 and TAD treatment groups as 
the % change in coronary flow compared to the pre-ischemia baseline when compared 
to control.  As the percentage of pre-ischemia baseline, the TAD group was 
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130.2±16.2%; HO-3867 was 132.2±8.0%; 116.5±7.1% for combination treated and 
96.7±5.7% in the DMSO treated control mice, (p<0.05 for all groups vs. control; Figure 
36). There was no significant difference in the pre-ischemia basal functional parameters 
(i.e., developed force, rate-force product, and resting tension) between the treatment 
groups (n=4-6/group). There was no significant change in post-ischemic rate-force 
product as the % of pre-ischemic baseline compared to the control group with TAD +/- 
HO-3867 treatment [63.9±8.6% (TAD alone), 31.9±12.3% (HO-3867 alone) and 
39.7±12.9% for combination therapy vs. 47.7±4.8% for control; Figure 37].  
Similarly, the combination treatment did not lead to any improvement rate-force 
product when compared to control. Table 3 shows the baseline cardiac functional 
parameters for each of the treatment groups.  
 
Table 3.  Baseline Cardiac Functional Parameters  
Group Control TAD HO-3867 Combination 
HR (bpm) 310.0±60 350.0±14.1 430.0±36.7 388.3±38.3 
DF (g) 0.97±0.11 1.16±0.7 0.94±0.16 1.01±0.25 
RFP (g 
beats/min) 
583.5±142.43 814±171 802.1±152.2 605.4±194.6 
CF (mL/min) 2.2±0.2 2.4±0.3 2.3±0.2 2.1±0.2 
Mean ± SE; HR- heart rate; DF- developed force; RFP- rate force product; CF – coronary flow; g- grams;  
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Figure 36.  Coronary flow rates. 
	  
Coronary effluent was collected over time during the stabilization period and then during 
reperfusion during each I/R heart protocol. Coronary flow rates (as the % of pre-
ischemia baseline) were improved in each of the treatment arms when compared to 
control.  
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Figure 37.  The Rate-Force product.  
	  
The cardiac function is presented as the double product of the heart rate and ventricular 
developed force (% of the pre-ischemic baseline). There were no significant changes 
between the groups in terms of cardiac function. 
 
 
R
at
e-
Fo
rc
e 
Pr
od
uc
t
 (%
 o
f P
re
-Is
ch
em
ia
 B
as
el
in
e)
Co
ntr
ol TA
D
HO
-38
67
Co
mb
o
0
20
40
60
80 p=ns for all groups
	   	   P a g e 	   | 	   1 2 8 	  
	  
	  
TAD, HO-3867 and Combination treatment attenuates oxidative stress induced by 
diabetes 
Diabetes is usually accompanied by increased production of free radicals and 
impaired antioxidant mechanisms. Hence we measured ROS generation by staining 
isolated ventricular cardiomyocytes from each treatment group with indicator dye 
H2DCFDA after 1 h simulated ischemia and 18 h reoxygenation.  ROS formation was 
significantly increased in the db/db control group (DMSO) following SI/RO. TAD, HO-
3867 and combination treatment all significantly attenuated ROS generation in db/db 
mice as shown in Figure 38.  
 
ROS Generation after Simulated Ischemia/Reoxygenation  
After 40 min SI and 18 RO, isolated cardiomyocytes from each of the treatment 
groups were subjected to 10 µM H2DCFDA staining and then ROS generation was 
determined as % of total control by fluorescence using a microplate reader (excitation of 
485 nm and emission of 538 nm). Despite our preliminary data showing a significant 
decrease in ROS production after chronic TAD treatment, we only found a decrease in 
ROS after HO-3867 and combination HO-3867 with TAD therapy (Figure 38).  
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Figure 38.   ROS generation. 
	  
 
Effects of Chronic Therapy on Mitochondrial Membrane Potential  
In the diabetic, ROS are involved in insulin resistance via its regulatory effects on 
mitochondrial function.252 Therefore we measured dissipation of Δψm of isolated 
ventricular cardiomyocytes following 40 min SI and 1 h RO by JC-1 staining. 
Cardiomyocytes from DMSO-treated diabetic mice exhibited a significant loss of Δψm 
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while myocytes isolated from those treated with TAD and/or HO-3867 demonstrated 
preserved Δψm and intact mitochondrial membranes (Figures 39-43). Hence, these drugs 
might preserve Δψm in diabetic hearts, at least in part, via mitochondrial activation.	  	  
	  
	  
Figure 39.  Ratio of JC-1 aggregate:monomer after SI/RO. 
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Figure 40.  JC-1 staining of cardiomyocytes from control (DMSO) treated mice. 
	  
Isolated cardiomyocytes from DMSO (control) treated mice showed loss of the 
mitochondrial membrane potential after SI/RO after JC-1 staining. More JC-1 exists in 
monomer form than aggregates as the mitochondria have lost the positive motive force 
required for oxidative phosphorylation.  
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Figure 41.  JC-1 staining of cardiomyocytes from combo treated mice. 
 
Figure 41, shows JC-1 stained cardiomyocytes after SI/RO, and JC-1 stain has mostly 
formed aggregates within the inner mitochondrial membrane given maintenance of the 
mitochondrial membrane potential.  
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Figure 42.  JC-1 staining of cardiomyocytes from HO-3867 treated mice. 
	  
After 12 weeks of treatment with TAD, cardiomyocytes subjected to SI/RO, showed a 
much higher level of JC-1 in aggregates when compared to myocytes isolated from 
control hearts.  
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Figure 43.  JC-1 staining of isolated myocytes from TAD treated mice after SI/RO 
 
As seen in Figures 40-43, isolated cardiomyocytes were subjected to 40 min SI 
and 1 h RO and then stained with JC-1 to evaluate for preservation of the mitochondrial 
membrane potential. Isolated cardiomyocytes from every treatment arm showed 
preservation of the Δψm by aggregate formation of JC-1 within the mitochondria as 
indicated by orange-red fluorescence. Control cardiomyocytes subjected to similar time 
period of SI and RO showed significant loss of the Δψm by a decrease in JC-1 
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aggregates (less accumulation within the inner membrane) and higher levels of JC-1 in 
monomer form as indicated by green fluorescence. Figure 39 shows the ratio of JC-1 of 
aggregate to monomer formation for each of the treatment groups. With maintenance of 
the membrane potential, the myocytes are still capable of oxidative phosphorylation and 
are less likely to create ROS.  
 
Role of AMPK-Akt signaling in Cardioprotection induced by TAD 
 
To confirm the NO-AMPK-Akt signaling pathway induction by TAD, myocardial 
protein levels of AMPK and Akt were assessed by Western blot analysis. Western blot 
showed that the phosphorylated forms of Akt and AMPK in db/db mice hearts were 
significantly lower than in non-diabetic C57BLKS/J control mice (n=3). Chronic 
treatment with TAD significantly enhanced phosphorylated Akt and phosphorylated 
AMPK, suggesting that TAD treatment increases NO-AMPK-Akt signaling in the diabetic 
hearts (Figure 44-45) and improved signaling through these pathways may be one of 
mechanisms for cardioprotection and increased glucose sensitivity.   
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Figure 44.  Western blot and densitometric results of Akt and AMPK. 
	  
The figure above illustrates the decrease in phosphorylated Akt to total Akt expression 
in the diabetic mouse, which was restored after chronic TAD therapy. Likewise, the 
diabetic mouse has lower myocardial levels of phosphorylated AMPK, which was also 
restored to physiological levels after chronic TAD treatment, as shown in the lower half 
of the Western blot. This may be one of the mechanisms by which TAD provides 
cardioprotection in diabetic mice and further augments the insulin signaling pathway. 	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Figure 45.  Densitometry results of phosphorylated AMPK:total AMPK 
 
The densitometry results show that the ratio of phosphorylated AMPK to total AMPK 
was significantly increased after chronic TAD therapy. The normal diabetic animal has 
been shown to have decreased levels of activated AMPK and reduced signaling via the 
critical metabolic regulator, AMPK. Treatment with TAD was able to restore AMPK in 
db/db mice by increasing activated AMPK to levels normally found in non-diabetic mice.  
 
Cardiomyocyte Necrosis  
Our method of cell preparation yielded at least 90% of the isolated 
cardiomyocytes with rod shape morphology. After 40 min of SI and 1 h of RO, the 
percent of trypan blue-positive (necrotic) cardiomyocytes was 79.8±1.5% in the control 
(DMSO) group. Treatment with TAD, HO-3867 and combination treatment resulted in a 
*p<0.05 vs. C57BLKS 
#p<0.05 vs. db/db 
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statistically significant decrease in the number of trypan-blue positive cardiomyocytes. 
The number of trypan-blue positive cells expressed as the % of total cells for each 
group was: 44.2±4.9% (TAD), 27.3±3.2% (HO-3867) and 34.9±3.9% (combination 
treatment), respectively; p<0.05 vs. 73.5±3.6% (control) for each group (Figure 46). In 
addition, we found a significant decrease of necrotic myocytes between the HO-3867 
treatment group and the TAD group as well (p<0.05).  
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Figure 46.  Number of trypan blue staining cardiomyocytes.  
	  
The total number of trypan-blue positive cells was significantly reduced after chronic 
therapy with TAD, HO-3867 and combination therapy. Surprisingly, HO-3867 provided 
the most potent benefit in preventing necrosis after 40 min SI and 1 h RO whereas 
combining TAD and HO-3867 did not provide any synergistic benefit. However, the 
possibility of any additive benefit cannot be totally excluded. The synthetic curcumin 
analogue, HO-3867 not only had a significant reduction when compared to control, but 
also when used alone it had statistically significant reduction when compared to TAD 
alone. Hence, not seeing a dramatic reduction or statically significant reduction between 
combination therapy and TAD or HO-3867 alone, the difference seen with HO-3867 and 
the significant decline with combination therapy (vs. control) does provide some 
evidence that an additive benefit may exist. Future experiments using several mice for 
cardiomyocyte isolation may provide further supportive data.  
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Figure 47.  Trypan-blue staining of cardiomyocytes from control (DMSO) treated mice after SI/RO 
	  
Trypan-blue exclusion of myocytes from control treated mice after 40 min SI and 
1 h RO reveals a significant number of necrotic cells with a very few number of 
preserved cells without trypan-blue staining and even fewer with rod-shaped 
morphology.  
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Figure 48.   Trypan-blue staining of cardiomyocytes from TAD treated mice after SI/RO. 
	  
Diabetic mice subjected to chronic TAD treatment and then had hearts isolated 
for cardiomyoyte isolation and subsequent SI/RO, showed less necrotic cells and 
increased preservation of myocytes with less trypan-blue positive cells and more cells 
having a rod-shaped morphology when compared to control.  
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Figure 49.  Trypan-blue staining of cardiomyocytes from combo treated mice after SI/RO. 
	  
	   Isolated cardiomyocytes from mice treated with combination therapy had an 
increase in cell survival with less trypan-blue positive cells when compared to control.  
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Figure 50.  Trypan-blue staining of cardiomyocytes from HO-3867 treated mice after SI/RO. 
	  
Figures 47-50, provide quantitative data of the in vitro effects of TAD, HO-3867, 
and combination therapy on isolated ventricular cardiomyocytes following 40 min SI and 
1h RO using a Nikon Eclipse Ti microscope (Melville, NY). After 1 h of RO, trypan-blue 
positive nuclei were counted in respect to the total number of cell nuclei seen. The TAD, 
HO-3867 and combination treated groups had significantly lower trypan-blue positive 
nuclei as compared with cardiomyocytes treated with control. In addition, myocytes 
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isolated from the HO-3867 group were much less necrotic when compared to myocytes 
isolated from TAD treated mice as well, p<0.05; Figure 46.   
 
Plasma Inflammatory Cytokine and Chemokine Levels  
There was a significant decrease in nearly all pro-inflammatory cytokines 
measured after 12 weeks of treatment with TAD, HO-3867 or combination therapy when 
compared to DMSO with the exception of IL-6 (Figures 51). Surprisingly, there was no 
decrease in the anti-inflammatory cytokine IL-10 in any of the treatment arms when 
compared to DMSO, (p=ns; Figure 55). There was however a trend towards an increase 
in IL-10 with combination therapy, but this did not achieve statistical significance.  
We found a significant reduction in circulating levels of the pro-inflammatory 
cytokines TNF-α and IL-1β (Figures 52 and 53).  Unfortunately, we did not find any 
additive or synergistic anti-inflammatory effect when combining the two therapies. 
Interestingly, we did not see a decrease in circulating IL-6 levels with any of the 
treatment therapies, in fact there was an increase in IL-6 with TAD therapy when 
compared to control and the other treatment arms (Figure 54). The other treatment 
groups had no significant decrease in IL-6 levels when compared to control. Currently 
there is an ongoing debate on whether IL-6 is beneficial or detrimental in diabetes and 
the use of leptin receptor null mice would only further complicate the cellular and 
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molecular dynamics. The chemokines MIP-1β (CCL-4), MCP-1 (CCL-2) and RANTES 
(CCL-5), were all significantly reduced with TAD, HO-3867 and combination therapy 
when compared with control (Figures 57-59). Plasma levels of the chemokine MIP-1α 
(CCL-3) however could not be interpreted as all levels measured using the Bio-Plex 
Magnetic beads assay were below the standardized concentration curve and could not 
be analysed.   
	  
Figure 51. Reduction of inflammatory cytokines and chemokines vs. control (DMSO). 
	  
The figure above shows the percent reduction of the eight assessed inflammatory 
cytokine and chemokines in the 3 treatment groups as compared to the DMSO treated 
mice.  There were notable reductions in the key pro-inflammatory cytokines, however 
given the increase in IL-6 in the TAD group; it is difficult to appreciate the changes. 	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Figure 52.  Reduction in inflammatory cytokines and chemokines vs. control (DMSO) treated mice. 
	  
Figure 52 also shows the percent reduction of the inflammatory cytokine and 
chemokines in the 3 treatment groups as compared to the DMSO treated mice although 
with the exclusion of IL-6, the reductions in each group is much easier to appreciate. 	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Figure 53.  Plasma levels of TNF-α.  
	  
After 12 weeks, circulating plasma levels of the inflammatory cytokine TNF-α was 
significantly reduced in each treatment group. There was a robust decline from control 
levels 264±12.8 pg/mL vs. 56.6±11.6 pg/mL for TAD, 60.3±10.9 pg/mL in the HO-3867 
group and 36.3±6.2 pg/mL for combination therapy (p<0.05 for all groups vs. control). 
The combination therapy group had the most profound reduction in TNF-α levels, 
although when compared to TAD and HO-3867 this reduction was not significant.  
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Figure 54.  Plasma levels of IL-1β. 
	  
Plasma levels of the pro-inflammatory cytokine IL-1β were reduced after 12 weeks of 
treatment in every group when compared to control. The combination group did not 
have any additive benefit in attenuating IL-1β. The control levels of IL-1β after treatment 
was 81.7±5.7 pg/mL vs. 39.3±4.5 pg/mL for TAD, 32.7±5.6pg/mL in the HO-3867 group 
and 40.7±9.1 pg/mL for combination therapy (p<0.05 for all groups vs. control). 
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Figure 55.  Plasma levels of IL-6. 
	  
Interestingly, no treatment group led to a decrease in IL-6 levels although there was not 
a statistically significant increase in either the HO-3867 (4.6± 1.2 pg/mL) or combination 
groups (2.8± 0.52 pg/mL) either. There was however, a dramatic increase in IL-6 after 
chronic TAD treatment (10.4± 3.5 pg/mL) as compared to control (2.6± 0.1 pg/mL).  
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Figure 56.  Plasma levels of IL-10.  
 
Plasma levels of anti-inflammatory cytokine IL-10 were not significantly different in the 
TAD (42.1±13.6 pg/mL) or HO-3867 (44.8±4.1 pg/mL) treatment groups when 
compared to control (64.6±2.6 pg/mL). We did find a trend towards an increase in IL-10 
levels after 12 weeks of combination treatment (71.8±8.0 pg/mL), however this did not 
reach statistical significance.  
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Figure 57.  Plasma levels of IFN-γ. 
	  
The dimerized soluble cytokine IFN-γ is a key mediator of macrophage activation and 
plays a significant role in autoinflammatory and autoimmune diseases. It has been 
shown to be upregulated and associated with obesity-induced inflammation. After 12 
weeks of therapy, plasma levels of IFN-γ were dramatically reduced with TAD (2.9±0.7 
pg/mL), HO-3867 (2.7±0.1 pg/mL) and combination treatment (3.9±0.5 pg/mL) when 
compared to control (7.1±0.8pg/mL), p<0.05 vs. all groups.  
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Figure 58.  Plasma levels of MIP-1β. 
	  
The chemokine MIP-1β or chemokine (C-C motif) ligand (CCL-4) is also a macrophage 
activator and helps recruit macrophages to adipose tissue which perpetuates the pro-
inflammatory cascade associated with insulin resistance and obesity. After treatment 
however, circulating levels of MIP-1β were reduced with TAD (12.0±0.9 pg/mL), HO-
3867 (10.9±2.9 pg/mL) and combination treatment (6.9±1.0 pg/mL when compared to 
control (24.8±2.3pg/mL), p<0.05 vs. all groups.  
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Figure 59.  Plasma levels of MCP-1. 
	  
Monocyte chemoattractant protein-1 (MCP-1), also known as CCL2, is a chemokine that 
activates monocytes, memory T cells, and dendritic cells to the sites of infection or 
inflammation. More recently, MCP-1 was shown to induce amylin expression through 
ERK1/2, JNK-AP1 and NF-κB related signaling pathways independent of the MCP-1 
receptor. Amylin upregulation by MCP-1 is known to contribute to the elevation of 
plasma amylin and insulin resistance in obesity. We found that treatment with each 
compound significantly reduced levels of MCP-1. Circulating levels after treatment with 
TAD were 30.5±5.7 pg/mL, HO-3867 (37.3±3.4 pg/mL) and combination treatment 
(27.2±2.2 pg/mL) when compared to control (61.5±1.8 pg/mL), p<0.05 vs. all groups.  
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Figure 60.  Plasma levels of RANTES. 
	  
Regulated upon and normal T-cell expressed and secreted (RANTES), also known as 
CCL-5 is a chemokine that plays a significant role in recruiting various leucocytes to 
inflammatory sites. It is currently unknown what exact role RANTES plays in the 
obesity-induced inflammatory disorder but given its chemotactic ability, we can 
hypothesize that attenuation of its production would decrease the inflammatory 
response. Accordingly, we found treatment with TAD (30.5±5.7 pg/mL), HO-3867 
(37.3±3.4 pg/mL) and combination of both (27.1±2.3 pg/mL) all significant reduced 
circulating levels of RANTES when compared to control (61.5±1.8 pg/mL), p<0.05 vs. 
each group.  
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The Effects of TAD therapy on MicroRNA -103/107 and Cav-1 
As shown in Figures 60 and 61, db/db mice treated with DMSO had a dramatic 
rise in myocardial miR-103 and miR-107 expression when compared to non-diabetic 
controls.  
 
	  
Figure 61.  Myocardial miR-103 expression after TAD treatment. 
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Treatment with TAD caused a significant reduction in miR-103 levels (Figure 60) 
and miR-107 (Figure 61) as compared to the db/db DMSO-treated control, to levels that 
were similar to the non-diabetic control.  Since the downstream target gene of miR-
103/107 has been predicted to be caveolin-1 based on complimentary sequence 
alignment, we evaluated myocardial mRNA levels of Cav-1 and confirmed this by 
Western blot analysis.  
	  
	  
 Figure 62.  Myocardial miR-107 expression after TAD treatment.  
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Figure 63.  Cav-1 mRNA after TAD treatment.  
	  
The total myocardial mRNA expression of Cav-1 was significantly reduced in the db/db 
mice, which correlated with the increased expression of myocardial miR-103 and -107. 
To further confirm the reduced mRNA levels of caveolin-1, we performed a Western blot 
analysis for protein expression and similarly found lower levels of CAv-1 protein in the 
diabetic controls. Conversely, after chronic TAD treatment, there was a significant 
increase in Cav-1 mRNA expression as well as protein levels (Figures 63 and 64).  
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Figure 64.  Western blot and densitometry data of Cav-1 protein. 
	  
Given that both miRs negatively regulate Cav-1, we found a statistically significant 
increase in Cav-1 expression with chronic TAD treatment, which appropriately 
correlated with the decrease in miR 103/107. Likewise, the db/db group had significantly 
lower levels of Cav-1, which corresponded with the much higher levels of both miRs 
(Figures 62-63).  
 
 
 
 
T-Caveolin
To
ta
l  
C
av
eo
lin
/G
ap
dh
Co
ntr
ol
db
/db
db
/db
 + 
TA
D
0.0
0.5
1.0
1.5
**
*
*  p<0.05 vs. control
** p<0.05 vs. control
Control db/db db/db + TAD
Gapdh (37 Kda)
T-Cav-1 (22 Kda)
	   	   P a g e 	   | 	   1 5 9 	  
	  
	  
Evaluating total protein expression of Cav-1, we found a significant increase in 
the non-diabetic controls which significantly downregulated in the diabetic mice. This 
could have been related to the elevated miR-103 and miR-107 expression since it is 
speculated that the downstream target gene of miR-103/107 is Cav-1. Chronic TAD 
therapy attenuated this dramatic decline in Cav-1 levels and this may be one 
mechanism by which chronic TAD treatment improves insulin signaling as Cav-1 is 
known to improve insulin receptor stabilization and enhance insulin signaling.  
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CHAPTER 7 
 
DISCUSSION 
 
For the first time, we have demonstrated that chronic administration of a 
synthetic analogue of curcumin attenuates inflammation, significantly improves insulin 
sensitivity, reduces mean body weight and ameliorates infarct size after I/R injury both 
with and without the concomitant administration of the PDE-5 inhibitor TAD. The 
treatment regimens of TAD and HO-3867 exhibited beneficial effects on various 
systemic metabolic abnormalities induced by insulin resistance and obesity and 
together were effective in improving the metabolic status of obese mice as evidenced by 
improvements in body weight, fasting blood glucose and both insulin and glucose 
tolerance tests. The db/db mouse model is a model of severe type II diabetes in 
morbidly obese animals and we hypothesized that the moderate reductions in terms of 
body weight and blood glucose observed in our preliminary investigations could be 
further accelerated and potentiated if TAD treatment was coupled with another anti-
hyperglycemic drug.  Although clinical studies indicate that the incidence and severity of 
AMI are greater in the diabetic population compared to the non-diabetic 
populations,253,255 experimental data reveals conflicting data on the vulnerability of the 
diabetic heart to ischemia in diabetic animal models.256 These inconsistent results can 
be partially explained by different durations and severity of diabetes and interspecies 
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variability.257-259 Moreover, the severity and type of ischemic challenge can modify the 
response of the diabetic heart to injury.257 In this investigation, we challenged the 
diabetic hearts to 30 min global ischemia followed by 1 h reperfusion that resulted in 
increased sensitivity to ischemic insult as evidence by larger infarct sizes in the 
untreated diabetic mice hearts (Figures 31-35). Cardiac function did not significantly 
improve in the treatment group during isolated I/R, albeit significant variability between 
isolated hearts in the same treatment group quite possibly lead to this non-significant 
finding. We speculate that possible differences at the time of experimentation such as 
quality of buffer preparation (given the requirement for daily preparation), pH variability, 
and in our model, external temperature, which could not be stringently regulated to be 
maintained continuously at 37° C without any variance.  Each issue could potentially 
limit and/or hinder cardiac performance in the isolated perfused heart model. We did 
however find a difference in coronary flow rates with improvements in coronary flow in 
the treatment groups when compared to the DMSO treated controls (Figure 36).  
 Likewise, in vitro studies using isolated cardiomyocytes from each treatment 
arm yielded a reduction in necrotic cells after chronic administration with TAD both with 
and without HO-3867 after 40 min SI and 1 h RO. The cardioprotective effects of these 
drugs, specifically TAD, are consistent with our previous studies that demonstrate that 
PDE-5 inhibitors can induce powerful cardioprotective effects against in vivo myocardial 
I/R injury, yet in the normoglycemic mice.260 
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 A number of cellular signaling pathways have been demonstrated to be 
involved in the cardioprotective effects of TAD.  Previously we reported that TAD 
treatment enhances cGMP and PKG levels in murine models of I/R injury indicating that 
the cardioprotective effect of TAD is through the NO-cGMP-PKG signaling 
cascade.260,261 Likewise, we have shown that other PDE-5 inhibitors, such as sildenafil 
and vardenafil, upregulate PKGIα, eNOS/iNOS protein expression, open the 
mitochondrial KATP channel and through phosphorylation and inactivation of GSK-3β, 
prevent opening of the mPTP—all of which lead to cardioprotection (Figure 64).30, 32, 211, 
262, 263  
 The phosphorylation and activation of PI3K leads to activation and 
phosphorylation of Akt, which phosphorylates and inactivates GSK-3β. We evaluated 
the myocardial expression of phosphorylated Akt (pAkt) in non-treated db/db controls, 
non-diabetic controls, and db/db mice treated chronically with TAD. We found a 
significant decline in phosphorylated Akt in diabetic mice, which was restored after TAD 
treatment. Similarly, db/db mice are known to have lower than normal levels of 
activated/phosphorylated AMPK (pAMPK), a key regulator of metabolism, which were 
significantly lower in the diabetic mouse yet restored to basal non-diabetic levels with 
TAD therapy. These observations confirm previous studies that demonstrate the critical 
role of Akt and AMPK in mediating the cardioprotective effects in diabetic hearts.264    
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 PDE-5 inhibitors have also been shown to increase hydrogen sulfide (H2S) 
levels through PKG which upregulates the enzyme responsible for H2S production--- 
CSE. Recent data support a number of beneficial and cardioprotective effects of H2S. 
Through increased H2S levels, downstream effects include opening of the mitochondrial 
KATP channel, increased PKC which decreases intracellular calcium load and prevents 
opening of the mPTP. Likewise, through PI3K, Akt and PKC-θ signaling cascade it can 
increase expression of anti-apoptotic proteins, Bcl-2 and Bcl-XL. Another beneficial 
effect of H2S is that is a known activator of Nrf2, which allows its translocation to the 
nucleus for transcription of antioxidant genes such as heme oxygenase-1 (HO-1), 
glutathione peroxidase (GPX), catalase, and glutathione-S-transferase (GST) (figure 
64).  
 Oxidative stress mediated by hyperglycemia-induced generation of ROS 
contributes significantly to the development and progression of diabetes and related 
vascular damage.265 Impaired antioxidant defenses coupled with an increase in ROS, 
both contribute to oxidative stress and numerous studies have shown that ROS 
generation increases in both type I and type II diabetes.266-269 Moreover, ROS are 
involved in insulin resistance via its regulatory effects on mitochondrial function.270  
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Figure 65.   Possible mechanisms by which TAD attenuates inflammation, improves glucose levels 
and offers cardioprotection 
The illustration above represents the various pathways that TAD may affect signaling to 
attenuate inflammation, glucose levels, myocyte apoptosis and necrosis. TAD through 
inhibition of PDE-5 can increase cGMP leading to increases in phosphorylated PI3K 
and Akt. This can inactivate GSK-3β by phosphorylation, which will inhibit opening of 
the mPTP. Likewise, cGMP increase PKGIα levels, which phosphorylates and activates 
VASP. VASP has been shown to attenuate inflammation by blocking NF-κB. PKGIα also 
can directly open the mitoKATP channel, which further leads to cardioprotection. Through 
the insulin receptor substrate (IRS) and the increased Akt and PI3K from downstream 
PDE-5 inhibition, there can be an increase in GLUT4, which promotes glucose uptake.   
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In the present investigation we demonstrate that chronic treatment with TAD and HO-
3867 attenuates oxidative stress induced in an animal model of type II diabetes and 
likewise decreases the ROS production in isolated ventricular myocytes following SI/RO 
injury. In addition, increased ROS generation augments impairment of mitochondrial 
function in diabetic hearts.271 
As both pharmacological agents have shown the capability to attenuate ROS 
generation and reduce oxidative stress, we investigated whether the proposed 
treatment regimen would preserve the Δψm. Accordingly, JC-1 immunofluorescent 
staining revealed dissipation and loss of mitochondrial integrity following SI/RO in 
cardiomyocytes isolated from db/db mice treated with DMSO alone. However, TAD with 
and without HO-3867 significantly preserved the loss of Δψm. These findings 
demonstrate that the protective effects of TAD and HO-3867 in diabetes-induced 
oxidative damage may be due effective ROS scavenging and thus maintaining a 
delicate balance in oxidant-antioxidant status of the myocardium. This effectively 
suggests that either therapeutic compound may be a promising drug in avoiding the 
development of diabetes-induced oxidative cardiotoxicity. In addition, we recently 
published that chronic treatment with TAD in diabetes improves redox signaling by 
enhancing the antioxidant enzyme glutathione-S-transferase kappa-1 and 
downregulates redox regulatory chaperones, HSP8 and 75 kDa glucose regulatory 
protein.272 One of the proposed mechanisms, as shown in Figure 65, may be through 
upregulation of hydrogen sulfide producing enzyme, CSE. This effectively increases 
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H2S which upregulates Nrf2 and enhances its nuclear translocation. One of the 
downstream target genes of the Nrf2 transcription activator is glutathione-S-transferase.  
Chronic inflammation induces insulin resistance through upregulating metabolic 
alterations in blood pressure, blood glucose levels, and lipids. Thus, a deleterious cycle 
begins as adipose tissue release pro-inflammatory cytokines, which in turn leads to the 
development of insulin resistance and atherogenesis.224,273 At the cellular level, nutrient 
excess has been shown to activate the IKK-β/ NF-κB pathway within adipose tissue, 
which is associated with the infiltration of macrophages. It is through this mechanism 
TNF-α and IL-1β both directly impair the insulin-signaling cascade whereas 
macrophages are the main source of inflammatory mediators within both murine and 
human adipose tissue. A significant finding advancing the study of obesity-induced 
inflammation was the discovery that the marked increase in inflammatory adipokine 
production was directly related to the number of macrophages within the adipose tissue.   
We also showed for the first time that circulating levels of key pro-inflammatory 
cytokines, TNF-α and IL-1β, were significantly reduced after chronic TAD± HO-3867 
treatment. However, the combination of the two therapies did not lead to any further 
reduction in circulating cytokines.  This could be arriving at a maximum reduction or 
attenuation of circulating cytokines achieved and that combination of the two 
compounds could not lead to any further decrease. On the standard concentration 
curve, values for both TNF-α and IL-1β were on the lower end and values were often 
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omitted because they were well below the standard curve.  Nevertheless, each 
compound reduced both inflammatory markers either individually or in combination.  
The anti-inflammatory cytokine IL-10 however did not change between the 
groups, although in our preliminary experiments we saw a slight, but statistically 
significant, increase in IL-10 after 4 weeks of TAD treatment. Previously published data 
and known physiological pathways show that IL-10 levels are inversely proportional to 
adiposity.74 Adipose tissue of lean mice secretes an unusually high level of IL-1, which 
suppresses adipose tissue inflammation. Furthermore, the number of T cells that 
secrete IL-10 dramatically decrease in proportion to increasing obesity.274 After 12 
weeks of therapy, there was not a statistically significant difference in IL-10 levels 
between the groups. A non-diabetic control group would have been helpful in 
determining if the levels were higher in a treated group than in the DMSO treated 
diabetic group. Likewise, performing cytokine analysis both at the start of the study and 
repeating an analysis at the end could also provide additional data for these conflicting 
results.  
Surprisingly, we found that there was an increase in IL-6 after chronic TAD 
treatment, whereas there was no difference in IL-6 levels between control and the other 
treatment groups. This finding is also different than our preliminary findings with TAD 
and DMSO treatment for 4 weeks. In the preliminary work, there was a small and 
statistically insignificant decline in IL-6 with TAD therapy. Currently after 12 weeks, 
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there was a greater increase in circulating IL-6 levels with TAD treatment alone. The 
combination and HO-3867 groups were no different than control.  Currently, the exact 
role of IL-6 in the pathophysiology of insulin resistance remains controversial and to 
date there is no consensus although various experiments have provided some critical 
information on its effects on the insulin signaling cascade. In insulin-resistant 
individuals, IL-6 levels were found to be significantly elevated in adipose tissue.275 
Moreover, IL-6 acts both centrally and peripherally to induce energy expenditure and 
impair insulin signaling.276 However, both deficiency and overexpression of IL-6 lead to 
severe hepatic inflammation and insulin resistance. In cell culture models, hepatic and 
adipocyte insulin signaling can be inhibited by IL-6 through IRS-1 inhibition.277 Future 
experiments with tissue specific targeting of IL-6 will likely improve our understanding of 
IL-6 and its pathophysiological role in insulin resistance.  
The monocyte chemoattractant protein-1 (MCP-1) is produced by adipose tissue 
in response to dietary excess and is a key factor in recruiting the macrophage 
precursor, the monocyte. Studies in MCP-1-/- and mice overexpressing MCP-1 confirm 
the role of this chemokine in attracting macrophages to adipose tissue and in reducing 
insulin sensitivity in high-fat diet induced obesity.278 Mice lacking the receptor for MCP-1 
showed a lower macrophage content in visceral adipose tissue and improved insulin 
sensitivity after high-fat diet feeding.279 Likewise, the expression of a dominant negative 
mutant for MCP-1 in obese db/db mice significantly decreased their insulin 
resistance.280 In addition to MCP-1, human studies have confirmed the increase of 
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MCP-2, RANTES, and macrophage inflammatory protein (MIP)-1α in obese individuals 
when compared to lean cohorts. 281  
Macrophage inflammatory protein-1β (MIP-1β), MCP-1 and RANTES are three 
chemokines with the C-C ligand (CCL) motif and play a significant role in the activation 
and proliferation of the inflammatory cascade, especially in adipose tissue and the 
endothelium.282 Not surprisingly, TNF-α can activate both MCP-1 and MIP-1β which 
further recruit macrophages to the adipose tissue, hence potentiating the inflammatory 
response.283 This invariably leads to the chronic low-level state of inflammation found in 
obesity. We found that along with reduced levels of TNF-α, the chemokines MIP-1β, 
MCP-1 and RANTES were all significantly reduced with all three treatments as 
compared with control.  
Early in obesity-related insulin resistance there is a reduction in vascular NO 
content, which predisposes to increased vascular inflammation, thrombosis and 
vasoconstriction. This precedes the increase in hepatic NF-κB signaling and impaired 
insulin signaling through phosphorylated Akt. Nitric oxide signaling includes activation of 
PKG and one downstream target is vasodilator-stimulated phosphoprotein (VASP), a 
protein implicated in the control of cytoskeletal dynamics and cell migration.169 Several 
studies have shown that diet-induced obesity and genetically induced murine models of 
obesity, both reduce vascular NO content which precedes a dramatic increase in 
hepatic inflammation and hepatic insulin resistance (decrease in insulin stimulation of 
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the IRS-1/PI3K/Akt pathway). In addition, the decline in NO content precedes the 
inflammation, which is characterized by an increase in NF-κB signaling. Several dozen 
studies have established the role of curcumin in inhibiting NF-κB signaling through 
directly blocking the HAT p300/CBP. In a study by Handa et al, they found that reduced 
VASP directly correlated with adipose tissue inflammation (increased TNF-α, IL-6) and 
was also associated with significantly low levels of NO and phosphorylated eNOS.169 In 
addition, they found that phosphorylation of VASP by PKG was critical in the attenuation 
of hepatic inflammation and insulin resistance and VASP-/- mice were especially 
vulnerable. Moreover, restoration and/or augmentation of VASP signaling with use of a 
PDE-5 inhibitor attenuated insulin resistance, inflammation and improved insulin 
signaling. Endothelial NO levels were also increased as a result of elevated eNOS 
expression. Conversely, eNOS-/- mice were quick to develop vascular inflammation and 
insulin resistance regardless of low or high fat diets. In our study, use of the long acting 
PDE-5 inhibitor could have increased phosphorylated VASP levels as a potential 
mechanism for ameliorating inflammation, improving insulin resistance and endothelial 
NO.  
We believe that restoration of NO-sGC-PKG signalling following chronic 
treatment with TAD is the critical mechanism behind improving fasting blood glucose 
levels and targeting insulin resistance. With improved NO bioavailability and 
vasodilatation with PDE-5 inhibitors,284 there is increased blood flow for muscle glucose 
utilization and additionally, the decreased TNF-α in the circulation may potentially 
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attenuate the amount of IRS-1 receptor phosphorylation and improve insulin signalling. 
It has also been postulated that chronic PDE-5 inhibitor treatment may increase fatty 
acid oxidation and may also be a potential mechanism for preventing insulin resistance. 
In a mouse model of diet-induced obesity and insulin resistance, chronic sildenafil 
treatment was able to improve insulin action and decrease body mass.3 In addition, 
chronic therapy with both a PDE-5 inhibitor and synthetic curcumin, lead to a significant 
reduction in body weight, which directly correlated with levels of inflammation. We 
believe the overall reduced inflammatory drive stimulated by adiposity was critical in 
glucose homeostasis as improvements in fasting glucose correlated with reductions in 
mean body weight.  
Treatment with TAD in C2C12 myoblasts improves oxidative capacity as 
demonstrated by increase in fatty acid metabolism, including the activities of citrate 
synthase and 3-OH acylCoA dehydrogenase.285 One possible explanation is that PKG 
has been shown to affect insulin signaling and mitochondrial biogenesis in brown 
adipose tissue by inhibiting the activity of RhoA and Rho-associated kinase (ROCK), 
thereby relieving the inhibitory effects of ROCK on IRS-1.286 This allows the activation of 
the phosphotidyl-inositol-3-kinase (PI3K)-Akt signaling cascade downstream of the 
insulin receptor. In addition, Haas et al showed that PKG mediated the ability of NO and 
cGMP to induce mitochondrial biogenesis and increase the expression of UCP-1, a 
protein necessary in energy expenditure through thermogenesis 286. Similarly, NO and 
eNOS have been shown to directly correlate with mitochondrial biogenesis as the 
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abundance of peroxisome proliferator activated receptor-gamma (PPAR-γ) and cold-
induced mitochondrial biogenesis were completed abrogated in an eNOS knock-out 
model.287,288   
We found that 12 weeks of treatment with a synthetic analogue of curcumin (HO-
3867) provided significant metabolic benefits with improvements in insulin sensitivity 
and body weight. The anti-inflammatory effects, as demonstrated by reductions in key 
cytokines and chemokines seen with HO-3867 therapy, were associated with 
improvements in glycemic control as determined by blood glucose levels, glucose and 
insulin tolerance tests. Treatment was also associated with a small, but statistically 
significant, decline in body weight during the 3-month treatment period. Interestingly, a 
study by Weisberg et al also found a notable reduction in hepatic NF-kB activity and an 
overall decreased inflammatory profile in the ob/ob and diet-induced obese murine 
models after 6 weeks of curcumin therapy. Likewise, they found reductions in body 
weight and hemoglobin A1c, and improvements in insulin and glucose tolerance tests, 
and fasting glucose levels. They went on to show a dramatic increase in mRNA and 
serum protein levels of the insulin-sensitizing protein, adiponectin. In addition, they 
showed curcumin reduced ER stress and the downstream benefits were improvements 
in hyperglycemia. They found curcumin therapy upregulated heat shock protein (HSP) 
70, HSP90, and Sirt1, which all attenuate the ER stress response and increase 
adiponectin levels.83  
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Figure 66. The various potential mechanisms by which curcumin provides anti-inflammatory, anti-
oxidant, cardioprotective and insulin sensitizing effects. 
This figure illustrates the various pathways by which curcumin has been shown to have 
protective anti-oxidant, anti-inflammatory, insulin-sensitizing and cardioprotective 
effects. Curcumin is a cell-permeable compound with inherent histone acetyltransferase 
(HAT) inhibitory activity for p300/CBP, which attenuates activation of NF-kB. Likewise, 
through Nrf2 signaling, can upregulate anti-oxidant genes and by inhibition of PKC, will 
prevent NADPH oxidase from generating ROS. Through the upregulation of AMPK, Akt, 
PPAR-γ, and CD36 it increases free-fatty acid oxidation and glucose utilization. As 
discussed earlier, increases in PKG and eNOS also have cardioprotective features. The 
inhibition of p38 MAPK attenuates cardiac fibrosis and hypertrophy that prevents post-
MI induced heart failure, whereas the inhibition of p300/CBP has been shown to be a 
critical signaling molecule through which curcumin therapy reduces infarct size. 
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The limitation of the Weinberg study was that an extremely high dose of 1.5g/Kg of 
curcumin was used because of the compound’s poor oral bioavailability. Such extremely 
high doses would be impractical to use in human clinical studies, albeit unlikely toxic. 
However, having similar benefits to organic curcumin but 10 times the absorption rate 
and potency, HO-3867 may be a promising alternative for future study especially for 
cardiometabolic diseases.78 In figure 66, the numerous pathways that curcumin has 
been shown to provide anti-inflammatory, anti-oxidant and even cardioprotective effects 
are illustrated. Numerous data supports that curcumin treatment can upregulate 
glutathione S-transferase and lead to nuclear translocation of Nrf2, which results in an 
increase in anti-oxidant gene expression.289  
In addition, through inhibiting the HAT p300/CBP and its transcriptional activating 
ability, it can block downstream activation of NF-κB, a key regulator of inflammation. 
Curcumin has also been shown to inhibit specific subunits of NADPH oxidase via PKC, 
which accordingly attenuates ROS production. Similarly, its affect on metabolism and 
glucose homeostasis has been shown to be via the upregulation of a number of 
regulatory signalling molecules such as AMPK, Akt, CD36, PPAR-γ and eNOS.  
Like most oral diabetic drugs, curcumin activates PPAR-γ and improves blood 
glucose levels without having to increase pancreatic β cell secretion of insulin and even 
induces gene expression of PPAR-γ. Likewise, PPAR-γ is known to be downregulated 
by TNF-α of which both TAD and HO-3867 decrease circulating plasma levels. 
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Moreover, curcumin can activate AMPK by phosphorylating its α subunit and increasing 
fatty acid oxidation within adipocytes.83 In a study by Seo et al, db/db mice were fed 
curcumin 0.02% (wt/wt) for 6 weeks. Curcumin significantly lowered hepatic activities of 
fatty acid synthase, beta-oxidation, 3-hydroxy-2-methylglutaryl coenzyme reductase, 
lowered plasma FFA, cholesterol, triglyceride concentrations, and increased hepatic 
glycogen and skeletal muscle lipoprotein lipase (LPL).290 
Curcumin has been shown to improve insulin signaling and glucose disposal 
through mitigating oxidative stress within the mitochondria via upregulating the Nrf2 
signaling pathway.289 A recent study by Yu et al showed in an in vivo model that 
oltipraz, a compound which upregulates Nrf2 signaling, could prevent insulin resistance 
and obesity in C57BL/6J mice fed a high-fat diet. Within 3T3-L1 adipocytes, curcumin 
could increase insulin-stimulated glucose uptake through inhibition of NF-κB and JNK, 
and through inhibition of the pro-inflammatory response by inhibiting phorbol myristate 
acetate induced (PMA)-induced MCP-1 expression and TNF-α secretion.73  
Through inhibition of p38 MAPK signalling, SOCS3, and the p300/CBP HAT and 
via upregulation of the JAK2/STAT3 pathway, curcumin also has favourable effects on 
cardiac remodeling and cardiac hypertrophy.291,292 This abrogates unfavourable 
remodeling after AMI and reperfusion injury and prevents the development of heart 
failure.  
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We found that chronic treatment with TAD had an effect on myocardial 
expression of miR-103 and miR-107—two miRs that have been shown to play a role in 
glucose regulation and insulin sensitivity. Chronic TAD therapy attenuated the increase 
in both miR-103/107 seen in the diabetic controls (DMSO-treated), which was 
significantly higher than that seen in non-diabetic mice (Figures 60 and 61). Moreover, 
recent data has shown that the downstream target gene for these miRs include Cav-1, 
which is a key component of caveolae within the plasma membrane and helps stabilize 
the insulin receptor and improve insulin signaling.219 Given that both miRs negatively 
regulate Cav-1 expression, db/db controls had a significant rise in miR expression and a 
dramatic decline in Cav-1 expression, which may present one mechanism by which 
insulin sensitivity is decreased. In contrast, chronic TAD treatment in db/db mice 
lowered myocardial expression of both miRs to levels comparable to that seen in the 
non-diabetic control. This ultimately led to a significant increase in Cav-1 mRNA 
transcript levels and protein expression.   
The underlying mechanism behind the decreased expression of miR-103 and -
107 is still unknown but we speculate it may not be secondary to a single enzyme or 
signaling molecule but rather a complex system inherently designed to work in concert 
with the metabolic systems of the body. As hormone dysregulation occurs with over 
nutrition and obesity, there is upregulation of these miRs, which leads to downregulation 
of their target gene, Cav-1.  
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Figure 67.  Potential mechanisms by which TAD treatment effects miR-103/107 and Cav-1 
expression. 
The figure above depicts the possible mechanism through which miR-103 and -107 
effect insulin sensitivity and inflammation. Cav-1 provides stabilization of the insulin 
receptor and enhances insulin signaling, and increased expression of miR-103 and -107 
downregulates Cav-1 therefore destabilizing the insulin receptor. Likewise, recent data 
suggest that this augments inflammatory signaling through TLRs thus increasing 
inflammation, which further affects insulin signaling. PDE-5 inhibitors increase PKGIα 
and VASP, and VASP is a protein known to attenuate inflammation. Whether a direct or 
indirect effect of PKG signaling effects miR-103 and -107 expression has yet to be 
determined.  
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Cav-1, being a critical protein within caveolae and known to help stabilize the 
insulin receptor and enhance insulin signaling, it is only intuitive to realize that proper 
signaling will be disturbed with its downregulation. Whether treatment with TAD has a 
direct effect on Cav-1 expression or has an indirect effect as a result of targeting miR-
103/107, will take further experimentation most likely with the use of genetically 
engineered murine models.  
In future studies, we will likely include several additional methods to further 
understand the intricacies of metabolic disease, the NO-cGMP signaling cascade, 
inflammation and the use of novel pharmacological therapies.  The use of nuclear 
magnetic resonance for body fat composition analysis will be a better method than basic 
weight measurements to identify fat loss between treatment groups as opposed to 
simply global weight loss which can include lean muscle mass loss as well. Assessing 
inflammatory cytokines both pre- and post pharmacological intervention would also be 
valuable. We would also plan to include a large control set of non-diabetic mice for all 
experiments. Additionally, given that we did not see a change in IL-6 levels we would 
pursue the assessment of IL-6 in various tissue samples, especially hepatic and 
adipose tissue.  
Interestingly, a newer device used in human clinical studies called a Dexcom 
could possibly be used in animal studies. This would dramatically accuracy of blood 
glucose recordings and furthermore allow for continuous monitoring. The small 
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implantable device could be implanted under the skin, which would continuously report 
interstitial glucose levels. The only caveat is that it requires venous glucose samples 
twice a day to be put into the wireless monitoring device for calibration.  
We found that miR-103 and -107 are elevated in the obese, diabetic model and 
that TAD therapy reduced these levels. Whether a direct correlation to PKG signaling 
can be made at this time is not possible. In the future, using a PKG viral knockdown 
model or drug inhibitor and LNA-antagomir therapy/overexpression, whether or not PKG 
is directly involved or is part of the signaling can begin to be sorted out.  
In summary, these studies provide new insight into the potential role of TAD and 
curcumin-induced cardioprotection, anti-oxidant and anti-inflammatory effects in type 2 
diabetes.  In particular, we demonstrated that both TAD and HO-3867 attenuated ROS 
formation induced in the diabetic myocardium following I/R injury and improves 
mitochondrial integrity while providing cardioprotective effects via Akt-AMPK signaling. 
In addition, we showed profound effects on insulin sensitivity and glucose homeostasis 
with both compounds and specifically that TAD may impact the metabolic system 
through attenuation of key microRNAs (miR-103/107) and their downstream target, Cav-
1.  
Overall our investigation is unique and may have significant implications for the 
management and treatment of insulin resistance, oxidative stress and obesity-induced 
inflammation—three conditions that co-exist long before CV disease clinically manifests. 
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PDE-5 inhibitors are a promising class of compounds already approved for the 
treatment of pulmonary arterial hypertension and erectile dysfunction, and curcumin is a 
natural compound with potent anti-inflammatory, anti-thrombotic, anti-oxidant and 
cardioprotective effects.73, 292 However in its natural form, curcumin is poorly absorbed, 
has low bioavailability and potency. HO-3867 is a synthetic analogue of curcumin and 
has been shown to have a 10-fold greater cellular uptake than natural curcumin thus 
making it an extremely effective, potent and powerful alternative.78 Therefore as we 
move forward, therapeutics designed to target vascular inflammation, improve insulin 
sensitivity via restoring critical signaling pathways such as the NO-cGMP-PKG pathway 
and target specific miRs, may prove to be extremely promising in the field of 
cardiometabolic medicine.  
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CHAPTER 9 
 
APPENDICES 
 
Appendix A 
Based on the results of the basic science conducted, a translational clinical trial has 
been initiated using the FDA approved drug TADALAFIL for inflammation, endothelial 
dysfunction and cardioprotection: 
 
CHRONIC TADALAFIL TREATMENT FOR THE ATTENUATION OF INFLAMMATION 
AND ENDOTHELIAL DYSFUNCTION IN THE TYPE II DIABETIC PATIENT: A 
RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY (THE 
VCU T3 STUDY) 
 
HYPOTHESIS 
Insulin resistance and type II diabetes trigger a number of mechanisms and signaling 
pathways that all lead to tissue injury and functional damage to the cardiovascular 
system. The exact pathophysiological significance remains to be fully understood, but 
inflammation and oxidative stress are imperative to the development of vascular 
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dysfunction. In addition, inflammation plays a central role in vascular disease, from 
plaque inception to progression and destabilization, which represents a significant 
paradigm shift from the old idea that vascular disease and atherosclerosis is a problem 
of lipid accumulation and oxidized cholesterol. This study is unique and may have 
significant implications for the management and treatment of type II diabetes, insulin 
resistance and endothelial dysfunction—conditions that exist long before cardiovascular 
disease clinically manifests itself. Therefore, studying these conditions is extremely 
relevant since one of our goals is to effectively target and treat the underlying pathology 
of atherosclerosis in diabetic patients.  
 
a) Type II obese diabetic patients have increased levels of circulating inflammatory 
cytokines and oxidative stress and as a result of vascular inflammation have 
endothelial damage and poor nitric oxide availability. This leads to poor blood flow 
and is at the crux of atherosclerosis.   
b) Phosphodiesterase-5 inhibitors have been shown in a number of pre-clinical studies 
and a few short-term clinical studies to reduce fasting blood sugar values, reduce 
hemoglobin A1c and improve the amount of microalbuminuria. We propose the 
chronic daily treatment may also help the diabetic patient improve plasma glucose 
levels and reduce microalbuminuria through restoring the nitric oxide-cyclic GMP 
pathway.	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SPECIFIC AIMS 
Chronic daily treatment for 8 weeks with Tadalafil 5mg for type II diabetic patient 
will: 
• Attenuate cytokines and inflammatory markers (TNF-alpha, IL-1β, IL-6), hs-CRP 
and homocysteine  
• Decrease blood levels of microRNA 103/107 (possible regulators of insulin 
sensitivity) 
• Ameliorate oxidative stress by decreasing levels of 8-isoprostane (a known 
marker of oxidative stress) 
• Increase circulating levels of nitric oxide and urinary cyclic GMP (both indirect 
measurements of endothelial health) 
• Not change urinary cyclic AMP levels thus showing that the primary effects have 
been mediated through PDE-5 inhibition and not through other PDE inhibition 
that may result in increased levels of cyclic AMP 
• Improve the following commonly followed clinical parameters in diabetic patients:  
o Fructosamine, microalbuminuria and hemoglobin A1c 
• Decrease left ventricular volumes (LV end-diastolic and end-systolic volume) 
• Reduce pulsed-wave Doppler-derived (PWD) transmitral filling indices (E- and A- 
wave velocities, E/A ratio) on transthoracic echocardiogram  
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• Increase left ventricular ejection fraction (LVEF) as measured by the Simpson’s 
rule, deceleration time [DT], diastolic filling time [DFT], and isovolumetric 
relaxation time [IVRT] on transthoracic echocardiogram. 
• Improve brachial artery flow-mediated dilatation  
 
 
RESEARCH DESIGN AND METHODS 
The purpose of this research study is to evaluate whether a medication called 
Tadalafil (Cialis™) can decrease vascular inflammation, oxidative stress and two insulin 
sensitivity regulators (microRNA 103/107); improve blood flow (as measured by urinary 
cGMP and cAMP, serum nitric oxide levels, and brachial artery flow mediated 
dilatation); decrease hemoglobin A1c, microalbuminuria and decrease left ventricular 
volumes (LV end-diastolic and end-systolic volume), reduce pulsed-wave Doppler-
derived (PWD) transmitral filling indices (E- and A- wave velocities, E/A ratio), increase 
left ventricular ejection fraction (LVEF) as measured by the Simpson’s rule, deceleration 
time [DT], diastolic filling time [DFT], and isovolumetric relaxation time [IVRT] on 
transthoracic echocardiogram.  
Tadalafil has been approved by the FDA for the use in erectile dysfunction, 
pulmonary hypertension (high pressure in the arteries going to the lungs), and an 
enlarged prostate causing urinary symptoms.  In this study, tadalafil will be compared to 
placebo (a look-alike, inactive substance). Tadalafil has not been approved to lower 
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inflammation in the body, lower blood glucose levels, or improve heart function—these 
parameters are being studied in this trial.  
The total participation time for each study subject will last up to 12 to 14 weeks.  
Approximately 40 individuals will participate in this study.  
At the first study visit (Visit 1), a comprehensive medical history will be taken and 
a physical exam will be performed.  This exam will include measurements of height, 
weight and vital signs (pulse, blood pressure and temperature).  Blood and urine 
samples will be collected for routine lab tests.  Approximately 2 tablespoons of blood 
(30mL) will be collected to measure blood levels of inflammation, hemoglobin A1c and 
nitric oxide. Women of childbearing potential will have a urine pregnancy test done and 
if positive for pregnancy cannot be enrolled in the study.  At the end of the enrollment 
and procedures (visit 1 and 2), the patient will be randomized by the VCUHS 
investigational drug pharmacy services and be provided with a 30-day supply of study 
drug (Tadalafil vs. placebo).  
After this initial assessment and blood work, a transthoracic echocardiogram 
(TTE) will be performed as part of the initial visit of the study (during visit 1), which will 
be repeated again at end of the study (at 12-14 weeks). This will take place 4 weeks 
after taking the last dose of the study drug. Various parameters will be recorded from 
the TTE including: left ventricular volumes (LV end-diastolic and end-systolic volume), 
pulsed-wave Doppler-derived (PWD) transmitral filling indices (E- and A- wave 
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velocities, E/A ratio), left ventricular ejection fraction (LVEF) as measured by the 
Simpson’s rule, deceleration time [DT], diastolic filling time [DFT], and isovolumetric 
relaxation time [IVRT].  
During the same week, the study patient will come for visit 2 after fasting for 6 
hours and have a brachial-flow mediated dilatation test. This will measure how well 
blood is flowing in the artery in the arm which is an accepted marker of endothelial 
function. This test will be performed at the start of the study and again at the end of the 
study (at 12-14 weeks). This is a test that measures how well blood is flowing in the 
brachial artery in using ultrasound to measure flow and dilatation. To perform this test 
the patient will be asked to come in fasting for at least 6 hours. Lying supine they will 
have a standard sphygomomanometer cuff applied to the right arm. This will monitor 
blood pressure and pulse throughout the examination at 5 min intervals. After resting for 
5 min, another blood pressure cuff will be applied to your left arm just below the 
antecubital fossa and inflated 50 mmHg above the measured systolic pressure and stay 
inflated for 5 min. Baseline images of the left brachial artery will be taken with an linear 
array multifrequency transducer operating at 9 MHz (GE Logiq 700 devices) just above 
the cuff for 30 seconds before inflation and then for 2 minutes immediately before 
deflation to document vasodilator response.	  	  
Within 3-4 weeks after Visit 2, the patient will come in for Visit 3.  The patient will 
be asked about his or her health since the last visit and about their overall experience 
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with the study drug, then have a repeat physical exam, which will include 
measurements of height, weight and vital signs (pulse, blood pressure and 
temperature). You will have a small amount of blood drawn (5mL or 1 teaspoon) to 
check your kidney and liver function as well as fructosamine (to give a estimate of blood 
sugar values of the past several weeks). If no issues have arisen in the interim, 
participants will receive a new supply of study drug. 
Approximately 7-8 weeks after Visit 2, the patient will come in for Visit 4.  The 
patient will have another physical exam with vital signs documented and again have 
blood and urine samples collected for testing.  Approximately 2 tablespoons of blood 
(30mL) will be collected to measure blood levels of inflammation, oxidative stress (8-
isoprostane), microRNA 103/107, fructosamine and nitric oxide. A urine sample will be 
collected to measure levels of cGMP, cAMP and microalbumin. Upon completion of a 
total of 8 weeks of treatment the patient will have completed the drug treatment phase 
of the study.  
Visit 5 will be scheduled at 12-14 weeks from visit 2.  At this time a repeat 
echocardiogram to see if there has been any change in left ventricular ejection fraction 
and brachial-flow mediated dilatation test to see if there has been any change in 
flow-mediated dilatation compared with measurements take from the start of the study.	  	  
The patient will have the last physical exam and vital signs with blood and urine 
samples collected for testing.  Approximately 2 tablespoons of blood (30mL) will be 
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collected to measure blood levels of inflammation, oxidative stress (8-isoprostane), 
microRNA 103/107, hemoglobin A1c and nitric oxide. A urine sample will be collected to 
measure levels of cGMP, cAMP and microalbumin. 
 
DATA ANALYSIS AND PLAN 
The plan is to enroll a total of 40 patients with 20 patients in each arm of the 
study.  The analyses planned include an assessment of blood for markers of 
inflammation (TNF-alpha, IL-1β, IL-6, hs-CRP), homocysteine, hemoglobin A1c, 
fructosamine, microRNA 103/107, 8-isoprostane (marker of oxidative stress), urinary 
cGMP and cAMP, improvement of various parameters on echocardiography and 
brachial artery flow-mediated dilatation. Standard descriptive statistical analysis will be 
applied to the data when patient enrollment is completed.   
 
The primary endpoint: Attenuation of the following: inflammatory markers (TNF, IL-1β, 
IL-6), hs-CRP, homocysteine, microRNA 103/107 levels (possible regulators of insulin 
sensitivity), 8-isoprostane (marker of oxidative stress); improvement in the following 
commonly followed clinical parameters for diabetic patients: hemoglobin A1c levels, 
fructosamine and microalbuminuria. We also propose an improvement in circulating 
levels of NO and urinary cGMP without significant changes in urinary cAMP. 
 
	   	   P a g e 	   | 	   2 1 5 	  
	  
	  
The secondary endpoint: We propose a decrease in left ventricular volumes (LV end-
diastolic and end-systolic volume), reduction in pulsed-wave Doppler-derived (PWD) 
transmitral filling indices (E- and A- wave velocities, E/A ratio) with increase in left 
ventricular ejection fraction (LVEF) as measured by the Simpson’s rule, increase in 
deceleration time [DT], diastolic filling time [DFT], isovolumetric relaxation time [IVRT] 
on transthoracic echocardiogram. The TTE will be performed and read by same 
investigator. Furthermore, we propose an improvement in brachial artery flow mediated 
dilatation from the start to end of the study as a result in improved nitric oxide 
bioavailability.   
Categorical variables (such as tobacco user) will be reported as absolute and 
percent values.  Continuous variables (such as stage of hypertension) will be expressed 
as median and interquartile ranges.  Chi-square and Mann-Whitney tests will be used to 
compare categorical and continuous variables among the different groups using the 
SPSS 11.0 Software for Windows. 
 
HUMAN SUBJECTS PARTICIPATION 
Participation in the study will require blood samples (approximately 30 mL) at 
study visit 1, visit 4 and visit 5, and 5mL at visit 3 for a total of 95mL of blood per patient 
during the entire study period of 12-14 weeks. The blood samples will be analyzed for 
inflammatory cytokines including TNF-alpha, IL-1β, IL-6, hs-CRP; homocysteine, 
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hemoglobin A1c, fructosamine, microRNA 103/107, 8-isoprostane, nitric oxide and urine 
sample will be taken for urine cGMP, cAMP and microalbumin and a urine pregnancy 
test for women at visit 1 only.  A complete metabolic profile will be checked at visit 3, to 
ensure renal and hepatic function has not changed significantly since the start of the 
study (one teaspoon or 5mL of blood will be drawn at this visit). Transthoracic 
echocardiogram and brachial artery flow-mediated dilatation results will be recorded 
from visits 1, 2, and 5 and will be documented in patient chart, Cerner.  
The study will also collect data available in the patient medical record: medical 
history, prior medications, body weight, vital signs, blood chemistry, hematology, and 
12-lead electrocardiogram. If there is no complete metabolic profile and hematology 
profile available from 60 days prior to visit 1, one will be done prior to start of the study 
as part of routine care (at visit 1). 
 
INCLUSION AND EXCLUSION CRITERIA 
INCLUSION CRITERIA FOR TADALAFIL TREATMENT FOR TYPE II DIABETICS STUDY (THE VCU T3 
STUDY) 
Section 1.01 To be eligible to participate in this study, candidates must have met the 
following eligibility criteria at the time of enrollment either at the time of enrollment: 
1. Age ≥18 or ≤65 
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2. Currently diagnosed type II Diabetic with current Hemoglobin A1c ≥6.5% AND 
taking one or more oral hypoglycemic agents and/or stable insulin therapy (no 
changes to insulin regimen during 12 weeks of treatment) 
3. Known diagnosis of hypertension on at least one anti-hypertensive agent; Stage I 
or II Hypertension - but ≤180/110 at the time of enrollment  
4. Dyslipidemia (must have at least 3 of 4); (LDL≥100, Total Cholesterol ≥200, 
Triglycerides ≥150, HDL≤40 or Non-LDL ≥100) or on medical therapy for 
dyslipidemia (statin, fibrates, niacin, or ezetimibe)  
5. Obesity with BMI ≥30 or waist circumference ≥102cm (40in) for men and 88cm 
(35in) for women or waist:hip ratio >0.9 for men and >0.85 for women   
EXCLUSION CRITERIA FOR TADALAFIL TREATMENT FOR TYPE II DIABETICS STUDY (THE VCU T3 
STUDY) 
Section 1.02 Unless otherwise specified, candidates will be excluded from study entry if 
any of the following exclusion criteria exist at the time of enrollment:   
	  
1. Age <18 or >65 
2. Concomitant use of nitrates, alpha blockers, CYP 3A4 inhibitors (including anti-
retrovirals for HIV and ketoconazole) 
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3. Known chronic inflammatory disease (Rheumatoid arthritis, Systemic Lupus 
Erythematosus, Inflammatory bowel disease, etc.) requiring immunosuppressant 
therapy including steroids  
4. Chronic kidney disease with creatinine clearance ≤ 50 ml/min 
5. Liver Disease defined by Childs-Pugh Stage C or D  
6. Raynaud’s phenomenon  
7. Known hereditary retinal degenerative disorders including retinitis pigmentosa  
8. Predisposition to priapism such as those with sickle cell anemia, leukemia and 
multiple myeloma 
9. Prior history of priapism 
10. Penile deformity (angulation, cavernosal fibrosis, or Peyronie’s disease) 
11. Prior myocardial infarction within the past 90 day 
12. Unstable angina 
13. Uncontrolled hypertension (>180/110) 
14. Uncontrolled arrhythmias  
15. Systolic dysfunction with left ventricular ejection fraction <40% 
16. Stroke within the last 6 months 
17. History of seizure disorder 
18. Hypotension with blood pressure ≤90/60 
19. Patients with New York Heart Association Class III or greater heart failure 
exacerbation within the last 6 months 
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20. Patients with left ventricular outflow obstruction, aortic stenosis, idiopathic 
hypertrophic subaortic stenosis, mitral stenosis 
21. Hypersensitivity to phosphodiesterase-5 or phosphodiesterase-3 inhibitors  
22. Excessive alcohol intake (≥5 drinks daily)  
23. Patients with severe anemia (hemoglobin ≤7 g/dL) 
24. Patients with active malignancy or receiving cancer treatment 
25. Prisoners 
26. Nursing mothers, pregnant women or women planning to become pregnant 
27. Prior radical mastectomy on either side (contraindication for brachial artery flow 
mediated dilatation) 
28. Congenital abnormality of either arm or hand (contraindication for brachial artery 
flow mediated 
 
RECRUITMENT PLAN 
Patients presenting to the general internal medicine clinic, the cardiovascular 
medicine clinic or the endocrinology clinic that meet the inclusion criteria will be 
recruited for this study. Initial contact will be made by one of the co-investigators or the 
research coordinator who will explain the details of the study and provide the initial 
information and consent form for patient review. The patient will have up to 3 days to 
decide after discussing with family, other health professionals, etc. whether or not they 
wish to participate in the study. If a patient agrees to enroll, contact will be made by the 
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research coordinator who will ensure inclusion criteria is met and perform an intake 
evaluation over the phone. She will schedule visit 1 and 2 for the patient at a time when 
lab-work, echocardiogram and brachial-artery flow mediated dilatation testing (visit 2) 
can all be conducted and the patient can pick up the investigational drug (after visit 2) 
from the VCUHS investigational drug pharmacy services for a 4 week supply. The 
coordinator will also ensure a follow-up appointment within the 3-4 week time period has 
been made. No vulnerable populations (i.e. children, pregnant women, human fetuses, 
neonates, prisoners) will be enrolled. 
 
POTENTIAL RISKS 
The risks of participation in this study are primarily those resulting from the study 
drug, Tadalafil. There are some side effects associated with this drug that were 
documented in phase II and phase III clinical trials where tadalafil was compared to 
placebo for the treatment of erectile dysfunction or pulmonary hypertension. In 
clinical trials for once daily use of tadalafil, discontinuation rate was similar to 
placebo and was less than 1%. The most common side effects (which occurred 
≥2%) across all tadalafil trials are: 	  
• Headache 
• Flushing 
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• Heartburn 
• Nasal congestion 
• Muscle aches 
• Back pain 
• Limb pain  
Rare but dangerous adverse effects that may occur: 
• Hypotension: when taken with alpha blockers or nitrates (both of which are 
contraindicated)  
• Priapism (an erection last greater than 4-6 hours that becomes painful)  
 
Extremely rare adverse effects identified in the post-marketing period that were shown 
to possibly have a causal relationship to tadalafil use include:  
• Sudden vision loss in one or both eyes (Non-arteritic anterior ischemic optic 
neuropathy – NAION) 
• Sudden hearing loss or tinnitus  
 
More serious side effects from rare allergic reaction include:  
• Stevens-Johnsons Syndrome  
• Exfoliative dermatitis  
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The risk of an allergic reaction such as Stevens-Johnson syndrome or exfoliative 
dermatitis is extremely rare <1% across all trials conducted. Sudden vision loss, NAION 
and hearing loss were documented during post-marketing surveillance and tadalafil use 
and these clinical findings may have had a temporal relationship however it was not 
possible to determine if a direct relationship existed.  
 
There is some risk with the blood draws that will be taken on 4 visits (visit 1, 3, 4, 5). 
The total volume of blood is not expected to significantly contribute to overall patient 
health with 20mL of blood taken at visit 1, 4 and 5 and 5mL taken at visit 3. The 
transthoracic echocardiogram should not cause any discomfort as the patient will be 
required to lay comfortably, supine for about 20 min and will have gel placed on the 
chest wall. An ultrasound probe will be placed on top of the gel to obtain images in 
various views to visualize the chambers and valves of the heart. There may be 
discomfort during the brachial artery flow mediated dilatation test during inflation of the 
blood pressure cuff, which requires the cuff to stay inflated for 5 min. This may cause 
some pain, sensation of pins/needles or tingling in the arm that will resolve upon 
deflation of the cuff. 
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RISK REDUCTION 
Throughout the study, several measures will be taken to monitor the safety of the 
patients. After the patient enrolls in the study, he or she will again be explained all the 
major adverse side effects and potential life threatening complications. A physician 
(medically-responsible investigator or a physician co-investigator) will remain on-call 
and available via pager through the telepage system for research patients at all times 
throughout the study period. A special virtual pager number for this research study will 
be created and will be covered at all times. A complete history and physical examination 
along with comprehensive metabolic panel will be performed at the time of visit one in 
the event patients will need to be excluded based on most up to date clinical data 
available.   Subjects will be under the observation of VCUHS medical staff during 
procedures including the transthoracic echocardiogram and brachial artery mediated 
dilatation study. Furthermore, to minimize potential complications from blood draws 
such as bruising, pain, irritation, swelling, infection, all blood draws will be performed by 
skilled nurses from VCUHS.  
 
A steering committee of investigators not involved in the design or execution of 
the study will be responsible for the monitoring of safety and the evaluation of potential 
drug-related adverse effects, without breaking the randomization code unless strictly 
necessary for patient safety. The first interim analysis will be performed after the first 10 
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patients, and then after half of the patients have been enrolled (20 patients) and at the 
end of the study (40 patients). 
 
RISK/BENEFIT 
This study may provide benefit to the patients enrolled given that an 
improvement in serum inflammatory cytokine and mediator levels (TNF-α, IL-1β, IL-6) 
and NO, cGMP has been seen with tadalafil use in pre-clinical animal studies. Needless 
to say, patients randomized to tadalafil may experience no benefit when compared to 
placebo. The potential benefits of being enrolled include improvement in endothelial 
function since a dysfunctional endothelium is at the crux of cardiovascular 
pathophysiology in insulin resistant patients and improvement in endothelial function 
with chronic PDE-5 inhibitor use has been shown both pre-clinically and in several small 
clinical studies with sildenafil. We plan to show this by checking urinary levels of cyclic 
GMP, cAMP, and serum levels of nitric oxide before and after 8 weeks of treatment. 
Several pilot clinical studies with the use of sildenafil, a shorter-acting PDE-5 inhibitor, 
showed improvements in endothelial function by measuring urinary cGMP and brachial 
artery flow-mediated dilatation. The potential knowledge that may come from this study 
may result in therapies that benefit future type II diabetics and in slowing the 
progression and development of atherosclerosis along with reducing CV morbidity and 
mortality in this patient population. The risks associated with the drug are small and 
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were not significantly different than placebo in the randomized clinical trials conducted 
with tadalafil for erectile dysfunction and pulmonary hypertension. Furthermore, the 
more major adverse effects are extremely rare. Nevertheless, we plan to set up a data 
safety monitoring board and will have a study physician (medically responsible 
investigator or physician co-investigator) available 24 hours a day/7 days a week 
throughout the study period. 
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APPENDIX B 
 
The Effects of Soluble Guanylate Cyclase (BAY 58-2667) in db/db mice after I/R 
injury 
 
	  
Figure 6866.  The infarct-sparing effects of chronic BAY therapy in diabetic mice. 
Two separate groups of mice (n=6/group) were treated with 10 mcg/Kg daily for 4 
weeks with BAY 58-2667 or an equal volume of 10% DMSO to evaluate the effects of 
the heme- and NO-independent soluble guanylate cyclase activator on I/R injury. We 
found a significant reduction of infarct size with BAY 58-2667 treatment (16.6±3.42% vs. 
44.7±10.42%, P<0.001) when compared to DMSO.  
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The Effects of BAY 58-2667 on Circulating Inflammatory Cytokines and 
Chemokines 
 
	  
Figure 69. The % reduction of circulating cytokines and chemokines after chronic BAY treatment 
in diabetic mice. 
In figure 70, treatment with BAY lead to a dramatic reduction in inflammatory cytokines 
and chemokines, specifically IL-1β, TNF-α, MIP-1β, and MCP-1. The promising results 
found with use of BAY 58-2667 in db/db mice should lead to further investigations with 
this promising compound on its effect on inflammation and various metabolic 
parameters.  
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